



Malaysian
Genomics
Resource
Centre


Malaysian Genomics Resource Centre Berhad
200401014287 (652790-V)



DECODE



REPAIR



TRANSFORM



Annual Report 2025

GENOME SEQUENCING | GENOME ANALYSIS | GENETIC SCREENING |
BIOINFORMATICS ANALYSIS | CELL THERAPY | ADVANCED PERSONALISED HEALTHCARE

Malaysian Genomics Resource Centre Berhad (hereafter referred to as 'MGRC') is a public-listed company focussing on realising the enormous potential within the evolving space of health technologies for the benefit of mankind. To achieve this, we need to provide quality innovations to lead MGRC into the future and keep it at the forefront of reliable healthcare products and services.

Our journey of discovery at MGRC is inspired by hope, driven by necessity and fuelled by passion to help shape a better future for mankind.

Our Vision



To be Asia's leading innovator in genomics, regenerative medicine, and immunotherapy—improving lives through the science of tomorrow.

To deliver world-class, personalised healthcare solutions through cutting-edge biotechnology, anchored in safety, integrity, and scientific excellence.

Our Mission



Our Corporate Values

- To be innovative and reliable.
- To evolve accountably and sustainably.
- To develop products with integrity and honesty.
- To offer products that are accessible and affordable for everyone.
- To work with respect and care for our customers and for the environment.



This annual report is available on the web at <https://www.mgrc.com.my/investor-relations/annual-report> or you can scan here to download

MGRC diversified into biopharmaceutical services, in distributing of immunotherapy and cell therapies. We will continue to discover possibilities and evolve to adapt the changing in healthcare industry.



What's Inside This Report

21ST ANNUAL GENERAL MEETING

- VENUE -

Westside Room 1, Level 8,
St. Giles Boulevard, Mid Valley City,
Lingkar Syed Putra,
59200 Kuala Lumpur,
Wilayah Persekutuan

- DATE -

22 June 2026 (Monday)

- TIME -

11:00 am



Malaysian
Genomics
Resource
Centre

Corporate Information

- 04 Corporate Directory
- 05 Corporate Structure
- 06 Profile of Directors

Performance Review

- 13 Chairman's Statement and Management Discussion and Analysis

Sustainability Statement

- 19 Sustainability Statement
- 47 Bursa Malaysia Prescribed Table

Corporate Governance

- 50 Corporate Governance Overview Statement
- 62 Other Compliance Information
- 63 Statement on Risk Management and Internal Control
- 67 Audit and Risk Management Committee Report
- 72 Disclosure of Financial Data For Shariah Screening

Financial Statements

- 75 Directors' Report
- 79 Statement by Directors
- 79 Statutory Declaration
- 80 Independent Auditors' Report
- 85 Statements of Financial Position
- 86 Statements of Profit or Loss and Other Comprehensive Income
- 87 Statements of Changes in Equity
- 88 Statements of Cash Flows
- 90 Notes to the Financial Statements

Other Information

- 125 List of Material Properties
- 126 Analysis of Shareholdings
- 128 Notice of 21st Annual General Meeting

Form Of Proxy



Corporate Information

- 04 Corporate Directory
- 05 Corporate Structure
- 06 Profile of Directors and Managements



“ BOARD OF DIRECTORS

LEONG YIEN HUNG

(Executive Chairman/Managing Director)

YAP KOK WEI

(Independent Non-Executive Director)

TAN YIING FUNG

(Independent Non-Executive Director)

CHUNG ENG LAM

(Independent Non-Executive Director)

LER PEI FEN

(Independent Non-Executive Director)

LIM KOK KIONG

(Independent Non-Executive Director)

▶ REGISTERED OFFICE

B-21-1, Level 21, Northpoint Mid Valley City,
No. 1, Medan Syed Putra Utara,
59200 Kuala Lumpur.

Tel : (+603) 9770 2200

Fax : (+603) 2201 7774

▶ PRINCIPAL PLACE OF BUSINESS

8F, Jalan Teknologi 3/6, Taman Sains Selangor 1,
Kota Damansara (PJU5), 47810 Petaling Jaya,
Selangor Darul Ehsan, Malaysia.

Tel : (+603) 7890 0015 / (+603) 7890 0016

▶ AUDITORS

Jamal, Amin & Partners (AF 1067)

No. 62-1, 1st Floor, Jalan 2/23A,
Off Jalan Genting Klang, Taman Danau Kota Setapak,
53300 Kuala Lumpur.

Tel : (+603) 4142 1626

Fax : (+603) 4142 1601

▶ SHARE REGISTRAR

Aldpro Corporate Services Sdn Bhd

[Registration No.: 202101043817 (1444117-M)]

B-21-1, Level 21, Northpoint Mid Valley City,
No. 1, Medan Syed Putra Utara,
59200 Kuala Lumpur.

Tel : (+603) 9770 2200

Fax : (+603) 2201 7774

▶ AUDIT AND RISK MANAGEMENT COMMITTEE

- Lim Kok Kiong (Chairman)
- Tan Yiing Fung
- Yap Kok Wei

▶ NOMINATION AND REMUNERATION COMMITTEE

- Yap Kok Wei (Chairman)
- Lim Kok Kiong
- Tan Yiing Fung

▶ COMPANY SECRETARIES

Tan Tong Lang
SSM PC No. 202208000250
(MAICSA 7045482)

Thien Lee Mee
SSM PC No. 201908002254
(LS0010621)

▶ STOCK EXCHANGE LISTING

ACE Market
Bursa Malaysia Securities Berhad

Sector : Health Care
Stock Name : MGRC
Stock Code : 0155

▶ PRINCIPAL BANKER

RHB Bank Berhad
CIMB Islamic Bank Berhad


▶ WEBSITE

www.mgrc.com.my



MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

200401014287 (652790-v)



“



PROFILE OF DIRECTORS

LEONG YIEN HUNG

Executive Chairman / Managing Director

Nationality

Malaysia

Age

42

Mr Leong Yien Hung ("Mr Leong"), was appointed to the Board as Managing Director on 19 February 2025 and re-designated as Executive Chairman / Managing Director on 23 April 2025.

He obtained his Bachelor in Computer Science from Coventry University, United Kingdom in 2003. He has more than 15 years of experience in Malaysia's finance industry specializing in full fledge financial services and alternative investments.

He is a member of Investment Committees of Proven Venture Capital, which is managed by 5 Pillars Ventures Sdn Bhd, a venture capital management corporation licensed by the Securities Commission Malaysia.

Presently, he is a Director of an unlisted public company namely Octowill Trustees Berhad and an Independent and Non-Executive Director at Aldrich Resources Berhad.

He has no family relationship with any other Director and/or major shareholders of the company nor any conflict of interest or potential conflict of interest, including interest in any competing business with the Group.

He has not been convicted of any offences within the past five (5) years other than traffic offences, if any, and has not been imposed any public sanction or penalty by the relevant regulatory bodies during the financial year ended 31 December 2025.

He attended a total of five (5) Board Meetings of the Company held during the financial year ended 31 December 2025.

PROFILE OF DIRECTORS

YAP KOK WEI

Independent Non-Executive Director

Nationality

Malaysia

Age

50



Mr Yap Kok Wei (“Mr Yap”) was appointed to the Board as an Independent Non-Executive Director on 4 October 2024. He is the Chairman of the Nomination and Remuneration Committee and a member of the Audit and Risk Management Committee of the Company.

Mr Yap served as a Portfolio Manager (Asia Pacific) at Sumitomo Mitsui DS Asset Management in Hong Kong for more than 10 years, covering Asia Pacific region. During this period, he plays a crucial role in conducting macro and equity research, significantly contributing to the organizations fund performance, marketing and fund-raising endeavors. Mr. Yap’s international experience extends to his time as a Senior Analyst at Huatai-Pinebridge Fund Management in Shanghai, China where he focused on macro and equity research. Currently, Mr Yap is the Chief Investment Officer of Proven Venture Capital PLT. He has extensive experience in the investment industry and responsible in managing equity funds.

He does not have any directorship in other public companies and listed issuers in Malaysia, except he also sit on the Board of unlisted public company, Octowill Trustees Berhad.

He has no family relationship with any other Director and/or major shareholders of the company nor any conflict of interest or potential conflict of interest, including interest in any competing business with the Group.

He has not been convicted of any offences within the past five (5) years other than traffic offences, if any, and has not been imposed any public sanction or penalty by the relevant regulatory bodies during the financial year ended 31 December 2025.

He attended a total of five (5) Board Meetings of the Company held during the financial year ended 31 December 2025.

“



PROFILE OF DIRECTORS

CHUNG ENG LAM

Independent Non-Executive Director

Nationality

Malaysia

Age

60

Mr Chung Eng Lam ("Mr Chung") was appointed to the Board as an Independent Non-Executive Director on 19 February 2025.

Mr Chung graduated with a Certificate in Mechanical and Automotive Engineering from Tunku Abdul Rahman College, Kuala Lumpur, in 1986. He began his career in 1986 as a Technician at Syarikat Sunto Trading, where he was involved in the maintenance and installation of medical equipment, mechanical and electrical systems, and other hospital-related equipment. He was also responsible for designing hospital stainless steel furniture used in sterile and mortuary departments across various hospitals, including Hospital Ampang, Hospital Serdang, and Hospital Putrajaya, among others.

In 1996, he was promoted as Technical Manager in Syarikat Sunto Trading. During the same year, he became one of the co-founding team members of CS Laundry System Sdn Bhd. In 2006, he co-founded Maymedic Technology Sdn Bhd and has since played an instrumental role in spearheading the company's business. Mr Chung was appointed as an Executive Director of BCM Alliance Bhd on 4 November 2015, a company that was listed on the ACE Market of Bursa Malaysia. Subsequently, he resigned from his position as Executive Director of BCM Alliance Bhd in 2021.

He was the Managing Director of Maymedic Technology Sdn Bhd. As the business unit head for Maymedic, he was responsible to oversee the day-to-day operations of the company. With over thirty-eight (38) years of industry experience, he specializes in supplying disinfection, sterilization, and surgical room equipment, as well as providing related repair and maintenance services. Currently he has retired from his position as Managing Director of Maymedic Technology Sdn. Bhd.

He does not have any directorship in other public companies and listed issuers in Malaysia.

He has no family relationship with any other Director and/or major shareholders of the company nor any conflict of interest or potential conflict of interest, including interest in any competing business with the Group.

He has not been convicted of any offences within the past five (5) years other than traffic offences, if any, and has not been imposed any public sanction or penalty by the relevant regulatory bodies during the financial year ended 31 December 2025.

He attended a total of five (5) Board Meetings of the Company held during the financial year ended 31 December 2025.

PROFILE OF DIRECTORS

LER PEI FEN

Independent Non-Executive Director

Nationality

Malaysia

Age

39



Ms Ler Pei Fen ("Ms Ler") was appointed to the Board as an Independent Non-Executive Director on 19 February 2025.

Ms. Ler is a highly experienced professional with a successful track record in the financial industry. With a career spanning over a decade, she has held key roles in reputable organizations, demonstrating her expertise and leadership capabilities.

Ms. Ler served as a Remisier at RHB Investment Bank Bhd in 2011. She leveraged her deep understanding of financial markets to provide exceptional service to her clients. She was responsible for overseeing and analyzing market trends, executing trades, and offering valuable investment advice to help her clients.

In 2012, Ms. Ler served as a Senior Agent at Hong Leong Assurance Bhd until 2022. She showcased her comprehensive knowledge of insurance products and risk management strategies. Ms. Ler demonstrated her ability to assess clients' insurance needs and tailor solutions that protected their assets and provided financial security.

In 2018, she was appointed as a Director at Finicon Venture Holdings Sdn Bhd, where she played a vital role in overseeing the company's operations and driving its growth initiatives. Her leadership acumen and business expertise have contributed to the company's success in navigating industry challenges and capitalizing on emerging opportunities.

Throughout her career, Ms. Ler has consistently demonstrated strong analytical skills, deep industry knowledge, and dedication to delivering excellent results for clients and organizations. Her extensive experience in the financial sector, coupled with her strategic mindset, makes her a valuable asset in navigating the complexities of the ever-evolving financial landscape.

She does not have any directorship in other public companies and listed issuers in Malaysia.

She has no family relationship with any other Director and/or major shareholders of the company nor any conflict of interest or potential conflict of interest, including interest in any competing business with the Group.

She has not been convicted of any offences within the past five (5) years other than traffic offences, if any, and has not been imposed any public sanction or penalty by the relevant regulatory bodies during the financial year ended 31 December 2025.

She attended a total of five (5) Board Meetings of the Company held during the financial year ended 31 December 2025.

“



PROFILE OF DIRECTORS

LIM KOK KIONG

Independent Non-Executive Director

Nationality

Malaysia

Age

54

Mr Lim Kok Kiong ("Mr Lim") was appointed to the Board as an Independent Non-Executive Director on 19 February 2025. He also the Chairman of the Audit and Risk Management Committee and a member of the Nomination and Remuneration Committee of the Company.

Mr. Lim is a Chartered Accountant of the Malaysian Institute of Accountants ("MIA") and Certified Public Accountant of the Malaysian Institute of Certified Public Accountants ("MICPA") with over 35 years of working experience in corporate finance, treasury, accounting, and auditing. He began his career as an auditor at KPMG Peat Marwick. Subsequently, he held key leadership positions in various private, public, and multinational companies across diverse industries, including water treatment, industrial products, luxury car distribution and assembly, computer manufacturing, and retail.

In 2012, Mr. Lim was appointed as Independent, Non-Executive Director and Chairman of the Audit Committee at a listed company, serving until March 2013. At the same time, he also held the role of Finance Director at a private college. He was engaged in the management of a company involved in oil palm cultivation in Ranau, Sabah.

Mr. Lim also accumulated significant experience in other listed companies, working in fields such as data communications, hardware and software solutions, e-business strategy, as well as the supply, installation, testing, and commissioning of commercial laundry equipment, medical devices, clinical aesthetics, traditional healing and wellness centres with beauty and healthcare.

He does not have any directorship in other public companies and listed issuers in Malaysia.

He has no family relationship with any other Director and/or major shareholders of the company nor any conflict of interest or potential conflict of interest, including interest in any competing business with the Group.

He has not been convicted of any offences within the past five (5) years other than traffic offences, if any, and has not been imposed any public sanction or penalty by the relevant regulatory bodies during the financial year ended 31 December 2025.

He attended a total of five (5) Board Meetings of the Company held during the financial year ended 31 December 2025.

PROFILE OF DIRECTORS

TAN YIING FUNG

Independent Non-Executive Director

Nationality

Malaysia

Age

37



Ms Tan Yiing Fung ("Ms Tan") was appointed to the Board as an Independent Non-Executive Director on 19 February 2025. She also the member of the Audit and Risk Management Committee and the Nomination and Remuneration Committee of the Company.

Ms. Tan began her career with Messrs. Teh & Lee as an Associate in 2012. During her tenure at Messrs. Teh & Lee, her main areas of practice were corporate and commercial laws, where she was involved in equity and debt transactions, including mergers and acquisitions, joint ventures, corporate restructuring, takeovers, as well as private debt securities, corporate loans, and private funds transactions. She left Messrs. Teh & Lee in March 2021 and joined Messrs. CY Poon & CM Lim as a Partner. Currently, she oversees the business operations of the firm's branch office in Kuala Lumpur. Her main areas of practice include corporate law, conveyancing, and banking, specializing in equity and debt capital markets and advising on the establishment of private equity funds.

Currently, she sits on the Board of Aldrich Resources Berhad, West River Berhad and Camaroe Berhad.

She has no family relationship with any other Director and/or major shareholders of the company nor any conflict of interest or potential conflict of interest, including interest in any competing business with the Group.

She has not been convicted of any offences within the past five (5) years other than traffic offences, if any, and has not been imposed any public sanction or penalty by the relevant regulatory bodies during the financial year ended 31 December 2025.



Performance Review

13 Chairman's Statement And Management Discussion And Analysis

**MG
RC** Malaysian
Genomics
Resource
Centre

CHAIRMAN'S STATEMENT & MANAGEMENT DISCUSSION AND ANALYSIS

Dear Shareholders,

On behalf of the Board of Directors and Management of Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Group"), we are pleased to present to you the Group's Annual Report for the financial year ended 31 December 2025 ("FYE 2025").

This combined Chairman's Statement to Shareholders and Management Discussion and Analysis ("MD&A") has been meticulously prepared to offer our valued shareholders a comprehensive overview of the Group's financial performance, recent developments in our business operations, and the products and services we pride ourselves on. Furthermore, this document sheds light on our strategic objectives and plans, which are set with the Group's long-term vision in mind and in the best interests of our shareholders.



Key Developments in FYE 2025

During FYE 2025, MGRC focused on strengthening its market presence and enhancing its brand visibility within the healthcare and biopharmaceutical industry.

The Group actively participated in several regional and international healthcare events, including Cell & Gene Therapy World Asia 2025 in Singapore, International Health Expo 2025 in Surabaya, Indonesia, and Aicare Health & Wellness Expo. These engagements provided valuable platforms for MGRC to showcase its capabilities in genetic screening, genomics, and cell therapies, while fostering relationships with healthcare professionals, industry players, and potential partners.

In addition, MGRC continued to enhance its product offerings through ongoing development initiatives, ensuring that its services remain relevant and aligned with evolving market demand and technological advancements in the healthcare sector.

Financial Review:

During FYE 2025, MGRC continued to execute its strategic initiatives aimed at driving sustainable growth and strengthening its position within the healthcare sector.

The Group recorded a revenue of RM8.02 million, representing an increase of 45% from RM5.52 million in the previous financial year. This growth was primarily driven by stronger market demand for the Group's immunotherapy and cell therapy offerings supported by competitive pricing strategies and targeted marketing initiatives.

From a profitability perspective, the Group reported a loss before tax of RM2.49 million, an improvement from loss before tax of RM4.51 million in FYE 2024. While core operations remained stable, the loss for FYE 2025 was primarily attributable to impairment losses on receivables. Despite this, the narrowing of losses was mainly driven by stricter credit control measures and ongoing cost optimisation initiatives undertaken during the year. These efforts reflect the Group's continued focus on improving operational efficiency and financial discipline.





Overall, while the Group remains in a loss-making position, the improvement in revenue and reduction in losses indicate a positive trajectory towards financial stabilisation. The Group remains committed to strengthening its core business segments while pursuing sustainable growth opportunities.

Return on shareholders' equity improved from negative 25% to negative 19%, indicating gradual progress towards financial stabilisation.

In terms of liquidity, the Group's cash and bank balances increased significantly to RM1.02 million as at FYE 2025, compared to RM0.27 million in the previous financial year. This improvement was mainly driven by enhanced collection efforts, resulting in a reduction in trade receivables and improved cash flow management.

On the liability front, total liabilities decreased to RM3.93 million from RM4.78 million in FYE 2024. The reduction was primarily due to the Group's timely repayment to suppliers, reflecting the Group's commitment to maintaining strong and reliable business relationships.

HISTORICAL FINANCIAL SUMMARY:



Financial Year / Period Ended	30.6.2021 (RM'000)	30.6.2022 (RM'000)	31.12.2023 18months (RM'000)	31.12.2024 (RM'000)	31.12.2025 (RM'000)
Results					
Profit/(Loss), net of tax	(4,293)	7,210	(23,696)	(4,515)	(2,797)
Equity and Liabilities					
Total equity	17,930	38,968	22,088	17,573	14,784
Total liabilities	4,853	2,922	3,616	4,782	3,925
Total Equity and Liabilities	22,783	41,890	25,704	22,355	18,709
Assets					
Property, plant and equipment	3,822	4,305	3,519	2,946	2,140
Rights-of-use assets	1,547	1,493	1,821	1,442	1,064
Intangible assets	1,752	4,950	4,294	3,879	3,458
Other non current assets	-	1,080	-	2,500	2,500
Current assets	15,662	30,062	16,070	11,588	9,547
Total Assets	22,783	41,890	25,704	22,355	18,709
Others:					
Cash and cash equivalents	11,309	20,518	1,423	271	1,019
Return on shareholders' equity (%)	(24)	19	(107)	(26)	(19)

COMPANY BACKGROUND OVERVIEW

Business Overview

Since its establishment in 2004, MGRC has been at the forefront of genomics innovation in Malaysia. Leveraging its proprietary bioinformatics technologies and expertise, the Group has evolved from a genome sequencing service provider into a broader precision healthcare solutions provider.

Today, MGRC operates across key segments within the healthcare value chain, including genetic screening, immunotherapy and cell therapy, as well as genome sequencing and bioinformatics services. These core segments reflect the Group's strategic focus on precision healthcare and its commitment to delivering innovative, science-driven solutions.

The Group operates from its facility in Kota Damansara, Selangor, which has been operational since April 2021 and houses its headquarters, a high-throughput sequencing laboratory, and a certified cell processing laboratory.

The facility is supported by ISO certifications under an Integrated Management System, as well as Biosafety Level 2 ("BSL-2") compliance for its cell processing laboratory, ensuring adherence to stringent biocontainment requirements. In addition, the Group's cGMP accreditation, aligned with international pharmaceutical standards, reinforces its commitment to quality and safety.





Products and Services

MGRC continues to deliver precision healthcare solutions through a focused portfolio of core offerings aligned with its strategic priorities.

The Group's genetic screening services remain a key pillar of its business. Through its proprietary Dtect® and Origene genetic testing solutions, MGRC provides individuals with insights into genetic predispositions related to health risks, wellness, and lifestyle traits. These services support personalised healthcare planning and preventive health management, while incorporating pharmacogenetic insights to enhance treatment outcomes.

In parallel, MGRC continues to expand its immunotherapy and cell therapy offerings, which represent an important growth segment for the Group. The Group provides mesenchymal stem cells derived from ethically sourced human umbilical cords, as well as natural killer ("NK") cell therapies designed to strengthen the body's immune response. These therapies are increasingly relevant in the treatment of cancers, autoimmune diseases, and other complex conditions.

Genome sequencing and bioinformatics services remain integral to MGRC's capabilities. By transforming biological data into actionable insights, the Group supports research, diagnostics, and applications across multiple sectors. This expertise complements MGRC's broader precision medicine initiatives.

Strategy and Outlook

MGRC remains focused on strengthening its core business segments while capitalising on emerging opportunities in precision healthcare.

The Group continues to expand its genetic screening services through broader market access and strategic partnerships, including B2B and white-labelling initiatives. In the area of immunotherapy and cell therapy, MGRC is committed to advancing research and development while enhancing the accessibility and affordability of treatment solutions.

The Group also continues to leverage its expertise in genome sequencing and bioinformatics to support a wide range of applications, while exploring the integration of artificial intelligence and big data analytics to enhance healthcare insights and outcomes.

Building on the strategic reorganisation undertaken in FYE 2024, the Group has placed greater emphasis in FYE 2025 on execution, optimisation, and improving the performance of its core business segments. MGRC continues to strengthen its operational efficiency, financial discipline, and resource allocation to support a more resilient and sustainable business model.

Looking ahead, MGRC will continue to focus on strengthening its core business segments, improving cash flow management, and pursuing opportunities aligned with its strategic priorities. While the operating environment remains competitive, the Group is confident that its strengthened foundation and clear strategic direction will support sustainable growth and long-term value creation.

Governance and Corporate Responsibility

MGRC remains committed to maintaining high standards of corporate governance and ethical conduct. The Group adopts a zero-tolerance approach towards bribery and corruption and ensures compliance with applicable laws and regulations across its operations. This commitment reinforces stakeholder confidence and supports long-term sustainability.

Dividend Policy

In light of the strategic decisions and investments made throughout the year, the Board of Directors opted not to recommend a dividend for FYE 2025. This decision aligns with our goal to harness resources for the expansion and diversification of MGRC's business operations in the forthcoming financial year.

Appreciation

As we reflect on the financial year ended 31 December 2025, we would like to express our sincere appreciation to all stakeholders who have supported MGRC throughout the year.

To our valued shareholders, we thank you for your continued trust and confidence in the Group. Your unwavering support has been instrumental in enabling MGRC to navigate challenges and pursue its strategic objectives.

To our customers and business partners, we are grateful for your continued collaboration and trust in our capabilities. Your support has been vital in driving the Group's operational progress and market presence.

To the Board of Directors, Management team, and all employees, we extend our heartfelt appreciation for your dedication, resilience, and commitment. Your collective efforts have played a crucial role in strengthening the Group's foundation and advancing its strategic initiatives.

As we move forward, MGRC remains committed to delivering sustainable value to our stakeholders while continuing to build a stronger and more resilient organisation. We look ahead with cautious optimism and confidence in the opportunities that lie ahead.

Mr Leong Yien Hung

Executive Chairman/ Managing Director



Sustainability Statement

- 19 Sustainability Statement
- 47 Bursa Malaysia Prescribed Table

EXECUTIVE CHAIRMAN'S MESSAGE

LEONG YIEN HUNG

Executive Chairman / Managing Director



Dear valued stakeholders,

As Chairman of MGRC, I am pleased to present our Sustainability Report for the financial year ended 31 December 2025 which reflects our continued dedication to sustainable growth and responsible business conduct. At MGRC, we firmly believe that sustainability is fundamental to our long-term value creation and to enhancing the well-being of the communities in which we operate.

Amid the evolving macroeconomic landscape, MGRC has remained steadfast in upholding excellence and responsible practices. We strive to make our healthcare products and services more accessible to the broader public by working closely with our partners to deliver innovative solutions at more affordable price points compared to conventional offerings.

Building on our focus in the previous year, MGRC continued to strengthen the social (“S”) pillar of ESG during the current financial year. We have made steady progress in enhancing talent retention initiatives, advancing employee development programmes, and ensuring that our products and services consistently meet evolving stakeholder expectations. These efforts remain central to our sustainability agenda as we further reinforce a resilient and people-centric organisation.

MGRC has made significant progress in embedding sustainability into its organisational culture and long-term strategy. This commitment is aligned with the Company’s core values and is reflected in our day-to-day operations, decision-making processes, and governance framework, including risk management practices. By integrating sustainability across all levels of the organisation, we ensure that every individual contributes towards creating positive economic, social, and environmental impacts.

We continue to actively engage with our stakeholders, recognising their importance within our business ecosystem. These stakeholders—both internal and external—form a vital network that supports MGRC’s operations and future growth. Insights derived from these engagements have been instrumental in shaping our sustainability priorities and initiatives.

In particular, our engagement efforts are largely centred on our employees, who remain the cornerstone of our organisation. Their feedback and perspectives have guided our efforts in enhancing workplace practices and fostering a supportive environment that encourages professional growth and career development. This reflects MGRC’s belief that meaningful collaboration and active stakeholder participation are key to achieving sustainable and impactful outcomes.

The financial year 2025 marks the third consecutive year MGRC has adopted the Global Reporting Initiative (GRI) Standards in the preparation of this Sustainability Report. Building on the foundation established in previous years, the Group continues to enhance its data collection processes, improve the quality of disclosures, and strengthen the measurement of its sustainability performance.

Moving forward, the Group will progressively align its sustainability reporting with the IFRS Sustainability Disclosure Standards, namely S1 (General Requirements for Disclosure of Sustainability-related Financial Information) and S2 (Climate-related Disclosures). In doing so, MGRC aims to further strengthen its sustainability governance, risk management framework, and disclosure practices, where appropriate, to ensure greater transparency, consistency, and comparability in its sustainability reporting.



ABOUT THIS REPORT (GRI 2-22)

Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group” or “the Company”) is pleased to present the Group’s Sustainability Report for the financial year ended 31 December 2025. This report outlines our sustainability strategy, approach, and key initiatives, reflecting our continued commitment to sustainability, accountability, and continuous improvement across the Economic, Environmental, and Social (“EES”) dimensions.

This report provides a comprehensive overview of how sustainability is embedded within the Group’s daily operations and decision-making processes. It aims to keep our stakeholders, both internal and external, informed on how the Group manages its environmental and social impacts while ensuring long-term economic resilience and value creation. The report also underscores the Company’s ongoing commitment to supporting the United Nations Sustainable Development Goals (“SDGs”).

Reporting Framework

This report is prepared with reference to Global Reporting Initiatives (“GRI”) Standards 2021, and meets the criteria of the Bursa Malaysia ACE Market Listing Requirements relating to Sustainability Statements in Annual Reports.

Scope (GRI 2-1, 2-2, 2-3)

Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”) is listed on the Bursa Malaysia ACE Market and is headquartered in Selangor, Malaysia. This Sustainability Report covers the operations of MGRC and its subsidiaries, all of which are based in Malaysia.

The reporting period for this report is for the financial year ended 31 December 2025, unless otherwise stated. The Group publishes its Sustainability Report on an annual basis, in conjunction with the release of its Annual Report.

Feedback (GRI 2-3)

We welcome any enquiries, views, and comments on this Report. To submit feedbacks or obtain further clarification, please contact us at:

8F Jalan Teknologi 3/6
Taman Sains Selangor 1
Kota Damansara (PJU5)
47810 Petaling Jaya, Selangor
Malaysia

Tel : +603-7890 0015, +603-7890 0016
Email : enquiries@mgrc.com.my
Website : www.mgrc.com.my



ABOUT OUR ORGANISATION (GRI 2-1, 2-28)

MGRC is a leading genomics and biopharmaceutical company based in Malaysia. The Group was established in 2004 and listed on the Bursa Malaysia Stock Exchange in 2010. The Company is focussing on realising the enormous potential within the evolving space of health technologies for the benefit of mankind. To achieve this, MGRC needs to provide quality innovations to lead the Company into the future and keep it at the forefront of reliable healthcare products and services.

From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, MGRC has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer. Our journey of discovery at MGRC is inspired by hope, driven by necessity and fuelled by passion to help shape a better future for mankind.

MGRC is a member of Malaysian Association for Cell & Gene Therapy (MACT).

<p>VISION</p> <p>To be Asia’s leading innovator in genomics, regenerative medicine, and immunotherapy - improving lives through the science of tomorrow.</p>	<p>MISSION</p> <p>To deliver world-class, personalised healthcare solutions through cutting-edge biotechnology, anchored in safety, integrity, and scientific excellence.</p>
---	--

OUR STORY (GRI 2-1, 2-6)

Since 2004, MGRC has pioneered innovative products and services in Malaysia and in the region. Our unique and innovative products and services began with genome sequencing and analysis services, and later expanded to genetic screening services, immunotherapy, mesenchymal stem cell (“MSC”) therapy and exosome therapy. Our involvement in biotechnology and healthcare sectors, especially in niche markets, contributed to the growth of Malaysia by facilitating technology transfer into the country, reducing capital outflow by making our products and services available locally and contributing to local infrastructure development by setting up the first privately owned Biosafety Level 2 (“BSL-2”) facility in the region for cell engineering services. The provision of better health solutions will enable our customers to take proactive actions to improve their health - leading to better health for the population, and result in improved health and increased productivity for the economy. MGRC continues to develop new and innovative healthcare solutions and expand into other areas of healthcare to benefit the growth of both local and worldwide economies.



Our Corporate Values



Group Structure (GRI 2-1)

MGRC is the parent company of the following subsidiaries, which are 100% owned,

- MGRC Healthcare Sdn. Bhd.
- MGRC Therapeutics Sdn. Bhd.
- MGRC Trading Sdn. Bhd.
- MGRC Biopharma Sdn. Bhd.
- Malaysian Genomics and Life Sciences Sdn. Bhd.
- MGRC Holdings Sdn. Bhd.
- Malaysian Immuno Sdn. Bhd.
- Malaysian Cell Gene Sdn. Bhd.
- Malaysian Cell Gene Research Sdn. Bhd.
- Aquahealth Sdn. Bhd. (51%)
- Malaysian Genomics Regenerative Centre Sdn. Bhd

Our Contributions To SDGS (GRI 2-23)

Guided by the United Nations Sustainable Development Goals (“SDGs”), the Group remains committed to contributing positively to the communities we serve, fostering inclusivity, and safeguarding the environment.

Out of the 17 SDGs, the Group has identified seven (7) goals that are most closely aligned with our business strategies and sustainability initiatives. These selected SDGs reflect our focused approach in contributing meaningfully to the global sustainability agenda while creating long-term value for our stakeholders.

SDGs	MGRC’s Initiatives
	<ul style="list-style-type: none"> • We strive to achieve zero accidents through continuous safety and health monitoring. • We have in place an “Emergency Response Plan” to ensure the safety of our employees at all times. • We provide complimentary genetic screening tests to our employees as well as discounts on products and services as part as employee benefits. • We provide discounts for employee’s extended family members and friends under the initiative “friends and families” campaign. • We made our cancer immunotherapy treatments more accessible and affordable to cancer patients through compassionate use basis
	<ul style="list-style-type: none"> • We provide equal opportunities, basic salary and remuneration for men and women of the same job level. • For this reporting period, our total workforce is made up of 79% (2024: 69%) female and 21% (2024: 31%) male
	<ul style="list-style-type: none"> • We continuously monitor and aim to minimise our energy consumption by purchasing energy efficient equipment. • Increasing energy awareness amongst our staff to iterate the importance of responsible energy consumption and avoiding wastage
	<ul style="list-style-type: none"> • We develop and maintain a dynamic workforce with diverse individuals from different ethnic groups, cultural background, age, experiences and skills. • We uphold fair employment practices and making a decent, safe, and secure workplace for our employees
	<ul style="list-style-type: none"> • We recognise the impact of climate change could be on our business and give consideration on climate in our every business activity. • We aim to reduce our greenhouse gas (“GHG”) emissions by optimizing our energy consumption.
	<ul style="list-style-type: none"> • We are dedicated to maintaining integrity and adhering to all relevant laws and regulations throughout our business activities. • We established Code of Conduct, Anti-Bribery and Corruption (“ABC”) Policy, Whistleblowing policy, Personal Data Protection Policy as part of our preventive measures. • Our governance strategy, risk management, and business practices are aligned with the Malaysian Code on Corporate Governance (“MCCG”), which serves as our guiding framework.
	<ul style="list-style-type: none"> • We collaborated with our partners to make our products and services available to much wider market.



Assurance And Verification

This Report has not been externally assured. Nonetheless, the Group's sustainability reporting processes are subject to internal validation and assessments disclosed in this Report.

In preparing this Report, we conducted internal validation to verify the accuracy and integrity of the data disclosed. The content of this Report has been reviewed and endorsed by our Board of Directors ("Board"), who have ensured the Report's relevance to the Group's business and that current and material issues are covered.

Sustainability Governance



The Board of Directors ("Board") of MGRC serves as the highest governing body and holds ultimate responsibility for the Group's sustainability strategy, governance, and overall direction. The Group adopts a top-down approach in driving its sustainability agenda, with the Board reviewing and approving all sustainability-related policies, initiatives, and disclosures to ensure alignment with both regulatory requirements and commercial objectives, while upholding responsible and sustainable business practices.

Oversight of sustainability matters is led by the Executive Chairman/Managing Director ("EC/MD"), who monitors the implementation of sustainability practices across the Group's operations and ensures alignment with Bursa Malaysia ACE Market Sustainability reporting expectations. Supporting this governance structure, sustainability-related matters are operationalised through a structured reporting line, whereby Heads of Department ("HODs") are responsible for implementing initiatives at the operational level and reporting to the Acting General Manager ("Acting GM"). The Acting GM, in turn, consolidates and escalates key sustainability matters, performance updates, and risks to the EC/MD, who subsequently reports to and engages with the Board for strategic deliberation and decision-making.

The Board is also responsible for identifying, evaluating, and managing MGRC's impacts on the economy, environment, and society. This is undertaken through ongoing engagement with both internal and external stakeholders, enabling the Group to better understand and address material sustainability matters. In support of this, the Group has established policies and practices aimed not only at contributing positively to sustainability objectives, but also at mitigating potential adverse impacts.

The Group's governance framework is further guided by the Malaysian Code on Corporate Governance, ensuring that corporate strategies, risk management practices, and internal controls are aligned with recognised best practices and support long-term sustainable value creation.



Roles And Responsibilities Within Sustainability Governance

To ensure effective implementation of the Group’s sustainability strategy, MGRC has established a clear governance and reporting structure, with defined roles and responsibilities across different levels of management:

Levels of Management	Roles and Responsibilities
Executive Chairman/ Managing Director ("EC/MD")	<p>The EC/MD provides overall leadership and strategic oversight of the Group’s sustainability agenda. As the key link between Management and the Board, the EC/MD is responsible for:</p> <ul style="list-style-type: none"> • Driving the integration of sustainability into the Group’s corporate strategy, business objectives, and decision-making processes; • Overseeing the development, implementation, and continuous enhancement of sustainability initiatives across the Group; • Reviewing sustainability performance, key risks, and opportunities, and ensuring alignment with regulatory requirements and stakeholder expectations; • Providing direction on governance, ethical standards, and sustainability priorities in line with the Group’s long-term vision; and • Reporting to the Board on sustainability matters, including progress against targets, material issues, and strategic initiatives for deliberation and approval.
Acting General Manager ("Acting GM")	<p>The Acting GM plays a pivotal role in translating the Group’s sustainability strategy into actionable plans and ensuring effective execution across the organisation. The GM’s responsibilities include:</p> <ul style="list-style-type: none"> • Coordinating and overseeing the implementation of sustainability initiatives across all departments; • Consolidating sustainability-related data, performance metrics, and progress updates from various departments; • Monitoring operational risks and ensuring that sustainability considerations are embedded into daily business activities; • Escalating key sustainability matters, challenges, and performance outcomes to the EC/MD; and • Ensuring alignment between departmental actions and the Group’s overall sustainability objectives and policies.
Heads of Department ("HODs")	<p>Heads of Department are responsible for the execution and operationalisation of sustainability initiatives within their respective functions. Their key responsibilities include:</p> <ul style="list-style-type: none"> • Implementing sustainability-related policies, procedures, and initiatives at the departmental level; • Identifying and managing environmental, social, and operational risks relevant to their areas of responsibility; • Monitoring and reporting sustainability performance, including key indicators and progress against targets; • Promoting awareness, engagement, and adherence to sustainability practices among employees within their departments; and • Reporting regularly to the Acting GM on sustainability matters, including challenges, improvements, and opportunities for enhancement.

Stakeholder Engagement (GRI 2-29)

Aligned with our commitment to openness, and with the aim to continuously improve our business process, we actively engage with internal and external stakeholders. Engagements are conducted directly or indirectly; the purpose is to gain insights into their concerns and perspective as well as to manage our impacts. Our stakeholders include employees, customers, suppliers, regulators, and local community.

Stakeholders	Areas of Interest/Concern	Engagement Approach and Frequency	Our responses
<p>Shareholders/ Investors</p> 	<ul style="list-style-type: none"> • Profitability and return on investment • Sustainable financial performance • Operational efficiency and growth 	<ul style="list-style-type: none"> • Quarterly financial results announcements • Annual report • Company website • AGM • Analyst briefings 	<ul style="list-style-type: none"> • Timely and transparent disclosures in accordance with Bursa Malaysia Listing Requirements • Integration of sustainability and material ESG risks into business strategy • Strengthened corporate governance, internal controls, and risk management framework • Focus on long-term sustainable value creation and business resilience
<p>Employees</p> 	<ul style="list-style-type: none"> • Career development and progression • Compensation and benefits • Training and development • Employee well-being • Health and safety • Technological advancement 	<ul style="list-style-type: none"> • Performance appraisals • Internal meetings/dialogue sessions • Training programmes • Engagement with Management • Employee surveys 	<ul style="list-style-type: none"> • Implementation of fair labour practices and equal opportunity in line with applicable laws (e.g. Employment Act) • Continuous training and development to enhance workforce capability • Promotion of a safe, healthy, and inclusive workplace • Strengthened employee engagement and retention initiatives (Celebrations and team building)
<p>Customers</p> 	<ul style="list-style-type: none"> • Product and service quality • Reliability and innovation • Customer satisfaction • Data privacy and trust 	<ul style="list-style-type: none"> • Site visits • Company website • Emails and feedback channels • Meetings and dialogue sessions • Customer satisfaction survey 	<ul style="list-style-type: none"> • Continuous improvement in product quality, safety, and service delivery • Strengthening of data privacy and confidentiality practices in line with regulatory expectations • Commitment to ethical business practices and customer-centric innovation
<p>Suppliers</p> 	<ul style="list-style-type: none"> • Sustainable business relationships • Fair selection and evaluation • Timely payments 	<ul style="list-style-type: none"> • Competitive sourcing (minimum three suppliers) • Supplier evaluations • Meetings and communications • Business partnerships 	<ul style="list-style-type: none"> • Adoption of transparent and competitive procurement practices • Strengthening supplier evaluation and performance monitoring processes • Timely payments in accordance with agreed credit terms • Encouraging suppliers to adhere to ethical, environmental, and social standards

Stakeholder Engagement (GRI 2-29) (Continued)

Stakeholders	Areas of Interest/Concern	Engagement Approach and Frequency	Our responses
<p>Government / Regulators</p> 	<ul style="list-style-type: none"> Regulatory compliance Corporate governance Anti-bribery compliance Health and safety Legal and regulatory adherence 	<ul style="list-style-type: none"> Audits Bursa Malaysia announcements Certifications Meetings and correspondence Workshops and seminars 	<ul style="list-style-type: none"> Compliance with applicable laws and regulations, including ACE Market Listing Requirements, Companies Act, and other relevant frameworks Implementation of Anti-Bribery and Corruption policies in line with governance best practices Strengthening internal controls, compliance monitoring, and risk management processes Commitment to occupational safety and health standards
<p>Local Communities & Public</p> 	<ul style="list-style-type: none"> Employment opportunities Economic contribution Community engagement Environmental impact 	<ul style="list-style-type: none"> Community engagement initiatives Internship programmes CSR activities Public communication 	<ul style="list-style-type: none"> Contribution to local economic development through employment and business activities Implementation of CSR and community engagement initiatives Responsible environmental practices, including proper waste management Ongoing efforts to minimise environmental impact and support sustainable development
<p>Analyst/Media</p> 	<ul style="list-style-type: none"> Financial performance Business growth Corporate governance Market positioning 	<ul style="list-style-type: none"> Financial announcements Annual Report Bursa Malaysia announcements Analyst briefings Media engagements 	<ul style="list-style-type: none"> Timely, accurate, and transparent public disclosures Clear communication of financial and sustainability performance Upholding strong governance and ethical business conduct Enhancing corporate reputation and stakeholder confidence



Risk Assessment

Risk Assessment refers to MGRC's sustainability factors that could create a bad reputation, such as by greenwashing or harming the company financially. The Stakeholder ESG Risk, Opportunities & KPI Table explain the mapping on two concerns, namely, key audit risk and key audit focus, with the integration with the mission of MGRC. This is based on the risk assessment via internal reports and discussions with internal stakeholders. We divided the key risks into three factors that relates to business economic sustainability, namely operational efficiency, operation disruptions and business expansion challenges.

Operational efficiency is concerned with how well a worker's talents are converted into his or her experiences on the cognitive level. As a result, the operating process is the work that they accomplish, and it will be evaluated based on how long it takes to complete a task, how much material is used, and how well the process produces its output. The publication of this information is desired in sustainability programmes. The concept goes beyond cost management because it also incorporates sustainability strategies that investigate the processes involved in producing goods or providing services.

Operational disruptions. Operations will therefore be less efficient when there are interruptions. The indications under this are to limit the disruption risk, employee training, growth, and retention because the nature of business is employee- or people-centric. This is because improving operational efficiency calls for regular work and a strong commitment to ongoing education. To do that, MGRC must do a process analysis to align the business strategy and goals to talents, establish a skills inventory and performing skill-gap analysis as well as exit interview data analysis to gather information to identify potential area for improvement.

The culture and values of a sustainable organisation are said to be linked to operational disruptions and operational efficiency. As a result, it develops a technique for connecting issues with business expansion to suggested corporate principles (Innovative, Accountability, and Sustainability). This is because long-term business success is dependent on strong business connections with internal and external stakeholders that are founded on corporate principles. The KPIs will track things like product quality and safety, customer retention rate, and cost-effectiveness.

Stakeholder ESG Risk, Opportunities & KPI Table

Stakeholders	Key Risks	Opportunities	Key Performance Indicators (KPIs)
Shareholders/ Investors	<ul style="list-style-type: none"> Weak financial performance impacting returns Failure to integrate ESG risks into strategy Non-compliance with Bursa Malaysia Listing Requirements 	<ul style="list-style-type: none"> Strengthen investor confidence through transparency Attract ESG-focused investments Enhance long-term business resilience 	<ul style="list-style-type: none"> Revenue growth (%) Profit margin (%) Timeliness of disclosures
Employees	<ul style="list-style-type: none"> High turnover and talent loss Workplace safety incidents Low engagement/productivity 	<ul style="list-style-type: none"> Build skilled and future-ready workforce Enhance retention and employer branding Improve productivity through training 	<ul style="list-style-type: none"> Employee turnover rate (%) Training hours per employee
Customers	<ul style="list-style-type: none"> Poor service/product quality Data privacy breaches Inability to meet market expectations 	<ul style="list-style-type: none"> Strengthen customer loyalty Develop innovative, affordable solutions Enhance brand reputation 	<ul style="list-style-type: none"> Number of complaints resolved
Suppliers	<ul style="list-style-type: none"> Supply chain disruptions Engagement with non-compliant suppliers Payment delays affecting relationships 	<ul style="list-style-type: none"> Build resilient and sustainable supply chain Strengthen long-term partnerships Promote ESG adoption in supply chain 	<ul style="list-style-type: none"> Supplier evaluation score (%) Average payment days
Government / Regulators	<ul style="list-style-type: none"> Regulatory non-compliance Exposure to bribery/corruption risks Health & safety breaches 	<ul style="list-style-type: none"> Strengthen governance and compliance culture Enhance corporate reputation Improve internal controls 	<ul style="list-style-type: none"> Number of regulatory breaches Anti-bribery training sessions (no.)
Local Communities & Public	<ul style="list-style-type: none"> Environmental impact from operations Weak community engagement Failure to support local economy 	<ul style="list-style-type: none"> Enhance reputation through CSR Support local employment Promote environmental responsibility 	<ul style="list-style-type: none"> Number of CSR programmes Local hiring rate (%) Community engagement activities (no.)
Analysts / Media	<ul style="list-style-type: none"> Negative publicity Miscommunication of performance Reputational risk impacting share price 	<ul style="list-style-type: none"> Strengthen market perception Enhance transparency and credibility Improve investor confidence 	<ul style="list-style-type: none"> Timeliness of disclosures Media engagements (no.)



Material Sustainable Matters

In the previous reporting period, MGRC conducted a materiality assessment based on insights gathered from both internal and external stakeholders through various engagement platforms. The materiality assessment process involved identifying relevant sustainability topics, obtaining stakeholder feedback on these topics, and subsequently prioritising them based on their significance. Material topics were derived from ongoing stakeholder engagements and aligned with the Group's operational and strategic context.

Our materiality assessment process followed three key stages:

IDENTIFICATION

- We undertook comprehensive stakeholder engagement to identify sustainability matters of concern. This included consultations with internal and external stakeholders.

REVIEW AND VALIDATION OF PROCESS AND OUTCOME

- The outcome of the materiality assessment was presented to the GM and EC for review and validation

PRIORITISATION


- Employing the concept of materiality, we evaluated the potential impacts of each identified sustainability matter on the Group's operations and strategy, as well as on our stakeholders interest.
- We further assessed the likelihood of each matter to significantly influence the decision of our stakeholders
- This information was used to prioritise the identified matters, highlighting those with the greatest potential impact and relevance.

The results of the materiality assessment are presented in the Materiality Matrix , where the identified topics are categorised into high, medium, and low priority based on their level of importance to both MGRC and its stakeholders. Topics positioned in the high priority quadrant represent the most critical areas requiring immediate focus and strategic attention, while medium and low priority topics continue to be monitored and managed accordingly. A total of thirteen (13) material topics were identified and prioritised through this process.

These outcomes enable the Group to refine its sustainability strategy, strengthen its reporting approach, and focus resources on areas that are most impactful to the business and stakeholders. For the financial year ended 31 December 2025, the Group has reviewed its materiality assessment and noted that there are no significant changes to the identified material topics. The existing prioritisation remains relevant and continues to reflect the Group's key sustainability priorities and stakeholder expectations.



FY 2025 Materiality Matrix





Indicators Covered In Materiality Assessment

Environment

Priority :

High Priority

Material Matters :

Environmental Impacts

Description :

Focusing on the responsible management of waste, water and energy consumption, while taking measures to reduce greenhouse gas (“GHG”) emissions and minimise the environmental impact of our operations.

Related UN's SDG :



Social

Priority :

High Priority

Material Matters :

Human Rights

Description :

Assessing how the Group's business activities, products and services may affect human rights, and taking appropriate steps to prevent, mitigate and address any adverse impacts.

Related UN's SDG :



Priority :

High Priority

Material Matters :

Fair Employment Practices

Description :

Promoting diversity, equal opportunity and merit-based employment practices, while eliminating all forms of discrimination and fostering a fair, inclusive and respectful workplace

Related UN's SDG :



Priority :

High Priority

Material Matters :

Employee well-being

Description :

Safeguarding the physical, mental and emotional well-being of employees by promoting a supportive, healthy and conducive working environment

Related UN's SDG :



Priority :

High Priority

Material Matters :

Human Capital Development

Description :

Undertaking initiatives to enhance employee competencies, create career progression pathways and expand opportunities for talent development to support long-term organisational growth.

Related UN's SDG :



Priority :

High Priority

Material Matters :

Occupational Safety and Health (“OSH”)

Description :

Taking appropriate measures to identify workplace hazards, manage safety risks and prevent work-related injuries, illnesses and unsafe conditions

Related UN's SDG :



Priority :

Low Priority


Material Matters :

Community Development

Description :

Contributing positively to local communities through charitable contributions, community engagement, internships, awareness programmes and other corporate social responsibility (“CSR”) initiatives

Related UN's SDG :





Indicators Covered In Materiality Assessment (Continued)

Economic Governance

Priority :
High Priority

Material Matters :
Regulatory
Compliance

Description :
Ensuring compliance with applicable laws, regulations, standards and listing requirements in all aspects of the Group’s business processes in order to safeguard public health, safety, integrity and stakeholder trust.

Related UN’s SDG :



Priority :
High Priority

Material Matters :
Data Security

Description :
Implementing measures to protect customers’ privacy and personal data, and safeguarding information against unauthorised access, misuse, loss or breach.

Related UN’s SDG :



Priority :
High Priority

Material Matters :
Customer Value
Creation

Description :
Providing products and services that are innovative, accessible and affordable to a broader range of customers, while enhancing customer satisfaction and supporting inclusive and sustainable value creation.

Related UN’s SDG :




Priority :
Medium Priority

Material Matters :
Business
Development

Description :
Pursuing sustainable business growth through innovation, strategic partnerships, market expansion and continuous improvement in products and services, while considering long-term economic resilience.

Related UN’s SDG :




Priority :
Medium Priority

Material Matters :
Supply Chain
Management

Description :
Integrating ethical, environmentally and socially responsible practices across the supply chain lifecycle, including supplier selection, evaluation and ongoing engagement

Related UN’s SDG :



Priority :
Low Priority

Material Matters :
Sustainable
Production

Description :
Encouraging efficient use of resources, reduction of waste, process optimisation and adoption of sustainable practices in operational and production activities, where applicable.

Related UN’s SDG :





Environmental (GRI 3-3)

Responsible Waste Management (GRI 306-1, 306-2, 306-3, 306-4, 306-5)

MGRC generates minimal waste from its operations and remains committed to complying with all applicable environmental laws and regulations to ensure that any waste by-products do not adversely impact the surrounding environment or communities.

The Group adopts responsible waste management practices to mitigate environmental and health risks. These include the proper handling, treatment, and disposal of waste, particularly those associated with biological and medical processes.

Specifically, waste materials that pose bio-contamination risks are subjected to decontamination through the use of autoclave equipment to neutralise pathogens prior to disposal. Potentially hazardous biological waste is securely stored in designated containment areas to prevent leakage, contamination, or unintended exposure. In addition, the Group engages licensed and professional medical waste disposal service providers to ensure that all waste is managed and disposed of in accordance with regulatory requirements and industry best practices.

Through these measures, MGRC aims to minimise its environmental footprint while maintaining a safe and compliant operational environment.

Clinical Waste Management

Item	FY2024	FY2025
Total waste generated (tonnes)	6.32	6.86

Reducing Our Energy Consumption (GRI 302-1)

MGRC is committed to improving energy efficiency across its operations in order to reduce reliance on non-renewable resources and minimise environmental impact. The Group adopts a proactive approach in managing energy consumption through continuous monitoring, operational controls, and the adoption of energy-efficient technologies.

To support this commitment, MGRC implements the following energy management practices:

- Regular monitoring and tracking of energy consumption across its facilities to identify opportunities for improvement;
- Periodic assessment of equipment energy efficiency to ensure optimal performance;
- Encouraging energy-saving practices among employees, including switching off equipment and energy sources when not in use, particularly during non-peak hours and break periods;
- Installation of motion-activated tinted sliding doors to optimise air-conditioning usage and reduce electricity consumption;
- Utilisation of energy-saving LED lighting throughout the Group's facilities; and
- Compliance with all applicable environmental laws and regulations. To date, the Group has not received any environmental-related complaints.

Through these initiatives, MGRC aims to enhance operational efficiency while contributing to environmental sustainability and responsible resource management



Energy Consumption

Item	FY2024	FY2025
Total energy consumption (kWh)	398,627	396,057

Water Consumption (GRI 303-5)

The Company is committed to promoting responsible water management and conservation across its operations. Efforts are made to encourage employees to adopt prudent water usage practices as part of the Group's broader sustainability initiatives.

Water Management

Item	FY2024	FY2025
Total water consumption (m ³)	856	851

Reducing Our Carbon Footprint (GRI 305-2, 305-3)

The reduction of greenhouse gas ("GHG") emissions remains an integral part of the Group's sustainability agenda. During the current financial year, the Group has taken its first steps towards formalising its GHG emissions inventory, marking an important milestone in quantifying and managing its carbon footprint.

At this stage, the Group's emissions data remains limited. Scope 1 emissions have not been established due to the absence of relevant data, while Scope 3 emissions currently cover only one category, namely employee commuting. All emissions are calculated based on methodologies and emission factors derived from the Greenhouse Gas Protocol.

Scope 2 Emissions

Scope 2 emissions arise from the consumption of purchased electricity used in the Group's office and operational equipment.

Item	FY2024	FY2025
Total scope 2 emission (tonnes)	276	293

Environmental Compliance

Item	FY2024	FY2025
Incidents of non-compliance with environmental laws and regulations	0	0

In FY2025, the Group recorded no instances of non-compliance with environmental laws and regulations resulting in fines or penalties. While no formal Environmental Impact Assessments (EIA) were required or implemented for new projects delivered during the year, the Group recognises the growing importance of proactive environmental integration within its business operations.

Moving forward, as the Group further expands its service portfolio, it intends to integrate environmental considerations into the early stages of project planning and infrastructure deployment. By embedding these considerations into its core business segments, the Group aims to transition from a status of baseline regulatory compliance to a more proactive model of environmental stewardship ensuring long-term sustainability for both the business and the communities it serves.



Social

Human Rights (GRI 406-1)

MGRC is committed to upholding fundamental human rights across all aspects of its operations. The Group maintains a zero-tolerance approach towards discrimination and ensures that all business activities are conducted in a manner that respects the dignity, rights, and well-being of all individuals.

Human rights considerations are embedded within the Group’s risk assessment processes to identify, prevent, and mitigate potential adverse impacts on stakeholders, including employees, customers, and the wider community. In addition, ongoing stakeholder engagement enables the Group to better understand and address concerns relating to human rights matters.

Human Rights

Item	FY2024	FY2025
Complains regarding violations of human rights	0	0
Discrimination cases	0	0


Fair Employment Practices (GRI 2-7, 202-2, 405-1, 405-2)

At MGRC, we are committed to building and sustaining a diverse and dynamic workforce comprising individuals from various ethnicities, cultural backgrounds, age groups, experiences, and skill sets. We believe that diversity fosters broader perspectives, enhances creativity, and drives innovation and productivity across the organisation.

The Group upholds fair and non-discriminatory employment practices in all aspects of its operations, including recruitment, remuneration, training, and career progression. All employment-related decisions are based on merit, qualifications, and performance, ensuring equal opportunities for all employees.

In line with our commitment to supporting local talent, the majority of the Group’s senior management positions are held by individuals from the local community (Malaysians), reflecting our contribution towards national workforce development and inclusive growth.

Statistics of our employees



Workforce and Diversity

Item	FY2024
Total number of employees	33

Category	Male	Female
Management	1	1
Executive	6	25
Total	7	26

Age Group	Below 30	Age 31-50	Above 50
Management*	-	2	-
Executive	18	13	-
Total	18	15	-

Note:

* Management consists of Executive Chairman/Managing Director and Acting General Manager

Employees Well-being (GRI 202-1, 401-1)

At MGRC, our approach to employee well-being extends beyond financial compensation to fostering a supportive environment where employees' overall happiness, work-life balance, and physical and mental health are prioritised. The Group recognises that a high employee turnover rate may disrupt business operations and impact organisational performance. As such, we strive to retain talent by providing a conducive working environment and meaningful opportunities for career growth and advancement.

To strengthen employee engagement and a sense of belonging, the Group promotes a collaborative and inclusive workplace culture through various initiatives. These include team-building programmes, townhall sessions, festive celebrations, departmental gatherings, and other social activities aimed at fostering camaraderie and teamwork. In addition, confirmed employees are offered complimentary genetic screening tests as part of the Group's health and wellness benefits, enabling them to better understand and manage their health.

The Group remains committed to managing and retaining its talent in a sustainable manner. Moving forward, MGRC aims to further enhance employee engagement and strengthen its internal risk assessment processes to support a safe, inclusive, and equitable workplace. Through continuous dialogue and open communication, the Group seeks to cultivate a culture of trust, collaboration, and innovation, recognising that employee feedback and diverse perspectives are key drivers of long-term performance and organisational success.

In terms of fair remuneration, the Group ensures that its salary structure is competitive and above the statutory minimum wage requirements prescribed under the Minimum Wages Order 2022 and Minimum Wages Order 2024 in Malaysia. This reflects MGRC's commitment to providing fair and equitable compensation, while supporting the financial well-being of its employees.

MGRC also ensures full compliance with applicable labour laws, including the timely contribution of statutory benefits such as the Employees Provident Fund (EPF) and Social Security Organisation (SOCSO).



Human Capital Development (GRI 404-1, 404-2)

MGRC recognises its employees as its most valuable asset and a key driver of the Group's success. Operating within a highly specialised industry, where the nature of work requires significant technical expertise and a steep learning curve, the retention of skilled and experienced personnel is essential to ensure operational effectiveness and continuity.

In today's dynamic and competitive business environment, the Group places strong emphasis on continuous learning and development to equip employees with the necessary skills and competencies to perform effectively and advance their careers over the long term. Employees are encouraged to participate in company-sponsored training programmes, with at least one training session provided annually. The Group continues to identify and facilitate relevant training opportunities to enhance employees' knowledge, capabilities, and overall contribution to the organisation.

Through these initiatives, MGRC aims to build a sustainable talent pipeline and empower employees to take on future leadership roles within the Group. During the reporting period, employees attended an average of 8.95 training hours (2024: 11 hours).

In addition, MGRC contributes to the development of local talent by providing employment opportunities for graduates, particularly within the biotechnology sector. The Group recognises the challenges faced by graduates in securing employment within their field of study and seeks to bridge this gap through strategic collaborations with educational institutions.

Occupational Health And Safety (GRI 403-1, 403-2, 403-3, 403-4, 403-5, 403-6, 403-7, 403-9, 403-10)

MGRC places the highest priority on the health, safety, and well-being of its employees, recognising that a safe working environment is fundamental to sustainable operations. The Group provides a clean, well-maintained, and air-conditioned workplace, along with access to safe drinking water, to ensure a comfortable and conducive working environment for all employees.

To further safeguard employee safety, MGRC has established a comprehensive Emergency Response Plan. This includes the appointment of designated Floor Marshals across all levels of the facility, the formation of an emergency response team equipped with first aid kits, and the provision of emergency showers in laboratories for use in the event of exposure to hazardous substances. In addition, the Group maintains clear standard operating procedures ("SOPs") covering emergency assembly points, evacuation routes, and the use of fire-fighting equipment such as fire extinguishers.

Appropriate personal protective equipment ("PPE") is also provided to employees based on the nature of their work. While laboratory personnel are required to wear standard lab coats, employees in specialised environments, such as the cell laboratory, are equipped with additional protective gear to safeguard against potential exposure to hazardous or contagious materials.

The Group actively engages with employees to gather feedback on workplace safety and address any concerns in a timely manner. Regular communication and awareness initiatives are conducted to reinforce the importance of adhering to established health and safety procedures.

During the financial year, the Group recorded zero (2024 zero) work-related injuries and work-related ill health cases, and to date, there have been no incidents of fatalities within the Group's operations. This reflects MGRC's ongoing commitment to maintaining a safe and secure working environment for all employees.

To ensure safety standards is practiced consistently, the Group has implemented proactive monitoring and reporting systems. The success of these frameworks is reflected in the Occupational Safety and Health ("OSH") records for FY2025:

Item	FY2025
Work-Related Fatalities	0
LTIs	0
Workers On Long Convalescence	0

Employee Engagement and Community Contribution

The Group places strong emphasis on cultivating employee engagement as an integral pillar of its workplace culture and communication approach. As such, the Group strives to foster an environment where employees feel consistently valued, motivated and empowered. In line with this commitment, the Group has strategically strengthened its employee engagement and community contribution efforts in FY2025 through a series of initiatives aimed at enhancing teamwork, promoting well-being and encouraging social responsibility.

Social and Recreational Activities

Activity	Timeline	Details
Malaysian Genomics Resource Centre Berhad Corporate Teambuilding & Engagement	3-4 January 2025	A corporate teambuilding programme designed to strengthen teamwork, improve communication and foster stronger relationships among employees across departments.
Festive Celebrations (e.g. Chinese New Year, Hari Raya, Merdeka Celebration, Malaysia Day, Deepavali, Christmas)	Various dates in 2025	Organised festive celebrations to promote cultural diversity, strengthen employee engagement and foster an inclusive workplace environment.

Health and Wellness Activities

Activity	Timeline	Details
Zumba	22 August 2025	A health and wellness initiative aimed at promoting active lifestyles, enhancing physical well-being and encouraging employee participation in fitness activities.

Economic Governance

Regulatory Compliance (GRI 2-27, 416-1, 416-2, 417-1, 417-2, 417-3)

MGRC is committed to upholding its responsibility towards customers by consistently delivering high-quality products and services. The Group recognises that maintaining product quality and driving continuous improvement are essential to sustaining business performance in an increasingly dynamic and competitive environment.

To ensure that its offerings meet established standards and customer expectations, MGRC has obtained the relevant certifications and adheres to applicable quality requirements. These measures support the reliability, safety, and effectiveness of the Group's products and services.

The Group also emphasises continuous improvement by regularly reviewing its processes and incorporating feedback to enhance service delivery and customer satisfaction. Through these efforts, MGRC aims to build long-term trust and deliver sustainable value to its customers.

Our facility has successfully obtained the following ISO certifications:

Certification	Details
ISO 9001:2015	Standards to meet the needs of customers and stakeholders within the statutory and regulatory requirements related to products and services.
GMP Certificate of Compliance	National Pharmaceutical Regulatory Agency ("NPRA") certification for a facility that has met the respective acceptance criteria for the grade mentioned in accordance with the requirements of good manufacturing practice ("GMP") guide for Biosafety Level 2 ("BSL-2") laboratory.



MGRC remains committed to maintaining high standards of regulatory compliance, product quality, and customer safety. During the financial year, the Group recorded no instances of non-compliance with applicable laws and regulations, and no cases that resulted in monetary fines.

The Group also implements stringent quality control (“QC”) processes to ensure that all products and services meet the required safety and quality standards prior to release. In addition, MGRC adheres to relevant ISO and Good Manufacturing Practice (“GMP”) requirements in relation to product quality, labelling, and marketing communications.

The Group’s compliance performance for the financial year is summarised below:

Compliance Performance Summary

Area	Indicator	FY2024	FY2025
Regulatory Compliance	Number of instances of non-compliance with laws and regulations	0	0
	Number of cases resulting in monetary fines	0	0
Customer Health & Safety	Number of incidents of non-compliance relating to health and safety impacts of products and services	0	0
Product & Service Information & Labelling	Number of incidents of non-compliance (ISO & GMP related)	0	0
Marketing Communications	Number of incidents of non-compliance	0	0

These outcomes demonstrate MGRC’s continued commitment to product integrity, regulatory compliance, and responsible communication with its customers.

Data Security (GRI 418-1)

MGRC places strong emphasis on safeguarding customers’ personal information and recognises the importance of maintaining data confidentiality and integrity. The Group complies with the requirements of the Personal Data Protection Act 2010 (“PDPA”) and has implemented appropriate controls to protect customer data throughout its operations.

To enhance data protection, the Group adopts anonymisation practices in its laboratory processes, whereby customer samples are identified using serial numbers instead of personal identifiers. This approach minimises the risk of unauthorised access to customer identities and prevents potential misuse of sensitive information.

Data Privacy Performance Summary

Area	Indicator	FY2024	FY2025
Customer Data Privacy	Number of complaints relating to customer privacy	0	0
	Number of data breach incidents (leakage, theft or loss)	0	0
	Number of regulatory complaints on data protection	0	0

(GRI 3-3)

Customer Value Creation (GRI 203-1, 203-2)

MGRC's pricing strategies, strategic collaborations, and infrastructure investments have generated positive indirect economic impacts for both local and international stakeholders. The Group is committed to improving accessibility to innovative healthcare solutions by working closely with its partners to deliver more affordable and effective treatments to the public.

Through these efforts, MGRC aims to support long-term health and well-being while contributing to the reduction of premature mortality associated with non-communicable diseases. The Group also recognises the importance of expanding healthcare access, particularly for patients requiring urgent and life-saving treatments.

The Group's key strategies and their corresponding impacts are summarised below

Economic Strategies and Impact

Area	Key Initiatives	Impact
Pricing Policy and Strategy	Provision of cell therapy solutions at competitive pricing through strategic collaborations and operational efficiencies.	Enhances affordability and accessibility of advanced cell therapy treatments, particularly for patients requiring timely care.
Collaborative Efforts	Establishment of local and international partnerships to expand market reach and awareness; integration with digital health platforms	Broadens access to MGRC's products and services, enhances market penetration, and supports cross-industry innovation
Infrastructure Development	Establishment of a privately owned Biosafety Level 2 ("BSL-2") laboratory to support cell engineering services	Enhances in-house capabilities, supports innovation, and strengthens the Group's position in advanced healthcare solutions

In addition, MGRC continues to build strong local and global collaborations with various organisations to promote sustainable business practices and stimulate economic development. These partnerships facilitate the transfer of technology and knowledge across borders, particularly benefiting developing economies.

Business Development

MGRC continues to pursue sustainable business growth through strategic initiatives, innovation, and expansion into new markets and service offerings. The Group actively explores opportunities to enhance its product and service portfolio, particularly in areas aligned with its core expertise in genomics, biotechnology, and advanced healthcare solutions.

Business development efforts are supported by strategic collaborations and partnerships with local and international stakeholders, enabling the Group to expand its market reach, strengthen its capabilities, and drive innovation. These collaborations also facilitate knowledge sharing and support the development of new solutions that address evolving healthcare needs.

In addition, MGRC continues to diversify its business through targeted investments and expansion into downstream healthcare services, thereby strengthening its value chain and enhancing long-term revenue potential. The Group remains focused on identifying growth opportunities that are aligned with its sustainability objectives and contribute to long-term value creation for stakeholders.



Supply Chain Management

MGRC recognises the importance of maintaining a reliable, responsible, and efficient supply chain to support its operations and service delivery. The Group adopts a structured approach in the selection and management of suppliers, ensuring that procurement decisions are based on quality, compliance, cost-effectiveness, and reliability.

Where applicable, the Group practices competitive sourcing and evaluates suppliers based on their ability to meet the required standards, including product quality, delivery performance, and adherence to regulatory requirements. MGRC also maintains ongoing communication and engagement with its suppliers to ensure alignment with operational needs and expectations.

In line with its sustainability objectives, the Group is committed to promoting responsible practices across its supply chain. This includes encouraging suppliers to comply with applicable laws and regulations, uphold ethical business conduct, and adopt environmentally and socially responsible practices where feasible.

Moving forward, MGRC aims to further strengthen its supplier evaluation processes and enhance visibility over its supply chain to support long-term operational resilience and sustainability.

Future Priorities

Looking ahead, MGRC remains committed to strengthening its sustainability framework and advancing its long-term value creation through continuous improvement across environmental, social, and governance (“ESG”) aspects.

From an environmental perspective, the Group will focus on enhancing its data collection and monitoring capabilities, particularly in relation to greenhouse gas (“GHG”) emissions, with the aim of progressively expanding coverage across Scope 1, Scope 2, and Scope 3 emissions. The Group will also continue to improve energy and water efficiency, while promoting responsible resource management practices within its operations.

On the social front, MGRC will continue to invest in human capital development, employee well-being, and workplace safety. Efforts will be directed towards strengthening employee engagement, enhancing training and development programmes, and fostering a diverse, inclusive, and supportive work environment. The Group will also maintain its commitment to safeguarding human rights and ensuring fair employment practices across all levels of the organisation.

In terms of governance and economic sustainability, the Group aims to further strengthen its compliance, risk management, and data protection frameworks to ensure adherence to regulatory requirements and maintain stakeholder trust. MGRC will also continue to enhance its quality assurance processes to uphold product safety and reliability.

Additionally, the Group will focus on expanding its business through strategic collaborations, innovation, and investments in downstream healthcare services, while strengthening its supply chain management practices to support operational resilience. Through these initiatives, MGRC seeks to enhance accessibility to innovative healthcare solutions and contribute positively to the broader healthcare ecosystem.

Overall, MGRC remains committed to embedding sustainability into its business strategy and operations, ensuring that its growth is aligned with responsible practices and long-term stakeholder value creation.

GRI Context Index

Statement of use	Malaysian Genomics Resource Centre Berhad has reported the information cited in this GRI content index for the year 1 January 2025 to 31 December 2025 with reference to the GRI Standards.
GRI 1 used	GRI 1: Foundation 2021

GRI STANDARD	DISCLOSURE	LOCATION
GRI 2: General Disclosures 2021	2-1 Organizational details	20, 21, 22
	2-2 Entities included in the organization's sustainability reporting	20
	2-3 Reporting period, frequency and contact point	20
	2-4 Restatements of information	Not reported
	2-5 External assurance	Not reported
	2-6 Activities, value chain and other business relationships	26
	2-7 Employees	42
	2-8 Workers who are not employees	Not reported
	2-9 Governance structure and composition	Not reported
	2-10 Nomination and selection of the highest governance body	Not reported
	2-11 Chair of the highest governance body	Not reported
	2-12 Role of the highest governance body in overseeing the management of impacts	Not reported
	2-13 Delegation of responsibility for managing impacts	Not reported
	2-14 Role of the highest governance body in sustainability reporting	Not reported
	2-15 Conflicts of interest	Not reported
	2-16 Communication of critical concerns	Not reported
	2-17 Collective knowledge of the highest governance body	Not reported
	2-18 Evaluation of the performance of the highest governance body	Not reported
	2-19 Remuneration policies	Not reported
	2-20 Process to determine remuneration	Not reported
	2-21 Annual total compensation ratio	Not reported
	2-22 Statement on sustainable development strategy	20
	2-23 Policy commitments	23
	2-24 Embedding policy commitments	Not reported
	2-25 Processes to remediate negative impacts	Not reported
	2-26 Mechanisms for seeking advice and raising concerns	Not reported
	2-27 Compliance with laws and regulations	39
	2-28 Membership associations	21
	2-29 Approach to stakeholder engagement	26
	2-30 Collective bargaining agreements	Not reported
GRI 3: Material Topics 2021	3-1 Process to determine material topics	Not reported
	3-2 List of material topics	Not reported
	3-3 Management of material topics	34, 41
GRI 201: Economic Performance 2016	201-1 Direct economic value generated and distributed	Not reported
	201-2 Financial implications and other risks and opportunities due to climate change	Not reported
	201-3 Defined benefit plan obligations and other retirement plans	Not reported
	201-4 Financial assistance received from government	Not reported



GRI STANDARD	DISCLOSURE	LOCATION
GRI 202: Market Presence 2016	202-1 Ratios of standard entry level wage by gender compared to local minimum wage	37
	202-2 Proportion of senior management hired from the local community	36
GRI 203: Indirect Economic Impacts 2016	203-1 Infrastructure investments and services supported	41
	203-2 Significant indirect economic impacts	41
GRI 204: Procurement Practices 2016	204-1 Proportion of spending on local suppliers	Not reported
GRI 205: Anti-corruption 2016	205-1 Operations assessed for risks related to corruption	Not reported
	205-2 Communication and training about anti-corruption policies and procedures	Not reported
	205-3 Confirmed incidents of corruption and actions taken	Not reported
GRI 206: Anti-competitive Behavior 2016	206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	Not reported
GRI 207: Tax 2019	207-1 Approach to tax	Not reported
	207-2 Tax governance, control, and risk management	Not reported
	207-3 Stakeholder engagement and management of concerns related to tax	Not reported
	207-4 Country-by-country reporting	Not reported
GRI 301: Materials 2016	301-1 Materials used by weight or volume	Not reported
	301-2 Recycled input materials used	Not reported
	301-3 Reclaimed products and their packaging materials	Not reported
GRI 302: Energy 2016	302-1 Energy consumption within the organisation	34
	302-2 Energy consumption outside of the organisation	Not reported
	302-3 Energy intensity	Not reported
	302-4 Reduction of energy consumption	Not reported
	302-5 Reductions in energy requirements of products and services	N/A
GRI 303: Water and Effluents 2018	303-1 Interactions with water as a shared resource	Not reported
	303-2 Management of water discharge-related impacts	Not reported
	303-3 Water withdrawal	Not reported
	303-4 Water discharge	Not reported
	303-5 Water consumption	35
GRI 304: Biodiversity 2016	304-1 Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas	Not reported
	304-2 Significant impacts of activities, products and services on biodiversity	Not reported
	304-3 Habitats protected or restored	Not reported
	304-4 IUCN Red List species and national conservation list species with habitats in areas affected by operations	Not reported
GRI 305: Emissions 2016	305-1 Direct (Scope 1) GHG emissions	Not reported
	305-2 Energy indirect (Scope 2) GHG emissions	35
	305-3 Other indirect (Scope 3) GHG emissions	35
	305-4 GHG emissions intensity	Not reported
	305-5 Reduction of GHG emissions	Not reported
	305-6 Emissions of ozone-depleting substances (ODS)	Not reported
	305-7 Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant air emissions	Not reported



GRI STANDARD	DISCLOSURE	LOCATION
GRI 306: Waste 2020	306-1 Waste generation and significant waste-related impacts	34
	306-2 Management of significant waste-related impacts	34
	306-3 Waste generated	34
	306-4 Waste diverted from disposal	34
	306-5 Waste directed to disposal	34
GRI 308: Supplier Environmental Assessment 2016	308-1 New suppliers that were screened using environmental criteria	Not reported
	308-2 Negative environmental impacts in the supply chain and actions taken	Not reported
GRI 401: Employment 2016	401-1 New employee hires and employee turnover	37
	401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees	Not reported
	401-3 Parental leave	Not reported
GRI 402: Labor/ Management Relations 2016	402-1 Minimum notice periods regarding operational changes	Not reported
GRI 403: Occupational Health and Safety 2018	403-1 Occupational health and safety management system	38
	403-2 Hazard identification, risk assessment, and incident investigation	38
	403-3 Occupational health services	38
	403-4 Worker participation, consultation, and communication on occupational health and safety	38
	403-5 Worker training on occupational health and safety	38
	403-6 Promotion of worker health	38
	403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	38
	403-8 Workers covered by an occupational health and safety management system	Not reported
	403-9 Work-related injuries	38
	403-10 Work-related ill health	38
GRI 404: Training and Education 2016	404-1 Average hours of training per year per employee	38
	404-2 Programs for upgrading employee skills and transition assistance programs	38
	404-3 Percentage of employees receiving regular performance and career development reviews	Not reported
GRI 405: Diversity and Equal Opportunity 2016	405-1 Diversity of governance bodies and employees	36
	405-2 Ratio of basic salary and remuneration of women to men	36
GRI 406: Non-discrimination 2016	406-1 Incidents of discrimination and corrective actions taken	36
GRI 407: Freedom of Association and Collective Bargaining 2016	407-1 Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk	Not reported
GRI 408: Child Labor 2016	408-1 Operations and suppliers at significant risk for incidents of child labor	Not reported
GRI 409: Forced or Compulsory Labor 2016	409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor	Not reported
GRI 410: Security Practices 2016	410-1 Security personnel trained in human rights policies or procedures	Not reported
GRI 411: Rights of Indigenous Peoples 2016	411-1 Incidents of violations involving rights of indigenous peoples	Not reported



GRI STANDARD	DISCLOSURE	LOCATION
GRI 413: Local Communities 2016	413-1 Operations with local community engagement, impact assessments, and development programs	Not reported
	413-2 Operations with significant actual and potential negative impacts on local communities	Not reported
GRI 414: Supplier Social Assessment 2016	414-1 New suppliers that were screened using social criteria	Not reported
	414-2 Negative social impacts in the supply chain and actions taken	Not reported
GRI 415: Public Policy 2016	415-1 Political contributions	Not reported
GRI 416: Customer Health and Safety 2016	416-1 Assessment of the health and safety impacts of product and service categories	39
	416-2 Incidents of non-compliance concerning the health and safety impacts of products and services	39
GRI 417: Marketing and Labelling 2016	417-1 Requirements for product and service information and labelling	39
	417-2 Incidents of non-compliance concerning product and service information and labeling	39
	417-3 Incidents of non-compliance concerning marketing communications	39
GRI 418: Customer Privacy 2016	418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data	40



Malaysian Genomics Resource Centre Berhad
BMLR Transition Period

Date & Time: 2026-04-16_16:04:14
FYE 31/12/2025

Sustainability Matter	Metric	Measurement Unit	2025	Target	Assurance	Remarks
Anti-corruption	Employees Trained on Anti Bribery	Percentage	100	Target under development. To be established in FY 2026.	Internal	
Diversity	Employees by gender - Male	Percentage	21	Target under development. To be established in FY 2026.	Internal	
Diversity	Employees by gender - Female	Percentage	79	Target under development. To be established in FY 2026.	Internal	
Diversity	Employees by age group - Executive to management <30	Percentage	55	Target under development. To be established in FY 2026.	Internal	Management consists of Executive Chairman/Managing Directors and Acting General Manager
Diversity	Employees by age group - Executive to management > 30	Percentage	45	Target under development. To be established in FY 2026.	Internal	
Diversity	Employee by Ethnicity - Bumiputera	Percentage	49	Target under development. To be established in FY 2026.	Internal	
Diversity	Employee by Ethnicity - Chinese	Percentage	39	Target under development. To be established in FY 2026.	Internal	
Diversity	Employee by Ethnicity - Indian	Percentage	12	Target under development. To be established in FY 2026.	Internal	
Diversity	Directors by Gender - Male	Percentage	67	Target under development. To be established in FY 2026.	Internal	
Diversity	Directors by Gender - Female	Percentage	33	Target under development. To be established in FY 2026.	Internal	
Diversity	Directors Age above 50 years	Percentage	33	Target under development. To be established in FY 2026.	Internal	
Diversity	Number of Board of Directors	Number	6	Target under development. To be established in FY 2026.	Internal	Included Executive Chairman/Managing Director
Diversity	Number of Independent Directors in the Board	Number	5	Target under development. To be established in FY 2026.	Internal	



Date & Time: 2026-04-16_16:04:14
FYE 31/12/2025

Malaysian Genomics Resource Centre Berhad
BMLR Transition Period

Sustainability Matter	Metric	Measurement Unit	2025	Target	Assurance	Remarks
Diversity	Number of Women Director in the Board	Number	2	Target under development. To be established in FY 2026.	Internal	
Energy Management	Total Electricity Consumption	Kilowatt-hour	396,057	Target under development. To be established in FY 2026.	Internal	
Energy Management	Total Clinical Waste Generated	Tonnes	6.66	Target under development. To be established in FY 2026.	Internal	
Labour Practices & Standards	Total Training Hours	Hours	295.5	Target under development. To be established in FY 2026.	No assurance	
Water Management	Total Water Consumption	Cubic Metres	851	Target under development. To be established in FY 2026.	Internal	
Environmental Compliance	Incidents of Non-Compliance with Environmental Laws and Regulations	Number	0	0	No assurance	
Human Rights	Complains Regarding Violations of Human Rights	Number	0	0	No assurance	
Human Rights	Discrimination cases	Number	0	0	No assurance	
Data Security	Complaints relating to Customer Privacy	Number	0	0	No assurance	
Data Security	Data Breach Incidents	Number	0	0	No assurance	
Data Security	Regulatory Complaints on Data Protection	Number	0	0	No assurance	
Scope 2 Emission	Consumption of Purchased Electricity	Tonnes	293	Target under development. To be established in FY 2026.	No assurance	



Corporate Governance

- 50** Corporate Governance Overview Statement
- 62** Other Compliance Information
- 63** Statement On Risk Management And Internal Control
- 67** Audit And Risk Management Committee Report
- 72** Disclosure of Financial Data for Shariah Screening



INTRODUCTION

The Board of Directors (“**Board**”) of Malaysian Genomics Resource Centre Berhad (“**MGRC**” or “**Company**”) acknowledges good corporate governance as its priority in conducting the business and affairs of the Company. The Board is responsible and committed in ensuring and maintaining the highest standard of corporate governance within the Company and adhering to the principles and best practices as prescribed by the Malaysian Code on Corporate Governance 2021 (“**Code**” or “**MCCG**”) with the objective of protecting and enhancing long-term shareholders’ values and stakeholders’ interests. This statement complies with Rule 15.25 of the ACE Market Listing Requirements (“**ACE LR**”) of Bursa Malaysia Securities Berhad (“**Bursa Securities**”) and shall be read together with the Corporate Governance Report (“**CG Report**”) of the Company for the financial year ended 31 December 2025.

The detailed application of each Practice as set out in the Code is disclosed in the CG Report can be downloaded from the Company’s website at www.mgrc.com.my.

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS

I. Duties and Responsibilities of the Board

The Board is responsible for, amongst others, establishing and communicating the strategic direction and corporate values of the Company, as well as supervising its affairs to strive for success within a framework of acceptable risks and effective controls in compliance with the relevant laws, regulations, guidelines and directives in the territories in which it operates.

The Board reviews management performance and ensures that the necessary financial and human resources are available to meet the objectives of the Company.

The duties and responsibilities of the Board include determining the Company’s overall strategic plans, performing periodic reviews of business and financial performance, and engaging in succession planning as well as adopting practical risk management and internal controls to implement a strong framework of internal controls for the Company.

In addition, the Board has delegated specific responsibilities to various Board Committees to assist the Board in the operations of the Company. The functions and Terms of Reference of the Board Committees have been clearly defined. There are two (2) Board Committees namely, the Audit and Risk Management Committee (“**ARMC**”), as well as the Nomination and Remuneration Committee (“**NRC**”). These Committees would deliberate and discuss the relevant issues within their respective Terms of Reference and thereafter report their recommendations to the Board for final approval and decision making.

The Company does not have a Chief Executive Officer (“**CEO**”) and the role typically assumed by Acting General Manager (“**Acting GM**”). The roles and responsibilities of the Executive Chairman/Managing Director and the Acting GM of MGRC are clearly defined. The Acting GM has the overall responsibility for the Company’s business operational matters with the objective of driving the Company and the Group towards achieving strategic goals and objectives, alongside the implementation of the Company’s policies, corporate strategies, and decisions.

All Board members participate fully in decisions on key issues involving the Company. The Executive Chairman/Managing Directors, assisted by the Acting GM and the key senior management, are responsible for implementing the policies and decisions of the Board and managing the Company’s day-to-day operations. Together with the Independent Non-Executive Directors, they ensure that strategies are thoroughly discussed and examined, taking into account the long-term interests of various stakeholders, including shareholders, employees, financiers, customers, suppliers, and other communities.

The Independent Non-Executive Directors play an important role in providing unbiased and independent judgement to ensure a balance, and impartial Board decision-making process.

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS *(Continued)***I. Duties and Responsibilities of the Board** *(Continued)***1.1 Code of Conduct and Ethics**

The Board recognises the need to formalise and commit to ethical values through a Code of Conduct, and the implementation of appropriate internal systems to support, promote and ensure compliance. The Board has also established a Code of Conduct and Ethics,

The Code of Conduct and Ethics sets out basic principles to guide all the Directors of the Company and its subsidiaries, on the appropriate standards of conduct and ethical behaviour for Directors.

II. Board Composition

During the financial year, the Board consists of six (6) members, of which one (1) is the Executive Chairman/Managing Director and five (5) are Independent Non-Executive Directors, thus fulfilling the ACE LR, which stipulates that at least one-third of the Board should comprise Independent Directors. The profiles of the current members of the Board are set out in the section entitled Profile of Directors in this Annual Report.

The Board is of the opinion that its composition reflects a balance of Executive and Non-Executive Directors, ensuring that the interests of not only the Company but also its stakeholders and the public are upheld in the formulation and adoption of business strategies. Collectively, the Directors combine their diverse commercial, regulatory, industry, and financial experience to add value to the Board as a whole.

The Company has complied with Practice 1.4 of the MCCG, as the Chairman of the Board is not a member of the ARMC and the NRC. Additionally, the Company has complied with Paragraph 15.02(1)(b) of the ACE LR of Bursa Securities, as it currently has two (2) female Board members.

III. Appointment to the Board

To adhere to best practices in the appointment of new Directors, a formal and transparent procedure is followed. The NRC, consisting exclusively of Non-Executive Directors, is responsible for making recommendations regarding any new appointments to the Board. In making these recommendations, the NRC considers the individual's skills, knowledge, expertise, experience, professionalism, integrity, and other commitments. Any new nominations received are submitted to the Board for assessment and approval.

The Board has access to the services of the Company Secretar(ies), who ensures that all appointments are properly formalised. All necessary information is obtained from Directors for internal records and to comply with statutory obligations, including those under the Companies Act, 2016, the ACE LR, and other applicable regulations.

The Board actively supports diversity in the boardroom, including gender and ethnic diversity, as recommended by the Code. During the financial year, the Board comprises four (4) male and two (2) female directors.

In line with the recommendations of the Code, the Directors are required to notify the Chairman before accepting any new directorships and to disclose the time commitment expected for these new appointments.

As set out in the Policy, upon the existence of a casual vacancy or upon the decision of the Board to invite an additional Director to the Board, the NRC shall examine the current composition of the Board and pre-define the desired characteristics/profile of the new Director.

**PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS** *(Continued)***III. Appointment to the Board** *(Continued)*

In so doing, the Board shall:

- uphold and implement best practices relating to gender diversity in the Boardroom;
- uphold and implement best practices relating to ethnic diversity, in ensuring that at least two (2) of the three (3) main ethnic groups in Malaysia, are represented on the Board at all times;
- consider the kinds of professional qualification, skill sets, industry experience and profile that the new Director should have, in order to preserve an all-rounded and balanced Board; and
- consider and discuss other pertinent or relevant factors that may arise.

The existing Directors may then propose the name of any potential candidate to the Chairman of the Board, from:

- their own personal contacts; and/or
- a registry of Directors, such as that maintained by the NAM Institute for the Empowerment of Women Malaysia (NIEW) at <http://www.wcdregistry.com>, or the Malaysian Alliance of Corporate Directors at <http://www.macd.org.my>.

The Chairman of the Board shall, within the stipulated timeframe, formally disclose the names of the nominated potential candidates to all members of the Board.

Subsequently, the Board members shall deliberate and determine to whom the invitation for appointment shall be extended, considering all relevant factors.

The Chairman of the Board, or any individual Director, may approach the potential candidate to ascertain their willingness to accept the appointment to the Board of the Company.

Should the potential candidate consent to the appointment, the Chairman of the Board, or any individual Director, shall promptly inform the remaining Directors and the Company Secretary of the candidate's acceptance.

The Company Secretary shall thereafter prepare the requisite documentation, which shall include:

- Customer due diligence and background checks,
- Resolutions of the Board and Board Committee for approval,
- The relevant declarations and statutory forms, including the consent to act,
- Announcement templates to facilitate the Company's compliance with the necessary disclosure requirements to Bursa.

IV. Audit and Risk Management Committee

The composition of the ARMC, its terms of reference, and its activities for the financial year ended 31 December 2025 are outlined in the ARMC Report.

The performance of the ARMC is assessed annually by the NRC.

A comprehensive account of the activities undertaken by the ARMC, along with its roles and responsibilities for the financial year under review, is provided in the ARMC Report.

V. Nomination and Remuneration Committee

The current NRC comprises solely Non-Executive Directors namely the following:

1. Yap Kok Wei (Chairman, Independent Non-Executive Director);
2. Lim Kok Kiong (Member, Independent Non-Executive Director);
3. Tan Yiing Fung (Member, Independent Non-Executive Director).

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS *(Continued)***V. Nomination and Remuneration Committee** *(Continued)*

The principal objectives of the NRC which also forms part of the Fit and Proper Policy are:

- a. to assist the Board in nominating new nominees of Board members;
- b. to assess the Board in overseeing the selection of, and assessing the performance of, the Directors of the Company on an on-going basis;
- c. to assist the Board in assessing the remuneration packages of the Executive Directors;
- d. to assess the performance of the ARMC; and
- e. to assess the performance of the Independent Directors.

During the financial year under review, the activities carried out by the NRC included the following:

- Reviewed the terms of office of the ARMC and assessed its effectiveness as a whole and the individual ARMC members;
- Reviewed the length of service of each Independent Non-Executive Director and assessed their independence;
- Reviewed the meeting attendance of the Board and Board Committees;
- Reviewed the training programmes attended by the Directors;
- Reviewed and recommended to the Board, the re-election of the Directors who will be retiring at the forthcoming Annual General Meeting (“**AGM**”) of the Company;
- Reviewed and recommended to the Board, the retention of Independent Director in accordance with Practice 5.3 of the Code, if applicable;
- Reviewed the contribution and performance of the Board as a whole, and of each individual Director;
- Reviewed and recommended to the Board, the Directors’ Fees commencing from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the Company;
- Reviewed and recommended to the Board, the benefits payable to the Directors under Section 230 of the Companies Act 2016; and
- Reviewed the remuneration packages of the Executive Directors.

VI. Re-Election of Directors

Upon the recommendation of the NRC and the Board, the Directors who are standing for re-election are stated in the Notice of the Twenty-First (21st) AGM.

As set out in the Board Charter, all Directors are subject to retire by rotation. Directors shall retire from office at least once in every three (3) years, but shall be eligible for re-election. In accordance with the Company’s Constitution, one-third (1/3) of the Directors (including a Managing Director) or if their number is not a multiple of three, then the number nearest to one-third, are required to retire from office at the AGM in every subsequent year. The retiring Director may offer himself/herself for re- election.

Directors appointed to fill a casual vacancy or as an addition to the Board shall hold office only until the next AGM of the Company. He/she shall be eligible for re-election but shall not be taken into account in determining the Directors who are to retire by rotation at that meeting.

VII. Annual assessment of the Directors, Board as a whole and Board Committees

The NRC is required to assess the Board’s effectiveness in terms of its composition, roles and responsibilities, and whether the Board Committees have discharged their functions and duties in accordance with the terms of reference. The NRC assesses on an annual basis the composition of the Board to ensure that the Board has the appropriate mix of expertise and experience and collectively possesses the necessary core competencies for effective functioning and informed decision-making. All assessments and evaluations carried out by the NRC in discharging its functions have been well documented.

**PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS** *(Continued)***VII. Annual assessment of the Directors, Board as a whole and Board Committees** *(Continued)*

The Board has, through NRC, conducted the following annual assessments in the FYE 2025:-

- a) Directors' self-assessment;
- b) Evaluation of the effectiveness of the Board as a whole and Board Committees;
- c) Assessment of Independent Directors; and
- d) Review of the term of office and performance of the ARMC and each of its members.

The annual assessment of individual Directors, Board as a whole and Board Committees commences with the completion of a set of self-assessment forms detailing all assessment criteria to be completed by all Directors for evaluation by the NRC. Criteria for the self-assessment include self-ratings on the Director's knowledge, support of the goals of the Company, time commitment, and active participation on the Board.

Based on the assessments conducted for FYE 2025, the NRC was satisfied with the performance of the Board as a whole, the Board Committees and each individual Director.

VIII. Remuneration

The Board has adopted a policy on the assessment of Directors' performance and remuneration. The objective of the Company's policy on Directors' remuneration is to ensure that the level of remuneration is sufficient to attract and retain high-profile Directors with a wealth of experience in diversified industries. Extracts from the policy are set out in the ensuing sections below.

The Board believes the remuneration policy fairly supports the Directors' responsibilities and fiduciary duties in steering the Group to achieve its long-term goals and enhance shareholders' value. The Board offers a competitive remuneration package in order to attract, develop and retain talented individuals to serve as directors.

The determination of the remuneration for Non-Executive Directors is a matter of the Board as a whole. The level of remuneration for Non-Executive Directors reflects the amount paid by other comparable organisations, adjusted based on the experience and levels of responsibilities undertaken by the particular Non-Executive Director concerned. The remuneration package of Non-Executive Directors will be a matter to be deliberated by the Board, with the Director concerned abstaining from deliberations and voting on deliberations in respect of his individual remuneration. In addition, the Company also reimburses reasonable out-of-pocket expenses incurred by all the Non-Executive Directors in the course of their duties as Directors of the Company. The aggregate annual Directors' fees and other benefits payable are to be approved by shareholders at the Annual General Meeting based on the recommendations by the Board.

The aggregate remuneration paid or payable to all Directors of the Company during the financial year ended 31 December 2025 is listed on named basis as required pursuant to Practice 8.1 of the CG Report. The Company has not complied with Practice 8.2 of the MCCG which requires it to make the detailed disclosures on named basis for the remuneration of the top five (5) senior management in the bands of RM50,000.00. The Company has explained its departure from this practice in the CG Report.

IX. Tenure of Independent Directors

The NRC carries out the evaluation of independence for each Independent Director annually.

The NRC has undertaken a review and assessment of the level of independence of the Independent Directors during FYE 2025 and is satisfied that they are able to discharge their responsibilities in an independent manner. The independence of Directors is measured based on the criteria prescribed under the ACE LR of Bursa Securities, in which a director should be independent and free from any business or other relationship that could interfere with the exercise of independent judgement or the ability to act in the best interests of the Company.

The Independent Directors have also declared their independence to the Board under the annual Board evaluation process during the FYE 2025.

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS *(Continued)***IX. Tenure of Independent Directors** *(Continued)*

Following the amendment to ACE LR of Bursa Securities, which restricts the tenure of an Independent Director to twelve (12) years. Consequent thereto, none of the Independent Directors has exceeded a cumulative term of twelve (12) years as at the date of this Statement.

The Company do not have a policy which limits the tenure of its independent directors to nine (9) years. However, the Board takes note that the MCCG 2021 recommends that the tenure of an Independent Director shall not exceed a cumulative term of nine (9) years unless shareholders' approval is obtained to retain such Director as an Independent Director. The Company has adopted the approach that upon completion of nine (9) years, an Independent Directors may continue to serve on the Board subject to the Director's re-designation as a Non-Independent Director. If the Board intends to retain the Independent Directors who have served the Company exceeding a cumulative term of nine (9) years, the Board will need to justify and seek shareholders' approval at the AGM through a two-tier voting process in accordance with the MCCG 2021.

As of the date of this Statement, none of the Independent Directors has exceeded 9 years of tenure.

X. Board Meeting

The Board is scheduled to meet four (4) times a year at quarterly intervals, with additional meetings to be convened as and when necessary, in which important decisions are required to be made between the scheduled meetings. The meeting agenda for these meetings includes the review of quarterly financial results and announcements, business directions, business plans and budgets, risk management report, macro strategies and discussions on other major matters such as acquisitions, investments and disposals, if any.

Proceedings of, and resolutions passed at each Board Meeting are documented in the minutes and signed by the Chairman at the subsequent Board Meeting. In addition to Board Meetings, the Board exercises control over matters that require Board's approval via circular resolutions. These minutes and resolutions are kept at the registered office of the Company.

During the financial year under review, a total of five (5) Board Meetings were held and the attendance of the Directors during the aforesaid period were as follows:

Directors	No. of Meetings Attended
Mr Leong Yien Hung ³	5/5
Mr Yap Kok Wei	5/5
Ms Tan Yiing Fung ³	5/5
Mr Lim Kok Kiong ³	5/5
Mr Chung Eng Lam ³	5/5
Ms Ler Pei Fen ³	5/5
Encik Muhammad Badri bin Hussin ¹	2/2
Encik Mohd Shakir bin Shahimi ¹	2/2
Datuk Wira Mohammad Faizal bin Zainol ²	2/2
Encik Mohamad Ruzaini bin Hamzah ¹	1/2
Chih Yi May ¹	2/2

Remarks :

- (1) Resigned on 5 May 2025
 (2) Resigned on 9 May 2025
 (3) Appointed on 19 February 2025

**PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS** *(Continued)***XI. Supply of Information**

The agenda for the Board Meetings together with appropriate reports and information on the Company's business operations and proposal papers meant for Board's consideration, are circulated to all the Directors prior to the meetings in a timely manner to enable the Directors to review the material and obtain additional information or clarification prior to the meeting.

The Directors will be given the notice of meeting setting out the agenda items together with the relevant meeting materials in advance as early as practicable.

The Directors have access to all information within the Company as well as to the advice and services of the Company Secretar(ies), whether individually or as a whole, to assist them in the decision-making process. Where necessary, the Directors may engage independent professionals at the Company's expense on specific issues, to enable the Directors to discharge their duties by utilising the available knowledge and resources.

XII. Time Commitment

The Board is satisfied with the level of time commitment extended by the Directors in fulfilling their roles and responsibilities as Directors of the Company. This is evidenced by the majority attendance record of the Directors at Board meetings.

Directors are expected to have the relevant expertise in order to for them to contribute positively to the Company's performance and to channel sufficient time and attention towards carrying out their responsibilities to the Company and Group. The Board obtains this commitment from its new members at the time of appointment. The Board has established policies and procedures where a Director should notify the Chairman officially, before accepting any new Directorship from any other company and the notification shall set out the expectation and an indication of time commitment that will be spent on the new appointment. The Directors are able to devote sufficient time commitment to their roles and responsibilities as Directors of the Company.

XIII. Company Secretaries

Each Director has immediate and unrestricted access to the advice and services of the Company Secretary(ies) to ensure the effective functioning of the Board. The Company Secretary ensures that Board policies and procedures are followed and regularly reviewed, and is legally responsible for ensuring that each Director is informed of, and provided with guidance on, his/her duties, responsibilities, and powers.

The Directors are also regularly updated and advised by the Company Secretary on new statutory and regulatory requirements issued by relevant authorities, along with the implications of these changes on the Company and the Directors' duties and responsibilities. The Company Secretary is also responsible for ensuring the Group's compliance with all relevant statutory and regulatory requirements.

The Board ensures that the appointed Company Secretary(ies) possess the necessary experience and skills and act in accordance with the Code of Ethics for Company Secretaries.

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS *(Continued)***XII. Company Secretary** *(Continued)*

The responsibilities carried out by the Company Secretar(eis) among others, include the following:

- Preparation and submission of statutory forms to the Companies Commission of Malaysia;
- Proper maintenance of statutory records;
- Transmissions/submissions of corporate announcements/replies to the Bursa Securities;
- Drafting the necessary Notices of Meetings, Directors' Resolutions, Minutes of Directors' and Shareholders' meetings and other relevant documents under the direction and instruction of the Board of Directors;
- Attendance in general meetings such as AGM and Extraordinary General Meeting ("EGM");
- Attendance in Board and Board Committee meetings;
- Preparation of board papers for Board and Board Committee Meetings and general meetings where required; and
- Advising the Board on matters pertaining to the statutory requirements prescribed under the various statutes, rules and regulations, particularly the Companies Act 2016, the ACE LR of Bursa Securities and in general, such other matters relating to secretarial practice.

Directors' Training

All Directors save for newly appointed Director have undergone the Mandatory Accreditation program ("MAP") Part I and MAP Part II prescribed by Bursa Securities. Although the Board does not have a policy requiring each Director to attend a specific number and types of training sessions each year, the Directors are encouraged to attend continuous education programmes/seminars/conferences and shall as such receive further training from time to time to keep themselves abreast of the latest development in statutory laws, regulations and best practices, where appropriate, in line with the changing business environment and enhance their business acumen and professionalism in discharging their duties to the Group.

The Board has undertaken an assessment of the training needs of each of the Directors and ensured that all the Directors undergo the necessary training programme to enable them to effectively discharge their duties.

The respective Directors who have served during the financial year ended 31 December 2025 have attended training and related events as follows:

Directors	Seminars / Conferences / Training Programmes Attended
Lim Kok Kiong	Mandatory Accreditation Programme Part II ; Leading For Impact (LIP)
Chung Eng Lam	Mandatory Accreditation Programme Part II ; Leading For Impact (LIP)
Ler Pei Fen	Mandatory Accreditation Programme Part II ; Leading For Impact (LIP)
Yap Kok Wei	Mandatory Accreditation Programme Part II ; Leading For Impact (LIP)
Tan Yiing Fung	Mandatory Accreditation Programme Part II ; Leading For Impact (LIP)
Leong Yien Hung	Mandatory Accreditation Programme Part II ; Leading For Impact (LIP)

All the Directors will continue to attend relevant training and education programmes and events in order to keep themselves abreast of the latest economic, technological, commercial and industry-related developments with a view to continuing to discharge their duties and responsibilities effectively.

The Board encourages its Directors to attend talks, seminars, workshops, events and conferences to enhance their skills and knowledge to enable them to carry out their roles effectively as Directors in discharging their responsibilities. The Directors are briefed by the Company Secretary on the letters and circulars issued by Bursa Securities, if any, at every Board Meeting.

XIV. Board Charter

The Board has formalised and established a Board Charter to govern the manner in which the Company conducts its affairs.

The Board Charter and the terms of reference of the respective Board Committees are published in the Company's website, which serves as a reference for the Directors' fiduciary duties and functions of the Board Committees respectively.



PRINCIPLE B: EFFECTIVE AUDIT AND RISK MANAGEMENT

I. Effective Risk Management and Internal Control Framework

The Board acknowledges its responsibility for maintaining a sound system of internal controls within the Company. This system provides reasonable, but not absolute, assurance against material misstatement, loss, or fraud. The Board seeks regular assurance regarding the continuity and effectiveness of the internal control system through independent reviews conducted by the internal auditors.

The internal audit function operates independently within the Group and provides reasonable assurance that the Group's system of internal control and risk management is satisfactory and functioning effectively. An Internal Audit Planning Memorandum, outlining the scope of the internal audit, is presented to the ARMC for review.

The Details Information for the Company's internal control and risk management system are provided in the Statement on Internal Control and Risk Management section of this Annual Report.

II. Relationship with Auditors

The Company's independent external auditors play an essential role in ensuring the reliability of the Company's financial statements and providing the assurance of accuracy to shareholders. The Company has always maintained a formal and transparent relationship with its external auditors, in seeking professional advice and ensuring compliance with the Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

III. Assessment of Sustainability and Independence of External Auditors

The ARMC undertakes an annual assessment of the suitability and independence of the external auditors. The ARMC meets with the external auditors at least twice a year to discuss their audit plan, audit findings and the Company's financial statements.

At least two (2) of these meetings are held without the presence of the Executive Chairman/Managing Director and the Management. The ARMC also meets with the external auditors additionally whenever it deems necessary.

In addition, the external auditors are invited to attend the AGM of the Company and are available to answer shareholders' questions on the conduct of the statutory audit and the preparation and contents of their audit report.

IV. Code of Conduct and Ethics

The Board recognises the need to formalise and commit to ethical values through a Code of Conduct and Ethics, and the implementation of appropriate internal systems to support, promote and ensure compliance. The Board has also established a Code of Conduct and Ethics, which has been uploaded to the Company's website.

The Code of Conduct and Ethics sets out basic principles to guide all the Directors of the Company and its subsidiaries, on the appropriate standards of conduct and ethical behaviour for Directors. It covers the following areas:

- Compliance with laws, rules and regulations
- Corporate governance
- Conduct of business and fair dealing
- Conflicts of interest
- Use of non-public information and disclosure (insider trading)
- Use of company funds, assets and information
- Social responsibility and the environment
- Proper records and communication
- Spokesman
- Whistleblowing
- Breaches, waiver and review

PRINCIPLE B: EFFECTIVE AUDIT AND RISK MANAGEMENT *(Continued)***V. Whistleblowers**

The Company has adopted a Policy on Whistleblowing in order to provide a transparent and confidential process for dealing with concerns.

The following general principles are set out in the policy:

- All concerns raised by employees will be treated fairly and properly, as long as it is a genuine concern;
- The Company will not tolerate harassment or victimisation of anyone raising a genuine concern;
- Any individual making a disclosure will retain anonymity unless the individual agrees otherwise;
- The Company will ensure that any individual raising a concern is aware of who is handling the matter; and/or
- The Company will ensure no one will be at risk of suffering some form of reprisal as a result of raising a concern in any circumstances.

A grievance procedure is also clearly outlined in the policy.

The Board has also established Anti-Bribery and Corruption policy. The said policy and the whistleblowing policy are published at the Company's website as follows:

Anti-Bribery And Corruption Policy

The Company had adopted the Anti-Bribery and Corruption Policy that set out the policies and adequate procedures against bribery and corruption activities in the conduct of its business under the gazetted Section 17A of the Malaysian Anti-Corruption Commission (Amendment) Act 2018. The said policy can be assessed at the Company's website at www.mgrc.com.my under Corporate Governance section.

Whistleblowing policy

The Board has adopted a Whistleblowing Policy for the Group as a measure to promote the highest standard of corporate governance. The whistleblowing policy outlines the avenues for the Directors, employees and stakeholders to raise concerns or disclose in good faith any improper conduct within the Group and to enable prompt corrective action and measures to resolve them effectively. The said policy can be assessed at the Company's website at www.mgrc.com.my under Corporate Governance section.

VI. Sustainability and Corporate Social Responsibility

The Board is aware of the importance of business sustainability and has formalised a plan to promote sustainability in developing its corporate strategies, taking into account the impact on the environmental, social, cultural and governance aspects of business operations.

The Board also encourages management transparency by engaging in an open culture and two-way communication that encourages employee participation in every aspect of operational processes. The Company's activities on corporate social responsibilities for the financial year under review are disclosed in this Annual Report under the Sustainability Statement.

The Board is also mindful of establishing processes to safeguard employees' health and safety and put in place the necessary procedures to respond to potential possible incidents.



PRINCIPLE C: INTEGRITY IN CORPORATE REPORTING AND MEANINGFUL RELATIONSHIP WITH STAKEHOLDERS

I. Financial Reporting

In preparing the financial statements, the Directors are required to select appropriate accounting policies and to ensure that they are consistently applied and supported by reasonable and prudent judgements and estimates. The Directors are responsible for ensuring that the Company keeps proper accounting records that are accurate at all times, the financial position of the Company; thereby enabling them to ensure that the financial statements comply with the Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia. The Directors are also responsible to take such steps as are reasonable so as to safeguard the assets of the Company against fraud and other irregularities.

The Statement of Directors' Responsibility for preparing the Audited Financial Statements pursuant to Rule 15.26(a) of the ACE LR is set out in this Annual Report.

II. Shareholders

The Board recognises the importance of accountability to shareholders on all major developments affecting the Company. Information is disseminated to shareholders and investors through various channels, which include the website, annual financial results, annual reports, as well as where appropriate, circulars and press releases. The Board regularly reviews the information that has been disseminated to ensure consistent and accurate information is provided to shareholders of the Company.

The AGM is the principal forum for dialogue with shareholders and serves as a platform on which Directors may promote and encourage bilateral communications with its shareholders. In addition, the Company has complied with Practice 13.3 of the MCCG which is to leverage technology to conduct the remote general meeting and electronic voting.

The external auditors are also present in order to provide their professional and independent clarification on issues or concern raised by the shareholders, if any.

In line with the recommendations of the Code, the Chairman of the general meetings will inform the shareholders of their right to demand a poll at all general meetings.

The Company has adopted a Corporate Disclosure Policy which sets out the standard operating procedures and guidelines for the Board and Management to follow in relation to dissemination of information to shareholders.

III. Compliance with Applicable Malaysian Financial Reporting Standards

In presenting the annual audited financial statements and quarterly announcements of financial results to the shareholders, the Board is responsible for presenting a balanced and meaningful assessment of the Group's position and prospects and ensuring that the financial statements are drawn up in accordance with the Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

The ARMC assists the Board in scrutinising information for disclosure to ensure accuracy, adequacy and completeness.

IV. Compliance Statement

The Board has deliberated, reviewed and approved this Corporate Governance Overview Statement. The Board considers and is satisfied that the Company has fulfilled its obligation under MCCG 2021, ACE LR and all applicable laws and regulations throughout the FYE 2025.

This Corporate Governance Overview Statement was approved by the Board of Directors on 27 April 2026.

PRINCIPLE C: INTEGRITY IN CORPORATE REPORTING AND MEANINGFUL RELATIONSHIP WITH STAKEHOLDERS *(Continued)*

V. Statement of Directors' Responsibility

The Directors are required to take reasonable steps to ensure that the financial statements of Malaysian Genomics Resource Centre Berhad are drawn up in accordance with the Malaysian Financial Reporting Standards, International Financial Reporting Standards, and the requirements of the Companies Act 2016, so as to give a true and fair view of the state of affairs of the Group and the Company as at the end of the financial year and of the financial performance and the cash flows for the financial year then ended.

In preparing the financial statements for the financial year ended 31 December 2025, the Directors have:-

- adopted the appropriate accounting policies and has applied them consistently throughout the year;
- made reasonable and prudent judgments and estimates;
- ensured that all applicable accounting standards in Malaysia have been followed, subject to any material departure and explained in the financial statements; and
- prepared the financial statements on a going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for ensuring that the Group and the Company have maintained proper accounting records which disclose with reasonable accuracy in the financial position of the Group and the Company and enable them to ensure that the financial statements comply with the requirements of the Companies Act 2016.

The Directors are also responsible for taking reasonable steps to ensure that proper internal controls are in place to safeguard the assets of the Group and the Company, and to prevent and detect fraud and other irregularities and material misstatements.

This statement has been approved by the Board of Directors on 27 April 2026.



OTHER COMPLIANCE INFORMATION

1. AUDIT AND NON-AUDIT SERVICES

For the financial year ended 31 December 2025, the external auditors of the Company rendered audit and non-audit services to the Company, as follows:

	Group RM	Company RM
Audit service rendered		
Statutory audit	128,000	85,000
Non-audit service rendered		
Review of Statement on Risk Management and Internal Control and ISA70	5,000	5,000
	133,000	90,000

2. MATERIAL CONTRACTS

There were no material contracts entered into by the Company and its subsidiaries involving the interests of the Directors, major shareholders and any chief executive who is not a Director, either still subsisting at the end of the financial year ended 31 December 2025 or entered into since the end of the previous financial year except for those disclosed in the Financial Statements of the Group.

3. STATUS OF UTILISATION OF PROCEEDS FROM PRIVATE PLACEMENT

Proposed Utilisation of Proceeds from Private Placement	Proposed Utilisation Timeframe	Proposed Utilisation (RM'000)	Variation (#) (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated (RM'000)
Future viable investment	Within 24 months from completion	3,620	(60)	(2,560)	1,000
Working capital*	Within 12 months from completion	413	-	(413)	-
Estimated expenses	Upon completion	-	(60)	(60)	-
		4,033	-	(3,033)	1,000

* In the event the Company is unable to identify any suitable and viable opportunities within the time frame stipulated (or any extended time frame, if applicable), the proceeds allocated for future viable investments shall be utilised as working capital of the Group.

STATEMENT ON RISK MANAGEMENT AND INTERNAL CONTROL

INTRODUCTION

Pursuant to Rule 15.26(b) of ACE Market Listing Requirements (“**ACE LR**”), Bursa Malaysia Securities Berhad (“Bursa Securities”), the Board of Directors (“**the Board**”) of Malaysian Genomics Resource Centre Berhad (“**MGRC**”) is pleased to provide the following statement on the state of internal control and risk management of the Group, comprising the Company and its subsidiaries, which has been prepared in accordance with Practices 10.1 and 10.2 of the Malaysian Code on Corporate Governance issued by the Securities Commission Malaysia and the “Statement on Risk Management and Internal Control: Guidelines for Directors of Listed Issuers” issued by the Institute of Internal Auditors Malaysia and adopted by Bursa Securities.

The Company was incorporated on 18 May 2004 and was listed on the ACE Market of Bursa Securities on 5 October 2010.

The Board is pleased to share the key aspects of the Group’s internal control and risk management systems for the financial year ended 31 December 2025.

BOARD RESPONSIBILITY

The Board is responsible to maintain a sound risk management framework and system of internal control to safeguard shareholders’ investment and the Group’s assets, as well as to review the adequacy and integrity of the system of internal control and risk management. The responsibility to review the adequacy and integrity of the Group’s system of internal control and risk management is delegated to the Audit and Risk Management Committee, which is empowered under its terms of reference to seek assurance on the adequacy and integrity of the internal control and risk management system from Management and through independent reviews carried out by the internal audit function.

The Board confirms that it has a formal process for identifying, evaluating, and managing the significant risks faced by the Group for the financial year under review and that this process is ongoing.

However, as there are inherent limitations in any system of internal controls, such systems put into effect by the Management can only reduce but cannot eliminate all risks that may impede the achievement of the Group’s business objectives. Therefore, the internal control and risk management system can only provide reasonable, and not absolute, assurance against material misstatement or loss.

KEY ELEMENTS OF THE GROUP’S INTERNAL CONTROL AND RISK MANAGEMENT SYSTEM

Key elements of the Group’s internal control and risk management system established to facilitate the proper conduct of the Group’s businesses are described below:

1. Control Environment

Internal policies and procedures undergo constant improvements to ensure that they continue to support the Group’s business and operations. Internal policies and procedures pertaining to the Group’s business activities and operations are regularly reviewed and tested during the internal audit fieldwork conducted by the Internal Auditors. Recommendations for enhancements to such policies and procedures are then implemented/addressed.

The Group maintains a formal organisational structure. In addition, a formal set of Authority Limits is in place to establish and enhance the internal control system of the Group’s various operations.



1. Control Environment *(Continued)*

The Authority Limits set out the limits of authority with regards to the following areas:

- Statutory Requirements;
- Annual Budget and Business Plan;
- Capital Expenditure and Fixed Assets;
- Staff, Financial and Other Matters;
- Sales and Marketing; and
- Acquisitions and Disposals.

Every financial year, the Group issues an annual budget, which is approved by the Board.

The Audit and Risk Management Committee, which comprises three (3) Independent Non-Executive Directors, reviews all internal audit reports and has regular meetings with the Management on all major internal control and risk management issues highlighted by the outsourced internal audit function.

2. Processes for Identifying, Evaluating and Managing Risk

The Board recognises that the identification, evaluation and management of significant risks faced by the Group are ongoing processes.

The Board reviews internal control and risk management issues identified by the Management and maintains an ongoing commitment to strengthen the Group's control environment and processes as well as its risk management processes.

The Board has established a Risk Management Framework which incorporates the Group's risk appetite. The risk appetite defines the nature and extent of risks that the Group is willing to accept in pursuit of its strategic objectives. While sustainability-related risks are not yet formally integrated into the Group's Risk Management Framework, the Board and Management are taking steps to incorporate Environmental, Social, and Governance ("ESG") considerations into the Group's risk management processes on a progressive basis.

Identified risks are assessed using a structured Risk Matrix, which evaluates both the likelihood of occurrence and the potential impact on the Group's strategic, operational and project objectives.

Risks assessed to be outside the approved risk appetite are escalated to Management, the ARMC and the Board, together with appropriate mitigation strategies and action plans to ensure that such risks are effectively managed and monitored.

Clear reporting structures are in place to ensure proper monitoring of the Group's operations and regular quarterly reports are issued which monitor the Group's performance.

A. INTERNAL AUDIT FUNCTION

The Board has outsourced its internal audit function to external service provider, Kloo Point Consulting Group Sdn Bhd ("Internal Auditors").

The Internal Auditors report directly to the Audit and Risk Management Committee and prepare the Internal Audit Plan ("IAP") once a year for two (2) cycles. The IAP is reviewed and approved by the Audit and Risk Management Committee and subsequently by the Board of Directors.

During the financial year under review, the Internal Auditors conducted two (2) internal audit cycles as follows:

Cycle 1 (November 2025): Sales Order and Billing Process

- i. Contract review
- ii. Quotation process
- iii. Pricing policies and control
- iv. Receiving of customer orders
- v. Sales ordering process
- vi. Discount and selling price authorization process
- vii. Billing process

2. Processes for Identifying, Evaluating and Managing Risk (Continued)

A. INTERNAL AUDIT FUNCTION (Continued)

Cycle 2 (February 2026): Product Quality Control Process

- i. Quality assurance strategy, criteria and plan
- ii. Incoming inspection of raw materials
- iii. In-process and outgoing inspection
- iv. Documentation of testing procedures for quality assurance
- v. Recording of defects
- vi. Handling internal rejections and rework
- vii. Follow-up actions for defects/non-conformity issues

Internal audits are conducted based on the IAP covering the adequacy, effectiveness and efficiency of governance, risk management and internal controls. During the internal audits, areas where internal control deficiencies are noted, improvement opportunities are recommended and follow-up audits on corrective actions are carried out.

The Audit and Risk Management Committee deliberates on the internal audit reports, which include the audit findings, recommended corrective actions and Management responses in areas where there are significant risks and internal control deficiencies. The Board and the Management will continuously review and improve the existing risk management processes and the internal control system to ensure their adequacy and effectiveness in the dynamic business environment.

B. INTERNAL RISK EVALUATION, IDENTIFICATION AND MANAGEMENT PROCESS

In addition to the implementation of the recommendations of the outsourced internal audit function, the Management, through a Risk Management Working Committee, also conducts its own internal risk assessments regularly throughout the financial year.

During every financial year, the Risk Management Working Committee identifies key risk areas for the financial year as well as how such risks can be managed or mitigated. The Management then tables a report on its findings in the form of a Risk Management Report, before the Audit and Risk Management Committee and the Board as a whole.

The Risk Management Report sets out the following:

- a. Risk Categories;
- b. Risk Evaluation;
- c. Control Effectiveness;
- d. Risk Metrics;
- e. Risk Treatment Option; and
- f. Mitigated Risk.

The risk areas covered by the Risk Management Report include operational, project and strategic risks. Some of the high priority risks that were identified include operational improvements to prevent bribery and corruption, disruptions caused by server malfunctions, and the need to upgrade inventory management systems.

WHISTLEBLOWING POLICY

The Group has established a Whistleblowing Policy which provides an avenue for all employees and external stakeholders to voice or raises genuine concerns, improper conduct or wrongdoing in a responsible and appropriate manner without fear of any form of victimisation, harassment, retribution or retaliation. The Whistleblowing Policy is available on MGRC's website at www.mgrc.com.my.

During the financial year under review, the Group did not receive any whistleblowing reports. The Board remains committed to ensuring that the whistleblowing mechanism continues to be effective and accessible, and encourages stakeholders to report any concerns in good faith.



DATA PROTECTION & CYBERSECURITY

The Group is aware of the increasing importance of cybersecurity risks in its operations. While a formal cybersecurity framework or policy has not yet been established, the Group has implemented basic IT controls such as system access restrictions and data backup procedure to minimise the risk of data loss.

The Board and Management are in the process of evaluating the development of a more formalised IT governance and cybersecurity framework to strengthen the Group's overall IT resilience.

OPINION OF THE BOARD

The improvement of the system of internal control is a continuous process, and the Board maintains an ongoing commitment to strengthening the Group's internal control and risk management environment and processes.

Based on the internal processes which have been put into place by the Management, as well as the activities carried out by, and subsequent reports of the outsourced Internal Audit function, the Board is of the view that the Group's system of internal control and risk management is sufficiently sound and adequate to safeguard the shareholder's investments and Group's assets for the financial year under review.

The Board has received assurance from the Management that the Group's internal control and risk management system will be continuously assessed, monitored and improved in ensuring operations are continuously running adequately and effectively. Moving forward, the Group plans to undertake the following initiatives:

- Formal integration of sustainability and ESG-related risks into the Group's risk management framework;
- Development and implementation of a cybersecurity and IT governance framework; and
- Continuous improvement of internal policies and procedures in line with evolving regulatory and business requirements.

REVIEW OF THE STATEMENT BY EXTERNAL AUDITORS

Pursuant to Rule 15.23 of the ACE LR of Bursa Securities, the external auditors have reviewed this Statement on Risk Management and Internal Control for inclusion in the Annual Report for the financial year ended 31 December 2025. Their review was carried out in accordance with the Malaysian Approved Standard on Assurance Engagements, ISAE 3000 (Revised), Assurance Engagements Other than Audits or Reviews of Historical Financial Information and Audit and Assurance Practice Guide 3 ("AAPG 3") - Guidance for Auditors on Engagements to Report on the Statement on Risk Management and Internal Control included in the Annual Report. Based on review, they have reported to the Board that nothing has come to their attention that cause them to believe the statement intended to be included in the Annual Report is not prepared, in all material respects, in accordance with the disclosures required by Section 7 of the Statement on Risk Management and Internal Control (SORMIC) Guide 2025: Guidelines for Directors of Listed Companies, or is factually inaccurate.

AAPG 3 does not require the external auditors to consider whether the Directors' Statement on Risk Management and Internal Control covers all risks and controls, or to form an opinion on the adequacy and effectiveness of the Group's risk management and internal control system including the assessment and opinion by the Directors and Management thereon. The report from the external auditors was made solely for, and directed solely to, the Board of Directors in connection with their compliance with the ACE LR and for no other purposes or parties. The external auditors do not assume responsibility to any person other than the Board of Directors in respect of any aspect of this report.

CONCLUSION

The Board is of the view that the Group's internal control and risk management systems in place for the financial year under review and up to the date of the approval of this statement, are adequate to safeguard shareholders' investment and the Group's assets. However, the Board recognises that the development of risk management and internal control systems is an on-going process. Therefore, the Board is committed to continuously strengthen the Group's system of internal control and risk management.

This statement is made in accordance with a resolution of the Board of Directors passed on 27 April 2026.

AUDIT AND RISK MANAGEMENT COMMITTEE REPORT

The Board of Directors of the Company is pleased to present the Audit and Risk Management Committee Report which provides insights as to the manner the Audit and Risk Management Committee discharged its functions for the Group for the financial year ended 31 December 2025, in compliance with Rule 15.15(1) of the ACE Market Listing Requirements (“**ACE LR**”) of Bursa Malaysia Securities Berhad (“**Bursa Securities**”) as well as the Malaysian Code on Corporate Governance 2021 (“**MCCG 2021**”).

The principal objectives of the Audit and Risk Management Committee are to assist the Board in discharging its statutory duties and responsibilities in relation to corporate governance, internal control systems, risk management, management, accounting and financial reporting practices of the Company and its subsidiary and to ensure proper disclosure to the shareholders of the Company.

COMPOSITION OF AUDIT AND RISK MANAGEMENT COMMITTEE

The current composition of the Audit and Risk Management Committee consists of three (3) Independent Non-Executive Directors in compliance with Rule 15.09(1)(a) & (b) of the ACE LR of Bursa Securities:

- **Lim Kok Kiong**
- (Independent Non-Executive Director) (Chairman)
- **Tan Yiing Fung**
- (Independent Non-Executive Chairman) (Member)
- **Yap Kok Wei**
- (Independent Non-Executive Director) (Member)

The Chairman of the Audit and Risk Management Committee, Mr. Lim Kok Kiong, is a Chartered Accountant and Member of the Malaysian Institute of Accountants as well as an Independent Non-Executive Director in compliance with Rule 15.09(1)(c)(i) and Rule 15.10 of the ACE LR respectively.

MEETINGS AND ATTENDANCE

During the financial year under review, a total of five (5) meetings held and the attendance of each committee member at each meeting is set out as follows:

Committee Members	No. of Meetings Attended
Lim Kok Kiong (Chairman)	5/5
Tan Yiing Fung (Member)	5/5
Yap Kok Wei ¹ (Member)	1/1

Notes:

⁽¹⁾ Appointed as Member on 27 August 2025.



TERMS OF REFERENCE

A copy of the latest Terms of Reference of the Audit and Risk Management Committee is available for viewing under “Corporate Governance” section of the Company’s website at www.mgrc.com.my.

SUMMARY OF WORKS DURING THE FINANCIAL YEAR

1. Oversight of the Financial Reporting Process and Related Party Transactions

During the financial year ended 31 December 2025, the Audit and Risk Management Committee carried out its duties as set out in its Terms of Reference. The Audit and Risk Management Committee discharged its oversight role by carrying out the following activities during the financial year:

- Reviewed the unaudited quarterly report on consolidated financial results and annual audited financial statements, as well as the audit report and issues arising from the audits with the external auditors of the Group and the Company including the announcements pertaining thereto, before recommending the same to the Board for approval and release of the Group’s unaudited quarterly report on consolidated financial results to Bursa Securities.
- In particular, the Audit and Risk Management Committee focused on changes in or implementation of major accounting policies, significant matters highlighted during financial reporting and/or significant judgments made by management, as well as significant and unusual events. Reviewed the Group’s Audit Planning Memorandum for the financial period under review prior to the commencement of the annual audit. The Audit Planning Memorandum was presented to the Audit and Risk Management Committee for review and approval.
- Met with external auditors during the financial year without the presence of Executive Board members and the Management, during which meetings the external auditors were given the opportunity to raise any issues of concern directly to the Audit and Risk Management Committee.
- Reviewed related party transactions and conflict of interest situations that may arise within the Group and the adequacy of the Company’s procedures and processes in identifying, monitoring, reporting and reviewing related party transactions in a timely and orderly manner. The Company has a policy in place whereby in every financial year, two directors must review and sign off on a related party transaction declaration document. This exercise is carried out on a yearly basis.
- Noted emerging financial reporting issues pursuant to the introduction of new accounting standards, as well as additional statutory, legal and regulatory disclosure requirements.
- Reviewed and discussed key audit matters with the External Auditors to ensure that issues that are most significant in the audit was disclosed, and to address the issues highlighted by the External Auditor with management.

2. Oversight of the External Audit Function

a) Procedures to Assess Suitability and Independence of External Auditors

The Audit and Risk Management Committee has established a clear policy framework on the assessment of suitability and independence of the external auditors, entitled “Policies Governing Internal and External Auditors”.

b) Assessment on Suitability and Independence of External Auditors

The Audit and Risk Management Committee reviewed and assessed the Independence and competency of the External Auditors on a yearly basis. The Audit and Risk Management Committee was satisfied with the services rendered by Messrs. Jamal, Amin & Partners and their technical competency i.e. effectiveness, suitability and independence and hence, recommended to the Board the re-appointment of Messrs. Jamal, Amin & Partners as external auditors of the Company for the financial year ending 31 December 2026. The Board has in turn, recommended the same for shareholders’ approval at the forthcoming Twenty-First Annual General Meeting of the Company.

2. Oversight of the External Audit Function (continued)

c) Summary of External Auditor's Activities

The summary of the external auditors' activities below discloses activities conducted during the financial year under review. It comprises information on significant issues raised and addressed by the external auditors.

In relation to audit and audit-related services, the Audit Planning Memorandum addressed the following areas:

- Purpose of the Audit Planning Memorandum & Responsibilities;
- Audit Team;
- Audit Scope;
- Audit Approach;
- Timeline;
- Audit Fieldwork;
- Significant Risk and Area;
- Subsidiaries; and
- Fees.

The Audit and Risk Management Committee reviewed and discussed with the External Auditors the audit planning memorandum covering the audit objectives and approach, audit plan, key audit areas and relevant technical pronouncements and accounting standards issued by MASB and regulating requirements applicable to the Group and the processes and controls in place to ensure effective and efficient financial reporting and disclosures under the financial reporting standards. Deliverables, upon completion of the external audit, include the issuance of auditors' reports, and a separate Audit Review Memorandum highlighting major audit and accounting issues encountered, and the resolution of such issues. Deliverables, upon completion of the external audit, include the issuance of auditors' reports, and a separate Audit Summary Report highlighting major audit and accounting issues encountered, and the resolution of such issues.

Specifically, the external auditors' report expresses opinions on, and reports to, the Audit and Risk Management Committee (or those charged with governance) the results of their audits of:

- The consolidated and separate financial statements of MGRC for the financial year ended 31 December 2025; and
- MGRC's Statement on Risk Management and Internal Control in accordance with Recommended Practice Guide 5 - Guidance for Auditors on the Review of Directors' Statement on Internal Control ("RPG 5") issued by Malaysian Institute of Accountants.
- The Audit and Risk Management Committee reviewed with External Auditors the memorandum of comments and recommendations arising from their studies and evaluation of the system of internal and accounting controls together with Management's response to the findings of the External Auditors and ensured where appropriate, that necessary corrective actions had been taken by Management.

3. Oversight of the Internal Control and Risk Management Audit Function

In discharging its duties and responsibilities, the Audit and Risk Management Committee is supported by an independent and adequately resourced internal audit function. The internal audit function is outsourced to Kloo Point Consulting Group Sdn Bhd.

During the financial year ended 31 December 2025, the internal audit function carried out audits in accordance with the internal audit plan approved by the Audit and Risk Management Committee and also other areas of significance that were recommended by the Management. The results of the internal audit reviews and the recommendations for enhancement of existing controls were duly presented to the Audit and Risk Management Committee. The Audit and Risk Management Committee has full access to the Internal Auditors and has received reports on audits performed.



3. Oversight of the Internal Control and Risk Management Audit Function *(Continued)*

The Audit and Risk Management Committee oversees the internal control and risk management framework of the Group. During the financial year under review, the Audit and Risk Management Committee performed the following activities:

- Reviewed the adequacy of the scope, function, competency and resources of the internal audit function and assessed the overall performance of the Internal Auditors;
- The internal audits performed met the objective in highlighting to the Audit and Risk Management Committee the audit findings which require follow-up actions by the Management, any outstanding audit issues which require corrective actions to be taken to ensure adequate and effective internal control system within the Group, as well as any weaknesses in the Group's internal control system;
- Ensure that those weaknesses were appropriately addressed and that recommendations from the internal audit reports and corrective actions on reported weaknesses were taken appropriately within the required timeframe by the Management;
- The Internal Auditors had been given the opportunity to raise any issues of concern directly to the Audit and Risk Management Committee;
- Reviewed the internal audit plan and internal audit reports issued by the Internal Auditors, considered the findings of Internal Auditors, as well as Management's response thereon, and monitored the implementation of agreed recommendations and action plans;
- Reviewed the Risk Management Report prepared by the Management and submitted to the Audit and Risk Management Committee once in every financial year, requested for more information and proposed amendments to the content to better address risk management best practices;
- Reviewed the Risk Management Framework and ensure that the risk management structure is embedded throughout the Company and it is consistently adopted throughout the Company and its subsidiaries, within the parameters adopted by the Company; and
- Sought and obtained periodic updates from the Internal Auditors on the status of implementation of post-audit recommendations from previous, as well as current, internal audit cycles.

The Audit and Risk Management Committee also conform to the Statement on Internal Control and Risk Management conducted by the external auditors. Prior to the conclusion of the external audit, the external auditors reviewed the Internal Audit Report and followed up on the status of the recommendations therein during their audit fieldwork.

Once completed, the external auditor will be issuing a written communication to the Management and the Audit and Risk Management Committee, describing significant deficiencies and material weaknesses identified during the audit, if any; and issued a management letter, including recommendations for improvements in controls and procedures, if applicable.

INTERNAL AUDIT FUNCTION

The Group's internal audit function is carried out by an outsourced internal auditor namely Kloo Point Consulting Group Sdn Bhd.

The purpose of the internal audit function is to provide the Board, through the Audit and Risk Management Committee, reasonable assurance of the effectiveness of the system of internal control in the Group.

The internal audit function is independent and performs audit assignments with impartiality, proficiency, and due professional care.

The internal auditors have affirmed that they were free from any relationships or conflicts of interest, which could impair their objectivity and independency in the internal audit function of MGRC.

INTERNAL AUDIT FUNCTION *(Continued)*

During the FY2025, the summary of works undertaken by the internal auditors comprised the following:-

- Reviewed compliance with policies, procedures and standards, relevant external rules and regulations;
- Assessed the adequacy and effectiveness of the Group's system of internal control and recommended appropriate actions to be taken where necessary;
- Presentation of audit findings and corrective actions to be taken by Management in the Audit and Risk Management Committee Meetings.

The Internal Auditors conducted two (2) internal audit cycles during the financial year under review, covering the following areas:

- Sales order and billing process
- Product quality control process

REVIEW OF THE PERFORMANCE OF THE AUDIT AND RISK MANAGEMENT COMMITTEE

The performance of the Audit and Risk Management Committee was reviewed once during the financial year by the Nomination and Remuneration Committee.

TOTAL COSTS INCURRED FOR OUTSOURCED INTERNAL AUDIT FUNCTION

The total costs incurred by the Company for the outsourced internal audit function of the Group for the financial year ended 31 December 2025 was amounted to RM41,544.80 (2024: RM42,003.90).

This Audit and Risk Management Committee Report was approved by the Board on 27 April 2026.



DISCLOSURE OF FINANCIAL DATA FOR SHARIAH SCREENING

Pursuant to Rule 9.25A of the ACE Market Listing Requirements, below are the financial data that are relevant for purpose of Shariah screening by the Shariah Advisory Council of the Securities Commission Malaysia. These include financial data on Shariah non-permissible income arising from the Group's business activities and interest-based financial position.

(a) Group Total Income and Total Assets

Total Income	Remarks	Group	
		2025 RM	2024 RM
Revenue		8,022,935	5,522,089
Other income		87,340	291,481
Total		8,110,275	5,813,570
Total Assets		18,708,588	22,355,231

(b) Business Activities

Shariah Non-Compliant Activities	Remarks	Group	
		2025 RM	2024 RM
N/A		N/A	N/A
		N/A	N/A

(c) Component of Financial Position

(i) Cash Component

Islamic Account/ Instruments	Remarks	Group	
		2025 RM	2024 RM
Cash and bank balances (exclude cash in hand)		1,001,651	254,725
Total		1,001,651	254,725

Conventional Account/ Instruments	Remarks	Group	
		2025 RM	2024 RM
Cash and bank balances (exclude cash in hand)		14,417	15,367
Total		14,417	15,367



(c) Component of Financial Position (Continued)

(ii) Debt Component

Islamic Financing	Remarks	Group	
		2025 RM	2024 RM
Current		N/A	N/A
Non-Current		N/A	N/A
Total Financing		N/A	N/A

Conventional Financing	Remarks	Group	
		2025 RM	2024 RM
Current		N/A	N/A
Non-Current		N/A	N/A
Total Financing		N/A	N/A



Financial Statements

- 75** Directors' Report
- 79** Statement By Directors
- 79** Statutory Declaration
- 80** Independent Auditors' Report
- 85** Statements of Financial Position
- 86** Statements of Profit or Loss and Other Comprehensive Income
- 87** Statements of Changes In Equity
- 88** Statements of Cash Flows
- 90** Notes to the Financial Statements

DIRECTORS' REPORT

The Directors hereby present their report together with the audited financial statements of the Group and of the Company for the financial year ended 31 December 2025.

Principal Activities

The Company's principal activities include enabling personalised and precision medicine through genetics, genomics, immunotherapy and biopharmaceutical services, as well as investment holding.

The principal activities of the subsidiaries are disclosed in Note 7 to the financial statements.

There have been no significant changes in the nature of these principal activities during the financial year.

Financial Results

	Group RM	Company RM
Loss for the financial year attributable to:		
- Owners of the Company	(2,381,172)	(1,853,821)
- Non-controlling interest	(416,258)	-
	(2,797,430)	(1,853,821)

Dividends

No dividend has been paid or declared by the Company since the end of the previous financial year. The Board of Directors does not recommend any dividend to be paid for the financial year under review.

Reserves and Provisions

There were no material transfers to or from reserves and provisions during the financial year under review.

Issue of Shares and Debentures

There was no issuance of shares and debentures by the Company during the financial year.

Options Granted Over Unissued Shares

No options were granted to any person to take up unissued shares of the Company during the financial year under review.

Directors of the Company

The Directors in office during the financial year and during the year from the end of the financial year to the date of this report are:

Leong Yien Hung*	
Yap Kok Wei	
Lim Kok Kiong	
Tan Yiing Fung	
Ler Pei Fen	
Chung Eng Lam	
Encik Muhammad Badri Bin Hussin	(Resigned on 5 May 2025)
Mohd Shakir Bin Shahimi	(Resigned on 5 May 2025)
Chih Yi May	(Resigned on 5 May 2025)
Encik Mohamad Ruzaini Bin Hamzah	(Resigned on 5 May 2025)
Datuk Wira Muhammad Faizal Bin Zainol	(Resigned on 9 May 2025)

* Also a Director of a subsidiary of the Company

The Director of the Company's subsidiaries in office (excluding those Directors listed above) during the financial year and during the year commencing from the end of the financial year to the date of this report is:

Ler Yi Bin

Directors' Interests in Shares or Debentures

According to the register of Directors' shareholdings required to be kept under Section 59 of the Companies Act 2016 in Malaysia, none of the Directors who held office at the end of the financial year held any shares in the Company or its subsidiaries during the financial year except as follow:

	No. of ordinary shares		As at 31.12.2025
	As at 1.1.2025	Acquired Disposed	
Interest in the Company			
Direct interest:			
Leong Yien Hung	-	8,433,000	- 8,433,000
Ler Pei Fen	-	3,887,000	- 3,887,000

By virtue of their interest in the ordinary shares of the Company, Leong Yien Hung and Ler Pei Fen are also deemed to have interest in the ordinary shares of all the subsidiary companies to the extent the Company has an interest.

Other than as stated above, none of the other directors in office at the end of the financial year had any interests in the ordinary shares or debentures of the Company and its related corporation during the financial year.

Directors' Benefits

There were no arrangements during and at the end of the financial year which had the object of enabling the Directors of the Company to acquire benefits by means of the acquisition of share in or debentures of the Company of any other body corporate.

Since the end of the previous financial year, no Director of the Company has received or become entitled to receive any benefit (other than a benefit included in the aggregate amount of emoluments received or due and receivable by Directors as shown in the financial statements) by reason of a contract made by the Company or a related corporation with the Director or with a firm of which the Director is a member, or with a company in which the Director has a substantial financial interest.

Corporation with the Director or with a firm of which the Director is a member, or with a company in which the Director has a substantial financial interest.

Directors' Remuneration

Directors' remuneration is as follows:

	Group/ Company RM
Directors' remuneration:	
- fees	148,390
- salaries and other emoluments	186,778
- employee provident fund	28,699
	363,867

Subsidiaries

Details of the subsidiaries are disclosed in Note 7 to the financial statements.

Auditors' Remuneration

Auditors' remuneration is as follows:

	Group RM	Company RM
	128,000	85,000

Indemnifying Directors, Officers or Auditors

No indemnities have been given or insurance premiums paid, during or since the end of the financial year, for any person who is or has been the director, officer or auditor of the Company.

Other Statutory Information

Before the financial statements of the Group and of the Company were prepared, the Directors took reasonable steps:

- (i) to ascertain that action had been taken in relation to the writing off of bad debts and the making of provision for doubtful debts and satisfied themselves that all known bad debts had been written off and that adequate provision had been made for doubtful debts; and
- (ii) to ensure that any current assets which were unlikely to be realised in the ordinary course of business including the value of current assets as shown in the accounting records of the Group and of the Company have been written down to an amount which the current assets might be expected so to realise.

- (b) At the date of this report, the Directors are not aware of any circumstances which would render:
- (i) the amount written off for bad debts or the amount of the provision for doubtful debts in the financial statements of the Group and of the Company inadequate to any substantial extent; or
 - (ii) the values attributed to the current assets in the financial statements of the Group and of the Company misleading; or
 - (iii) adherence to the existing method of valuation of assets or liabilities of the Group and of the Company misleading or inappropriate; or
 - (iv) any amount stated in the financial statements of the Group and of the Company misleading.
- (c) At the date of this report, there does not exist:
- (i) any charge on the assets of the Group or of the Company which has arisen since the end of the financial year which secures the liabilities of any other person; or
 - (ii) any contingent liability of the Group or of the Company which has arisen since the end of the financial year.
- (d) No contingent or other liability of any company in the Group has become enforceable, or is likely to become enforceable within the year of twelve months after the end of the financial year which, in the opinion of the Directors, will or may affect the ability of the Group and of the Company to meet their obligations when they fall due.
- (e) In the opinion of the Directors:
- (i) the results of the operations of the Group and of the Company for the financial year were not substantially affected by any item, transaction or event of a material and unusual nature; and
 - (ii) there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature likely to affect substantially the results of the operations of the Group and of the Company for the financial year in which this report is made.

Significant Event

Detail of the significant event is disclosed in Note 24 to the financial statements.

Subsequent Event

Detail of the subsequent event is disclosed in Note 25 to the financial statements.

Auditors

The auditors, have indicated that their willingness to accept the re-appointment as auditor of the Company.

Signed on behalf of the Board of Directors in accordance with a resolution of the Directors.

LEONG YIEN HUNG

YAP KOK WEI

STATEMENT BY DIRECTORS

Pursuant To Section 251(2) Of The Companies Act 2016

We, LEONG YIEN HUNG and YAP KOK WEI, being two of the Directors of MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD, do hereby state that, in the opinion of the Directors, the financial statements set out on pages 80 to 123 are drawn up in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia so as to give true and fair view of the financial position of the Group and of the Company as at 31 December 2025 and of their financial performance and cash flows for the financial year then ended.

Signed on behalf of the Board of Directors in accordance with a resolution of the Directors.

LEONG YIEN HUNG

YAP KOK WEI

Kuala Lumpur
Dated: 27 April 2026

STATUTORY DECLARATION

Pursuant To Section 251(1) Of The Companies Act 2016

I, LEONG YIEN HUNG, being the Director primarily responsible for the financial management of MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD, do solemnly and sincerely declare that the financial statements set out on pages 80 to 123 are to the best of my knowledge and belief, correct and I make this solemn declaration conscientiously believing the same to be true and by virtue of the provisions of the Statutory Declarations Act 1960.

Subscribed and solemnly declared by the above)
named LEONG YIEN HUNG at Kuala Lumpur)
in the Federal Territory on)
27 April 2026)

LEONG YIEN HUNG
NRIC No.: 830707-14-5397

Before me,

COMMISSIONER FOR OATHS

INDEPENDENT AUDITORS' REPORT

To the Members of Malaysian Genomics Resource Centre Berhad
Registration No.: 200401014287 (652790-V)
(Incorporated in Malaysia)

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of **MALYSIAN GENOMICS RESOURCE CENTRE BERHAD**, which comprise the statements of financial position as at 31 December 2025 of the Group and of the Company, and the statements of profit or loss and other comprehensive income, statements of changes in equity and statements of cash flows of the Group and of the Company for the year then ended, and notes to the financial statements, including material accounting policy information, as set out on pages 80 to 123.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Group and of the Company as at 31 December 2025, and of their financial performance and their cash flows for the year then ended in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

Basis for Opinion

We conducted our audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing. Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence and Other Ethical Responsibilities

We are independent of the Group and of the Company in accordance with the *By-Laws (on Professional Ethics, Conduct and Practice)* of the Malaysian Institute of Accountants ("By-Laws") and the International Ethics Standards Board for Accountants' *International Code of Ethics for Professional Accountants (including International Independence Standards)* ("IESBA Code"), as applicable to audits of financial statements of public interest entities and we have fulfilled our other ethical responsibilities in accordance with the By-Laws and IESBA Code.

Key Audit Matters

Key audit matters are those matter that, in our professional judgement, were of most significance in our audit of the financial statements of the Group and of the Company for the current year. These matters were addressed in the context of our audit of the financial statements of the Group and of the Company as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. The key audit matter for the Group is as below:

Report On The Audit Of The Financial Statements (Continued)

Key Audit Matters (Continued)

Key audit matters	How our audit addressed the key audit matters
<p>Impairment of financial assets</p> <p>As at 31 December 2025, as shown in Note 10 and Note 11 to the financial statements, the Group's trade and other receivables and the Company's amount owing by subsidiaries amounted to RM8.1 million and RM21.3 million which represented 43.3% and 65.8% respectively, of the Group's and of the Company's total assets.</p> <p>The Group and the Company assess at each reporting date whether there is any objective evidence that a financial asset is impaired.</p> <p>To determine whether there is objective evidence of impairment, the Group consider factors such as the Group contractual entitlement to a debt, the probability of insolvency or significant financial difficulties of the debtor and default or significant delay in payments.</p> <p>The recoverability of trade receivables, other receivables and amount owing by subsidiaries, allowance for expected credit losses is considered to be a significant risk due to the pervasive nature of these balances to the financial statements and affect the working capital management of the business.</p> <p>We focused our testing of the impairment and recoverability of trade receivables, other receivables and amount owing by subsidiaries on the key assumptions made by the management.</p>	<p>Our audit procedures in this area included, among others:</p> <ul style="list-style-type: none"> • We challenged the appropriateness and reasonableness of the assumptions applied in the Directors' assessment of the impairment of those balances; • We considered and concurred with the agreed payment terms; • We verified receipts subsequent to year end; and • We considered the completeness and accuracy of disclosures. • We have reviewed the adequacy of the policy disclosed to determine the accounting estimates for the impairment as disclosed in Note 2(c). • We tested the accuracy of the ageing against supporting documents on a sample basis. • We discussed with management to understand the underlying assumptions used when determining the Expected Credit Losses ("ECL") for trade and other receivables and amount owing by subsidiaries. • We obtained specific representation from management which has been included in the management's representation letters on the recoverability of those amount.
<p>Revenue and cost of sales recognition</p> <p>As at 31 December 2025, the Group's revenue and cost of sales amounting to RM8.0 million and RM2.8 million respectively are derived from personalised and precision medicine through genetics, genomics, immunotherapy and biopharmaceutical services.</p> <p>The core principle of MFRS 15 is entity recognizes revenue to depict the transfer of promised good or services to customers in an amount that reflects the consideration to which entity expects to be entitled in exchange for those goods or services. An entity recognises revenue in accordance with that core principle by applying the following steps: -</p> <ol style="list-style-type: none"> i. Identify the contract(s) with a customer; ii. Identify the performance obligations in the contract; iii. Determine the transaction price; iv. Allocate the transaction price to the performance obligations in the contract; and v. Recognise revenue when (or as) the entity satisfies 	<p>Our audit procedures in this area included, among others:</p> <ul style="list-style-type: none"> • We obtained an understanding of the Group's relevant internal controls and testing the controls over timing and amount of revenue recognised; • We inspected the terms of significant sales contracts to determine the point of transfer of control to customers; • We evaluated the transaction price by agreeing the invoices issued with the agreed purchase order from customers; • We evaluated whether the allocation of transactions price to the respective performance obligations; • We evaluated the appropriateness of the timing of revenue recognition based on the transfer of control of the related goods to the customer; and • We inspected documents evidencing the delivery of goods to customers;



Report On The Audit Of The Financial Statements (Continued)

Key Audit Matters (Continued)

Key audit matters	How our audit addressed the key audit matters
<p>Revenue and cost of sales recognition (Continue)</p> <p>Given its significant drivers of the Group and Company's financial performance, revenue and cost of sales recognition is identified as a key audit matter in our audit.</p> <p>There is a risk that revenue could be subject to misstatement, particularly in respect of the timing and amount of revenue recognized. As described in the Material Accounting Policy Information in 3 (o) to the financial statements, revenue is recognised upon the transfer of significant risk and rewards of ownership of the goods to the customer.</p>	<p>Our audit procedures in this area included, among others: (Continue)</p> <ul style="list-style-type: none"> We performed testing on the recording of sales transactions close to the year end, including credit notes issued after year end, to establish whether the transactions were recorded in the correct accounting period.

Information Other than the Financial Statements and Auditors' Report Thereon

The Directors of the Company are responsible for the other information. The other information comprises the information included in the Annual Report but does not include the financial statements of the Group and of the Company and our auditors' report thereon.

Our opinion on the financial statements of the Group and of the Company does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements of the Group and of the Company, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements of the Group and of the Company or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report the fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Statements

The Directors of the Company are responsible for the preparation of financial statements of the Group and of the Company that give a true and fair view in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia. The Directors are also responsible for such internal control as the Directors determine is necessary to enable the preparation of financial statements of the Group and of the Company that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements of the Group and of the Company, the Directors are responsible for assessing the Group's and the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Group or the Company or to cease operations, or have no realistic alternative but to do so.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements of the Group and of the Company as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with approved standards on auditing in Malaysia and International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Auditors' Responsibilities for the Audit of the Financial Statements *(Continued)*

As part of an audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements of the Group and of the Company, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's and of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's and the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements of the Group and of the Company or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group and the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements of the Group and of the Company, including the disclosures, and whether the financial statements of the Group and of the Company represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the group as a basis for forming an opinion on the group financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, action taken to eliminate threats of safeguards applied.

From the matters communicated with the Directors, we determine those matters that were of most significance in the audit of the financial statements of the Group and of the Company for the current year and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



Report on Other Legal and Regulatory Requirements

In accordance with the requirements of the Companies Act 2016 in Malaysia, we report that the subsidiaries of which we have not acted as auditors, are disclosed in Note 7 to the financial statements.

Other Matters

This report is made solely to the members of the Company, as a body, in accordance with Section 266 of the Companies Act, 2016 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the contents of this report.

JAMAL, AMIN & PARTNERS

(No: AF 1067)

Chartered Accountants

Kuala Lumpur

Date: 27 April 2026

NUR FATIMAH BINTI MOHAMAD KHIRRULZAKI

(No: 3731/04/27(J))

Chartered Accountant

STATEMENTS OF FINANCIAL POSITION

As at 31 December 2025

	Note	Group		Company	
		2025 RM	2024 RM	2025 RM	2024 RM
ASSETS					
Non-Current Assets					
Property, plant and equipment	4	2,140,461	2,945,565	1,957,624	2,573,087
Right-of-use assets	5	1,063,840	1,442,557	1,063,840	1,353,976
Intangible assets	6	3,457,680	3,879,586	1,345,956	1,438,762
Investment in subsidiaries	7	-	-	2,390,009	2,390,009
Other investment	8	2,500,000	2,500,000	2,500,000	2,500,000
		9,161,981	10,767,708	9,257,429	10,255,834
Current Assets					
Inventories	9	390,498	936,527	-	-
Trade and other receivables	10	8,097,914	10,150,608	1,643,719	3,318,477
Amount owing by subsidiaries	11	-	-	21,338,782	21,190,541
Tax recoverable		39,509	229,630	17,670	34,069
Cash and cash equivalents	12	1,018,686	270,758	172,235	107,772
		9,546,607	11,587,523	23,172,406	24,650,859
TOTAL ASSETS		18,708,588	22,355,231	32,429,835	34,906,693
EQUITY AND LIABILITIES					
EQUITY					
Share capital	13	17,435,566	59,435,566	17,435,566	59,435,566
Accumulated losses / Retained earnings		(1,661,375)	(41,280,203)	12,340,805	(27,805,374)
Equity attributable to the owners of the Company		15,774,191	18,155,363	29,776,371	31,630,192
Non-controlling interest	7	(990,187)	(582,844)	-	-
TOTAL EQUITY		14,784,004	17,572,519	29,776,371	31,630,192
LIABILITIES					
Non-Current Liability					
Lease liabilities	14	920,738	1,225,862	920,738	1,225,862
Current Liabilities					
Trade and other payables	15	2,698,722	3,172,979	1,068,389	1,406,023
Amount owing to subsidiaries	11	-	-	359,213	359,213
Lease liabilities	14	305,124	383,871	305,124	285,403
		3,003,846	3,556,850	1,732,726	2,050,639
TOTAL LIABILITIES		3,924,584	4,782,712	2,653,464	3,276,501
TOTAL EQUITY AND LIABILITIES		18,708,588	22,355,231	32,429,835	34,906,693

The accompanying notes form an integral part of the financial statements.



STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the Financial Year Ended 31 December 2025

	Note	Group		Company	
		2025 RM	2024 RM	2025 RM	2024 RM
Revenue	16	8,022,935	5,522,089	-	16,771
Cost of sales		(2,881,923)	(2,093,527)	-	(1,332)
Gross profit		5,141,012	3,428,562	-	15,439
Other income		87,340	291,481	3,805,900	5,410,491
Administrative expenses		(5,765,665)	(7,935,402)	(3,968,650)	(5,090,026)
Impairment loss	17	(1,749,392)	(127,118)	(1,522,896)	(121,130)
Marketing and distribution		(104,292)	(52,713)	(75,579)	(47,538)
Finance cost		(95,528)	(119,183)	(92,596)	(111,042)
(Loss)/Profit before taxation	17	(2,486,525)	(4,514,373)	(1,853,821)	56,194
Taxation	18	(310,905)	(348)	-	-
(Loss)/Profit/Total comprehensive (expense)/income for the financial year		(2,797,430)	(4,514,721)	(1,853,821)	56,194
(Loss)/Profit/Total comprehensive (expense)/ income for the financial year attributable to:					
- owners of the Company		(2,381,172)	(4,191,392)	(1,853,821)	56,194
- non-controlling interest		(416,258)	(323,329)	-	-
		(2,797,430)	(4,514,721)	(1,853,821)	56,194
Loss per share attributable to owners of the Company (sen per share):					
- Basic	19	(1.74)	(3.05)		
- Diluted	19	(1.74)	(3.05)		

The accompanying notes form an integral part of the financial statements.



STATEMENTS OF CHANGES IN EQUITY

For The Financial Year Ended 31 December 2025

	Attributable to the Owners of the Company					Total Equity RM
	Share Capital RM	Non-distributable	Accumulated Losses / Retained Earnings RM	Subtotal RM	Non- controlling Interest RM	
Group						
2025						
At 1 January	59,435,566		(41,280,203)	18,155,363	(582,844)	17,572,519
Loss/Total comprehensive expense for the financial year	-		(2,381,172)	(2,381,172)	(416,258)	(2,797,430)
Share capital reduction	(42,000,000)		42,000,000	-	-	-
Elimination of non-controlling interest at disposal of subsidiary	-		-	-	8,915	8,915
At 31 December	17,435,566		(1,661,375)	15,774,191	(990,187)	14,784,004
2024						
At 1 January	59,435,566		(37,088,811)	22,346,755	(259,515)	22,087,240
Loss/Total comprehensive expense for the financial year	-		(4,191,392)	(4,191,392)	(323,329)	(4,514,721)
At 31 December	59,435,566		(41,280,203)	18,155,363	(582,844)	17,572,519
Company						
2025						
At 1 January	59,435,566		(27,805,374)	31,630,192		
Loss/Total comprehensive expense for the financial year	-		(1,853,821)	(1,853,821)		
Share capital reduction	(42,000,000)		42,000,000	-		
At 31 December	17,435,566		12,340,805	29,776,371		
2024						
At 1 January	59,435,566		(27,861,568)	31,573,998		
Profit/Total comprehensive income for the financial year	-		56,194	56,194		
At 31 December	59,435,566		(27,805,374)	31,630,192		

The accompanying notes form an integral part of the financial statements.



STATEMENTS OF CASH FLOWS

For The Financial Year Ended 31 December 2025

	Note	Group		Company	
		2025 RM	2024 RM	2025 RM	2025 RM
Cash Flows From Operating Activities					
(Loss)/Profit before taxation		(2,486,525)	(4,514,373)	(1,853,821)	56,194
Adjustments for:					
Amortisation of intangible assets	6	421,906	422,372	92,806	93,273
Bad debt written off		-	-	28,757	-
Inventories written off	9	19,273	25,799	-	-
Depreciation of property, plant and equipment	4	665,262	773,380	615,463	730,999
Depreciation of right-of-use assets	5	378,717	378,720	290,136	290,136
Derecognition of liabilities		3,131	-	-	-
Loss on derecognition of subsidiary	7	5,784	-	-	-
Impairment loss on:					
- trade receivables	23	1,522,896	121,130	1,522,896	121,130
- plant and equipment	4	211,480	-	-	-
- inventories	9	15,016	5,988	-	-
Interest expense on lease liabilities		95,528	119,183	92,596	111,042
Interest income		-	(271)	-	-
Gain on disposal of property, plant and equipment	4	-	(29,300)	-	(29,300)
Reversal of ECL on trade receivables	23	(19,150)	(1,561,130)	(19,150)	(1,561,130)
Reversal of impairment loss on inventories	9	(16,983)	(29,463)	-	-
Operating gain/(loss) before working capital changes		816,335	(4,287,965)	769,683	(187,656)
Changes in working capital:					
Inventories		528,723	(319,748)	-	1,097
Trade and other receivables		548,948	2,737,606	171,012	2,267,174
Amount owing by/(to) subsidiaries		-	-	-	54,401
Trade and other payables		(575,656)	1,387,263	(337,634)	458,589
		502,015	3,805,121	(166,622)	2,781,261
Cash generated from/(used in) operations		1,318,350	(482,844)	603,061	2,593,605
Interest paid		(92,596)	(111,042)	(92,596)	(111,042)
Income tax paid		(120,784)	(151,085)	16,399	(11,777)
Net cash generated from/(used in) operating activities		1,104,970	(744,971)	526,864	2,470,786

The accompanying notes form an integral part of the financial statements.

	Note	Group		Company	
		2025 RM	2024 RM	2025 RM	2025 RM
Cash Flows From Investing Activities					
Interest received		-	271	-	-
Purchase of property, plant and equipment	4	(71,638)	(200,195)	-	(144,099)
Purchase of intangible assets	6	-	(7,903)	-	(7,903)
Proceeds from disposal of property, plant and equipment	4	-	29,300	-	29,300
Advances to subsidiaries		-	-	(176,998)	(2,184,838)
Net cash used in investing activities		(71,638)	(178,527)	(176,998)	(2,307,540)
Cash Flows From Financing Activities					
Repayment of lease liabilities	14	(285,404)	(228,958)	(285,403)	(228,958)
Repayment to subsidiaries		-	-	-	(18,008)
Net cash used in financing activities		(285,404)	(228,958)	(285,403)	(246,966)
Net decrease in cash and cash equivalents		747,928	(1,152,456)	64,463	(83,720)
Cash and cash equivalents at beginning of the financial year/period		270,758	1,423,214	107,772	191,492
Cash and cash equivalents at end of the financial year/period		1,018,686	270,758	172,235	107,772
Cash and cash equivalents at end of the financial year/period comprises:					
Cash and bank balances	12	1,018,686	270,758	172,235	107,772

The accompanying notes form an integral part of the financial statements.

NOTES TO THE FINANCIAL STATEMENTS

1. Corporate Information

The Company's principal activities include enabling personalised and precision medicine through genetics, genomics, immunotherapy and biopharmaceutical services, as well as investment holding.

The principal activities of the subsidiaries are described in Note 7 to the financial statements.

There have been no significant changes in the nature of these principal activities during the financial year.

The Company is a public company limited by shares, incorporated and domiciled in Malaysia, and is listed on the ACE Market of Bursa Malaysia Securities Berhad.

The registered office of the Company is B-21-1, Level 21, Northpoint Mid Valley City No. 1, Medan Syed Putra Utara, 59200 Kuala Lumpur.

The principal place of business of the Company is No. 8F, Jalan Teknologi 3/6, Kawasan Perindustrian Nouvelle Lot 8, Taman Sains Selangor 1, Kota Damansara, PJU 5, 47810 Petaling Jaya, Selangor.

2. Basis of Preparation

(a) Basis of preparation

The financial statements of the Group and of the Company have been prepared in accordance with Malaysian Financial Reporting Standards ("MFRS"), International Financial Reporting Standards and the requirements of the Companies Act 2016 in Malaysia.

The financial statements have been prepared under the historical cost convention except as disclosed in summary of significant accounting policies.

The preparation of financial statements in conformity with MFRS requires the use of certain critical accounting estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reported year. It also requires Directors to exercise their judgment in the process of applying the Group's and Company's accounting policies. Although these estimates and judgment are based on the Directors' best knowledge of current events and actions, actual results may differ. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Note 2(c) to the financial statements.

Accounting standards and amendments to accounting standards that are effective for the Group and the Company's financial year beginning on or after 1 January 2025 are as follows:

- Amendments to MFRS 121 "Lack of Exchangeability" (The Effects of Changes in Foreign Exchange Rates)

The above amendments to accounting standards effective during the financial year do not have any significant impact to the financial results and position of the Group and of the Company.

2. Basis of Preparation (Continued)

(a) Basis of preparation (continued)

Accounting standards and amendments to accounting standards that are applicable for the Group and the Company in the following years but are not yet effective:

Annual periods beginning on/after 1 January 2026

- Amendments to MFRS 9, Financial Instruments and MFRS 7, Financial Instruments: Disclosures – Classification and Measurement of Financial Instruments
- Amendments that are part of Annual Improvements - Volume 11:
 - Amendments to MFRS 1, First-time Adoption of Malaysian Financial Reporting Standards
 - Amendments to MFRS 7, Financial Instruments: Disclosures
 - Amendments to MFRS 9, Financial Instruments
 - Amendments to MFRS 10, Consolidated Financial Statements
 - Amendments to MFRS 107, Statement of Cash Flows
 - Amendments to MFRS 9, Financial Instruments and MFRS 7, Financial Instruments: Disclosures – Contracts Referencing Nature-dependent Electricity

Annual periods beginning on/after 1 January 2027

- MFRS 18, Presentation and Disclosure in Financial Statements
- MFRS 19, Subsidiaries without Public Accountability: Disclosures
- Amendments to MFRS 19 Subsidiaries without Public Accountability: Disclosures
- Amendments to MFRS 121 The Effects of Changes in Foreign Exchange Rates – Translation to a Hyperinflationary Presentation Currency

Effective date yet to be determined by the Malaysian Accounting Standards Board

- Amendments to MFRS 10, “Consolidated Financial Statements” and MFRS 128, “Investments in Associates and Joint Ventures” (Sale or Contribution of Assets between an Investor and its Associate or Joint Venture)

The adoption of the accounting standard and amendments to accounting standard are not expected to have any significant impact to the financial statements of the Group and of the Company.

(b) Functional and presentation currency

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The financial statements are presented in Ringgit Malaysia (“RM”), which is the Company’s functional and presentation currency.

(c) Significant accounting estimates and judgements

Estimates, assumptions concerning the future and judgements are made in the preparation of the financial statements. They affect the application of the Group’s and the Company’s accounting policies, reported amounts of assets, liabilities, income and expenses, and disclosures made. They are assessed on an on-going basis and are based on experience and relevant factors, including expectations of future events that are believed to be reasonable under the circumstances.



2. Basis of Preparation (Continued)

(c) Significant accounting estimates and judgements (continued)

The key assumptions concerning the future and other key sources of estimation or uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

(i) Measurement of expected credit loss allowance for financial assets

The loss allowances for financial assets are based on assumptions about risk of default and expected loss rates. The Group and the Company use judgement in making these assumptions and selecting the inputs to the impairment calculation, based on the Group's and the Company's past history, existing market conditions as well as forward looking estimates at the end of reporting year.

(ii) Depreciation of property, plant and equipment

The estimates for the residual values, useful lives and related depreciation charges for the property, plant and equipment are based on commercial factors which could change significantly as a result of technical innovations and competitors' actions in response to the market conditions. The Group and the Company anticipate that the residual values of its equipment will be significant. As a result, residual values are not being taken into consideration for the computation of the depreciable amount. Change in the expected level of usage and technological development could impact the economic useful lives and the residual values of these assets, therefore future depreciation charges could be revised.

The carrying amounts of the property, plant and equipment is disclosed in Note 4 to the financial statements.

(iii) Impairment of non-financial assets

The Group assesses whether there are any indicators of impairment for all non-financial assets at each reporting date. When such indicators exist, recoverable amounts of the cash-generating unit are determined based on the value-in-use calculation. These calculations require the estimation of the expected future cash flows from the cash generating unit and a suitable discount rate is applied in order to calculate the present value of those cash flows.

(iv) Taxation

Deferred tax asset is recognised for unutilised tax losses to the extent that it is probable that taxable profit will be available in future against which tax losses can be utilised. Significant management judgement is required to determine the amount of deferred tax asset that can be recognised, based upon the likely timing level of future taxable profits.

3. Material Accounting Policy Information

(a) Basis of consolidation

(i) Subsidiary companies

Subsidiaries are entities, including structured entities, controlled by the Group. The Group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity.

The Group considers it has de-facto power over an investee when, despite not having the majority of voting rights, it has the current ability in circumstances where the size of the Group's voting rights relative to the size and dispersion of holdings of other shareholders to direct the activities of the investee that significantly affect the investee's return.

Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

Business combinations are accounted for using the acquisition method on the acquisition date. The consideration transferred includes the fair value of assets transferred, equity interest issued by the Group and liabilities assumed. Identifiable assets acquired, liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date.

The Group recognises any non-controlling interest in the acquiree on an acquisition-by-acquisition basis, either at fair value or at the non-controlling interest's proportionate share of the recognised amounts of the acquiree's identifiable net assets.

Acquisition-related costs are recognised in the profit or loss as incurred.

The excess of the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired is recognised as goodwill. If the total of consideration transferred, non-controlling interest recognised and previously held interest measured is less than the fair value of the net assets of the subsidiary acquired in the case of a bargain purchase, the difference is recognised directly in the profit or loss.

Inter-company transactions, balances and unrealised gains and losses on transactions between group companies are eliminated. Accounting policies of subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Group.

Transactions with non-controlling interests that do not result in loss of control are accounted for as equity transactions. Any difference between fair value of any consideration paid and the relevant share acquired of the carrying value of net assets of the subsidiary is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity.

Upon the loss of control of a subsidiary, the Group derecognises the assets and liabilities, any non-controlling interests and other components of equity related to the disposed subsidiary. Any retained interest in the entity is re-measured to its fair value at the date when control is lost, with the change in carrying amount recognised in profit or loss. The fair value is the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate, joint venture or financial asset depending on the level of influence retained.



3. Material Accounting Policy Information (Continued)

(b) Investment in subsidiaries

In the Company's separate financial statements, investments in subsidiaries are carried at cost less accumulated impairment losses. On disposal of investments in subsidiaries, the difference between disposal proceeds and the carrying amounts of the investment are recognised in profit or loss.

(c) Property, plant and equipment

(i) Recognition and measurement

Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses. The cost of an item of property, plant and equipment initially recognised includes its purchase price and any cost that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are recognised as expenses in profit or loss during the financial year in which they are incurred.

When significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Gains and losses on disposals are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognised as net in the profit or loss.

(ii) Depreciation and impairment

Property, plant and equipment under construction are not depreciated until the asset are ready for their intended use. Property, plant and equipment are depreciated on the straight-line method to allocate the cost to their residual values over their estimated useful lives as follows:

Computer hardware and software	2 years
Development servers and laboratory equipment	3 - 5 years
Furniture, fittings and office equipment	10 years
Renovation and air-conditioners	10 years
Books and logo	10 years
Motor vehicle	5 years

Depreciation methods, useful lives and residual values are reviewed at end of each reporting year, and adjusted as appropriate.

At the end of the reporting year, the Group and the Company assess whether there is any indication of impairment. If such indications exist, an analysis is performed to assess whether the carrying amount of the asset is fully recoverable. A write down is made if the carrying amount exceeds the recoverable amount.

3. Material Accounting Policy Information (Continued)

(d) Impairment of non-financial assets

Assets that have an indefinite useful life, such as goodwill or intangible assets not ready to use, are not subject to amortisation and are tested annually for impairment. Assets that are subject to amortisation and depreciation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or cash-generating units.

The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or cash-generating unit.

An impairment loss is recognised if the carrying amount of an asset or its related cash-generating unit exceeds its estimated recoverable amount.

Impairment losses are recognised in profit or loss unless it reverses a previous revaluation in which it is charged to the revaluation surplus. Impairment losses recognised in prior years are assessed at the end of each reporting year for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount since the last impairment loss was recognised. An impairment loss is reversed only to the extent that the asset's carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised. Reversals of impairment losses are credited to profit or loss in the financial year in which the reversals are recognised.

(e) Intangible assets

License is carried at cost less accumulated amortisation and impairment losses. Amortisation is recognised in profit or loss on straight-line basis to allocate the cost over the estimated useful lives of 10 - 20 years.

At the end of the reporting year, the Group and the Company assess whether there is any indication of impairment. If such indications exist, an analysis is performed to assess whether the carrying amount of the asset is fully recoverable. A write down is made if the carrying amount exceeds the recoverable amount.

(f) Inventories

Inventories are valued at the lower of cost and net realisable value after adequate allowance has been made for all deteriorated, damaged, obsolete or slow-moving inventories. Cost is determined on the first-in-first-out method.

Net realisable value is the estimate of the selling price in the ordinary course of business, less the costs of completion and selling expenses.

(g) Cash and cash equivalents

Cash and cash equivalents consist of cash and bank balances and deposits with banks and highly liquid investments which have an insignificant risk of changes in fair value with original maturities of three month or less, and are used by the Group and the Company in the management of their short-term commitments. For the purpose of the statements of cash flows, cash and cash equivalents are presented net of bank overdrafts pledged deposits, if any.

3. Material Accounting Policy Information (Continued)

(h) Foreign currencies

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss, except for differences arising from borrowings in foreign currencies and other currency instruments designated and qualifying as net investment hedges and net investment in foreign operations, are recognised in other comprehensive income and accumulated in the exchange reserve.

Non-monetary items denominated in foreign currencies measured at fair value are translated using the spot exchange rates at the date when the fair value was determined. Exchange differences arising on the translation of non-monetary items carried at fair value are included in profit or loss, except for the differences arising on the translation of non-monetary items in respect of which gains and losses are recognised in other comprehensive income.

(i) Financial assets

(i) Classification

The Group and the Company classify their financial assets in the following measurement categories:

- Amortised cost;
- Fair value through other comprehensive income ("FVOCI"); and
- Fair value through profit or loss ("FVTPL")

The classification depends on the Group's and the Company's business model for managing the financial assets as well as the contractual terms of the cash flows of the financial asset.

Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

The Group and the Company reclassify debt instruments when and only when its business model for managing those assets changes.

(ii) Recognition and initial measurement

Regular purchases and sales of financial assets are recognised on the trade-date, the date on which the Group and the Company commit to purchase or sell the asset.

At initial recognition, the Group and the Company measure a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed in profit or loss.

(iii) Subsequent measurement

Debt instruments

Debt instruments mainly comprise of trade and other receivables, amount owing by subsidiaries and cash and bank balances.

3. Material Accounting Policy Information (Continued)

(i) Financial assets (Continued)

(iii) Subsequent measurement (Continued)

Debt instruments (Continued)

There are three subsequent measurement categories, depending on the Group's and the Company's business model for managing the asset and the cash flow characteristics of the asset:

- Amortised cost

Debt instruments that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. A gain or loss on a debt instrument that is subsequently measured at amortised cost and is not part of a hedging relationship is recognised in profit or loss when the asset is derecognised or impaired. Interest income from these financial assets is included in interest income using the effective interest rate method.

- FVOCI

Debt instruments that are held for collection of contractual cash flows and for sale, and where the assets' cash flows represent solely payments of principal and interest, are classified as FVOCI. Movements in fair values are recognised in Other Comprehensive Income ("OCI") and accumulated in fair value reserve, except for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses, which are recognised in profit and loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to profit or loss. Interest income from these financial assets is recognised using the effective interest rate method in profit or loss.

- FVTPL

Debt instruments that are held for trading as well as those that do not meet the criteria for classification as amortised cost or FVOCI are classified as FVTPL. Movement in fair values and interest income is recognised in profit or loss in the year in which it arises.

Equity instruments

The Group and the Company subsequently measure all its equity investments at fair value. Equity investments are classified as FVTPL with movements in their fair values recognised in profit or loss in the year in which the changes arise, except for those equity securities which are not held for trading. The Group and the Company has elected to recognise changes in fair value of equity securities not held for trading in OCI as these are strategic investments and the Group and the Company considers this to be more relevant. Movements in fair values of investments classified as FVOCI are recognised in OCI. Dividends from equity investments are recognised in profit or loss when the Group's and the Company's right to receive payments is established.

(iv) Expected credit losses ("ECL")

The Group and the Company assess ECL associated with its debt instruments carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. ECL represent a probability-weighted estimate of the difference between present value of cash flows according to contract and present value of cash flows the Group and the Company expect to receive, over the remaining life of the financial instrument.

For trade receivables, the Group and the Company apply the simplified approach, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

3. Material Accounting Policy Information (Continued)

(i) Financial assets (Continued)

(iv) Expected credit losses ("ECL")(Continued)

While cash and cash equivalents are also subject to the impairment requirements of MFRS 9, the identified impairment loss was immaterial.

In measuring ECL, trade receivables and contract assets are grouped based on shared credit risk characteristics and days past due. The contract assets relate to unbilled work in progress, which have substantially the same risk characteristics as the trade receivables for the same type of contracts. The Group and the Company has therefore concluded that the expected loss rates for trade receivables are a reasonable approximation of the loss rates for the contract assets.

In calculating the ECL rates, the Group and the Company considers historical loss rates for each category of customers and adjusts to reflect current and forward-looking factors affecting the ability of the customers to settle the receivables.

The Group and the Company define a financial instrument as default, which is aligned with the definition of credit-impaired, when the debtor meets unlikelihood to pay criteria, which indicates the debtor is in significant financial difficulty. The Group and the Company consider the following instances:

- Concessions have been made by the Group and the Company related to the debtor's financial difficulty
- It is becoming probable that the debtor will enter bankruptcy or other financial reorganisation
- The debtor is insolvent

Financial assets that are credit-impaired are assessed for impairment on an individual basis.

The Group and the Company write off financial assets, in whole or in part, when it has exhausted all practical recovery efforts and has concluded there is no reasonable expectation of recovery. The assessment of no reasonable expectation of recovery is based on unavailability of debtor's sources of income or assets to generate sufficient future cash flows to repay the amount. The Group and the Company may write-off financial assets that are still subject to enforcement activity.

(j) Financial liabilities

Financial liabilities are initially recognised at fair value net of transaction costs for all financial liabilities not carried at FVTPL. Finance liabilities carried at FVTPL are initially recognised at fair value, and transaction costs are expensed in profit or loss.

FVTPL category comprises financial liabilities that are derivatives (except for a derivative that is a financial guarantee or a designated and effective hedging instrument) or financial liabilities that are specifically designated into this category upon initial recognition.

All financial liabilities are subsequently measured at amortised cost using the effective interest method other than those categorised as FVTPL.

Other financial liabilities categorised as FVTPL are subsequently measured at their fair values with the gain or loss recognised in profit or loss.

(k) Offsetting financial instruments

Financial assets and liabilities are offset and the net amount presented in the statements of financial position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

3. Material Accounting Policy Information (Continued)

(l) Leases - Accounting by lessee

Leases are recognised as right-of-use assets and a corresponding liability at the commencement date on which the leased asset is available for use by the Group and the Company.

In determining the lease term, the Group and the Company considers all facts and circumstances that create an economic incentive to exercise an extension option, or not to exercise a termination option. Extension or termination options are taken into consideration in determining the lease term if it is reasonably certain that the lease will be extended or terminated.

Right-of-use assets are initially measured at cost comprising the following:

- The amount of the initial measurement of lease liability;
- Any lease payments made at or before the commencement date less any lease incentive received;
- Any initial direct costs; and
- Decommissioning or restoration costs

Right-of-use assets are subsequently measured at cost, less accumulated depreciation and impairment loss. The right-of-use assets are depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. If the Group and the Company is reasonably certain that it will exercise a purchase option, the right-of-use asset is depreciated over the underlying asset's useful life.

Lease liabilities are initially measured at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, the lessee's incremental borrowing rate is used. Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease year so as to produce a constant yearly rate of interest on the remaining balance of the liability for each year.

Short-term leases are leases with a lease term of 12 months or less. Payments associated with short-term leases of low-value assets are recognised on a straight-line basis as an expense in profit or loss.

(m) Current and deferred tax

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case the tax is also recognised in other comprehensive income or directly in equity, respectively.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted by the end of the reporting year, and any adjustment to tax payable in respect of previous financial years.

Deferred tax is recognised, using the liability method, on temporary differences arising between the amounts attributed to assets and liabilities for tax purposes and their carrying amounts in the financial statements. However, deferred tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit nor loss. Deferred tax is determined using tax rates that have been enacted or substantively enacted by the end of the reporting year and are expected to apply when the related deferred tax asset is realised or the deferred tax liability is settled.

Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, unused tax losses or unused tax credits can be utilised.

Deferred and current tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred tax assets and liabilities relate to taxes levied by the same taxation authority on either the taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.

3. Material Accounting Policy Information (Continued)

(n) Provisions

Provisions are recognised if, as a result of a past event, the Group and the Company have a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic resources will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as finance cost.

When the Group and the Company expect a provision to be reimbursed (for example, under an insurance contract), the reimbursement is recognised as a separate asset but only when reimbursement is virtually certain.

(o) Revenue and income recognition

(i) Revenue from contracts with customers

Revenue is recognised by reference to each distinct performance obligation promised in the contract with customer when or as the Group and the Company transfer the control of the goods or services promised in a contract and the customer obtains control of the goods or services. Depending on the substance of the respective contract with customer, the control of the promised goods or services may transfer over time or at a point in time.

A contract with customer exists when the contract has commercial substance, the Group and the Company and their customer has approved the contract and intend to perform their respective obligations, the Group's and the Company's and the customer's rights regarding the goods or services to be transferred and the payment terms can be identified, and it is probable that the Group and the Company will collect the consideration to which it will be entitled to in exchange of those goods or services.

Genetic screening and genome sequencing services

The provision of genetic screening and genome sequencing services is recognised when the services are rendered to the customer by the Group and the Company.

Biopharmaceutical and healthcare products

Revenue from the sale of biopharmaceutical and healthcare products is recognised when the Group and the Company satisfy a performance obligation by transferring a promised good to a customer. An asset is transferred as and when the customer obtains control of the asset, which coincides with the delivery of goods and services and acceptance by customers.

(ii) Other revenue and income

Interest income

Interest income is recognised on an accrual basis using the effective interest method.

(p) Employee benefits

(i) Short term employee benefits

Short-term employee benefit obligations in respect of salaries, annual bonuses, paid annual leave and sick leave are measured on an undiscounted basis and are expensed as the related service is provided.

A liability is recognised for the amount expected to be paid under short-term cash bonus or profit sharing plans if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

3. Material Accounting Policy Information (Continued)

(p) Employee benefits (Continued)

(ii) Defined contribution plans

As required by law, companies in Malaysia make contributions to the Employees Provident Fund ("EPF"). Such contributions are recognised as an expense in the profit or loss as incurred.

(q) Equity instruments

Ordinary shares are classified as equity. Dividends on ordinary shares are recognised in equity in the year in which they are declared.

The transaction costs of an equity transaction are accounted for as a deduction from equity, net of tax. Equity transaction costs comprise only those incremental external costs directly attributable to the equity transaction which would otherwise have been avoided.

(r) Operating segments

Operating segments are reported in a manner consistent with the internal reporting and are regularly reviewed by the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Executive Chairman that makes strategic decisions.

(s) Related Parties

A party is related to an entity (referred to as the "reporting entity") if:

- a) A person or a close member of that person's family is related to a reporting entity if that person: -
- i) has control or joint over the reporting entity; or
 - ii) has significant influence over the reporting entity; or
 - iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity.

Close members of the family of a person are those family members who may be expected to be influenced by, that person in their dealings with the reporting entity.

- b) An entity is related to a reporting entity if any of the following conditions applies: -

- i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others).
- ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member).
- iii) Both entities are joint ventures of the same third party.
- iv) One entity is a joint venture of a third entity and the other entity is an associate of that third entity.
- v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity itself has such a plan, the sponsoring employers are also related to the reporting entity.
- vi) The entity is controlled or jointly controlled by a person identified in (a) above.
- vii) A person identified in (a) (i) above has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity).
- viii) The entity or a member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity.

4. Property, Plant and Equipment

Group	Computer hardware and software RM	Development servers and laboratory equipment RM	Furniture, fittings and office equipment RM	Renovation and air-conditioners RM	Books and logo RM	Motor vehicle RM	Capital work-in-progress RM	Total RM
2025								
Cost								
At 1 January	349,857	6,486,981	545,816	2,451,639	12,854	-	211,480	10,058,627
Additions	-	34,418	-	-	-	37,220	-	71,638
Disposal	(9,072)	-	-	-	-	-	-	(9,072)
At 31 December	340,785	6,521,399	545,816	2,451,639	12,854	37,220	211,480	10,121,193
Accumulated depreciation								
At 1 January	333,303	5,815,432	183,965	712,182	3,427	-	-	7,048,309
Charge for the financial year	13,617	361,956	40,759	245,164	1,285	2,481	-	665,262
Disposal	(9,072)	-	-	-	-	-	-	(9,072)
At 31 December	337,848	6,177,388	224,724	957,346	4,712	2,481	-	7,704,499
Accumulated impairment loss								
At 1 January	-	64,753	-	-	-	-	-	64,753
Impairment during the financial year	-	-	-	-	-	-	211,480	211,480
At 31 December	-	64,753	-	-	-	-	211,480	276,233
Carrying amount								
At 31 December	2,937	279,258	321,092	1,494,293	8,142	34,739	-	2,140,461

4. Property, Plant and Equipment (Continue)

Group (Continue)	Computer hardware and software RM	Development servers and laboratory equipment RM	Furniture, fittings and office equipment RM	Renovation and air-conditioners RM	Books and logo RM	Motor vehicle RM	Capital work-in-progress RM	Total RM
2024								
Cost								
At 1 January	339,857	6,443,185	468,766	2,382,290	12,854	125,713	211,480	9,984,145
Additions	10,000	43,796	77,050	69,349	-	-	-	200,195
Disposal	-	-	-	-	-	(125,713)	-	(125,713)
At 31 December	349,857	6,486,981	545,816	2,451,639	12,854	-	211,480	10,058,627
Accumulated depreciation								
At 1 January	278,620	5,404,932	122,217	467,018	2,142	125,713	-	6,400,642
Charge for the financial year	54,683	410,500	61,748	245,164	1,285	-	-	773,380
Disposal	-	-	-	-	-	(125,713)	-	(125,713)
At 31 December	333,303	5,815,432	183,965	712,182	3,427	-	-	7,048,309
Accumulated impairment loss								
At 1 January/At 31 December	-	64,753	-	-	-	-	-	64,753
Carrying amount								
At 31 December	16,554	606,796	361,851	1,739,457	9,427	-	211,480	2,945,565

4. Property, Plant and Equipment (Continue)

Company	Computer hardware and software RM	Development servers and laboratory equipment RM	Furniture, fittings and office equipment RM	Renovation and air-conditioners RM	Books and logo RM	Total RM
2025						
Cost						
At 1 January	329,657	6,313,054	532,551	2,451,639	12,854	9,639,755
Disposal	(9,072)	-	-	-	-	(9,072)
At 31 December	320,585	6,313,054	532,551	2,451,639	12,854	9,630,683
Accumulated depreciation						
At 1 January	324,845	5,778,935	182,526	712,182	3,427	7,001,915
Charge for the financial year	4,792	324,789	39,433	245,164	1,285	615,463
Disposal	(9,072)	-	-	-	-	(9,072)
At 31 December	320,565	6,103,724	221,959	957,346	4,712	7,608,306
Accumulated impairment loss						
At 1 January/At 31 December	-	64,753	-	-	-	64,753
Carrying amount						
At 31 December	20	144,577	310,592	1,494,293	8,142	1,957,624

4. Property, Plant and Equipment (Continue)

Company (Continue)	Computer hardware and software RM	Development servers and laboratory equipment RM	Furniture, fittings and office equipment RM	Renovation and air-conditioners RM	Books and logo RM	Motor vehicle RM	Total RM
2024							
Cost							
At 1 January	329,657	6,313,054	457,801	2,382,290	12,854	125,713	9,621,369
Additions	-	-	74,750	69,349	-	-	144,099
Disposal	-	-	-	-	-	(125,713)	(125,713)
At 31 December	329,657	6,313,054	532,551	2,451,639	12,854	-	9,639,755
Accumulated depreciation							
At 1 January	277,345	5,402,517	121,894	467,018	2,142	125,713	6,396,629
Charge for the financial year	47,500	376,418	60,632	245,164	1,285	-	730,999
Disposal	-	-	-	-	-	(125,713)	(125,713)
At 31 December	324,845	5,778,935	182,526	712,182	3,427	-	7,001,915
Accumulated impairment loss							
At 1 January/ At 31 December	-	64,753	-	-	-	-	64,753
Carrying amount							
At 31 December	4,812	469,366	350,025	1,739,457	9,427	-	2,573,087



5. Right-Of-Use Assets

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Office buildings				
Cost				
At 1 January/31 December	3,034,997	3,034,997	2,592,081	2,592,081
Accumulated depreciation				
At 1 January	1,592,440	1,213,720	1,238,105	947,969
Charge for the financial year	378,717	378,720	290,136	290,136
At 31 December	1,971,157	1,592,440	1,528,241	1,238,105
Carrying amount				
At 31 December	1,063,840	1,442,557	1,063,840	1,353,976

6. Intangible Assets

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Licenses				
Cost				
At 1 January	5,147,121	5,139,218	1,856,123	1,848,220
Additions	-	7,903	-	7,903
At 31 December	5,147,121	5,147,121	1,856,123	1,856,123
Accumulated depreciation				
At 1 January	1,267,535	845,163	417,361	324,088
Amortisation for the financial year	421,906	422,372	92,806	93,273
At 31 December	1,689,441	1,267,535	510,167	417,361
Carrying amount				
At 31 December	3,457,680	3,879,586	1,345,956	1,438,762

(a) Impairment assessment of operating license

Included in the intangible assets of the Group is an amount of RM2,111,724 (2024: RM2,440,824) relating to an operating license for a hemodialysis centre granted by Dewan Perniagaan Islam Antarabangsa Malaysia. The Group has undertaken an impairment assessment of the operating license.

Key assumptions used to determine the recoverable amount

The recoverable amount of the operating license has been determined based on value-in-use calculation. These calculations use pre-tax cash flow projections based on financial budgets approved by management covering the 10 years licensing period.

6. Intangible Assets (Continue)

(a) Impairment assessment of operating license (Continue)

The key assumptions used for the value-in-use calculations include the following:

- i) Forecast revenue, direct costs and operating expenses based on maximum operation of 42 hemodialysis machines;
- ii) Forecast capital expenditure to set up the dialysis centre amounting to RM3,980,000; and
- iii) Pre-tax discount rate of 8.27% (2024:10.20%)

Management determined the revenue, direct costs and operating expenses during the forecast year based on future expectation of changes in the market. Management estimates discount rate using pre-tax rate that reflect current market assessments of the time value of money and the risk specific to the operating license.

The Group's review includes an impact assessment of changes on key assumptions. Based on the sensitivity analysis, the Board of Directors concluded that no reasonable change in the assumption above would cause the carrying amount of the operating license to exceed its recoverable amount.

7. Investment in Subsidiaries

(a) Investment in subsidiaries

	Company	
	2025 RM	2024 RM
Unquoted shares, at cost		
In Malaysia	460,009	460,009
Advance to a subsidiary company treated as quasi-investment	1,930,000	1,930,000
	2,390,009	2,390,009

The advances to a subsidiary is unsecured, non-interest bearing with no fixed terms of repayment. The Company does not anticipate repayment of the advances and it is determined to form part of the Company's net investment in the subsidiary.

(b) The subsidiaries and shareholding therein are as follows:

Name of subsidiaries	Country of incorporation and principal place of business	Effective ownership and voting interest		Principal activities
		2025 %	2024 %	
Direct holding:				
MGRC Therapeutics Sdn. Bhd. ("MGRC-T") ¹	Malaysia	100	100	Engaged in the business relating to life sciences/cell lab and by products.
MGRC Healthcare Sdn. Bhd. ("MGRC-H") ¹	Malaysia	100	100	To supply healthcare products and services.



7. Investment In Subsidiaries (Continue)

(b) The subsidiaries and shareholding therein are as follows: (Continue)

Name of subsidiaries	Country of incorporation and principal place of business	Effective ownership and voting interest		Principal activities
		2025 %	2024 %	
Direct holding:				
MGRC Trading Sdn. Bhd. ("MGRC Trading")	Malaysia	100	100	Investment holding in dealing with capital market and derivative instruments locally and internationally as well as in general merchants and provision of system developments and information technology in term of software and hardware.
MGRC Biopharma Sdn. Bhd. ("MGRC-B")	Malaysia	100	100	Research, development and commercialisation of biopharmaceutical products and services.
Malaysian Genomics and Life Sciences Sdn. Bhd. ("MGLS")	Malaysia	100	100	Enabling personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services as well as investment holding.
MGRC Holdings Sdn. Bhd. ("MGRCH") ¹	Malaysia	100	100	Investment holding company.
Malaysian Immuno Sdn. Bhd. ("MISB") ¹	Malaysia	100	100	Research, development and commercialisation of biopharmaceutical products and services.
Malaysian Cell Gene Sdn. Bhd. ("MCGSB") ¹	Malaysia	100	100	Research, development and commercialisation of biopharmaceutical products and services.
Malaysian Cell Gene Research Sdn. Bhd. ("MCGRSB") ¹	Malaysia	100	100	Research, development and commercialisation of biopharmaceutical products and services.
Indirect holding:				
<u>Subsidiary of MGRC-H</u> Aquahealth Sdn. Bhd. ("Aquahealth")	Malaysia	51	51	Engaged in the business of general medical services.
<u>Subsidiary of MGLS</u> Malaysian Genomics Regenerative Centre Sdn. Bhd. ("MGRCSB") ¹	Malaysia	100	100	Other human health services and general medical services.

7. Investment In Subsidiaries (Continue)

(b) The subsidiaries and shareholding therein are as follows: (Continue)

Name of subsidiaries	Country of incorporation and principal place of business	Effective ownership and voting interest		Principal activities
		2025 %	2024 %	
Subsidiary of MGRCH MGRC International Pte. Ltd. ^{1, 2}	Singapore	70	70	Distribution of Healthcare Products, Beauty Products and Precision Medicine.

¹ Not audited by Jamal, Amin & Partners.

² The indirect subsidiary was struck off from the companies register in Singapore on 6 November 2025. The striking off of the subsidiary has no material impact to the Group due to its dormancy. The derecognition of this subsidiary company resulted a loss of RM5,784 for the Group in the current financial year.

(c) Material non-controlling interest ("NCI") in a subsidiary

Financial information of subsidiaries which have material non-controlling interests that are material to the Group is set out below.

	Aquahealth	
	2025 RM	2024 RM
Non-current assets	2,111,724	2,740,887
Current assets	3,278	1,348
Current liabilities	(4,135,793)	(3,919,327)
Net assets	(2,020,791)	(1,177,092)
Carrying amount of NCI as at 31 December	(990,187)	(576,775)

Financial information of subsidiaries which have material non-controlling interests that are material to the Group is set out below.

	Aquahealth	
	2025 RM	2024 RM
Loss/Total comprehensive expense during the financial year	(843,697)	(654,877)
Loss/Total comprehensive expense allocated to NCI during the financial year	(413,412)	(320,888)
Cash flows used in operating activities	1,930	(518,415)
Net increase in cash and cash equivalents	1,930	(518,415)
Ownership interest and voting rights percentage held by NCI	49%	49%

NCI arising from MGRC International Pte. Ltd. up to the date of strike off is immaterial to disclose.

**8. Other Investment**

	Group/Company	
	2025 RM	2024 RM
Unquoted shares		
In Malaysia	2,500,000	2,500,000

The above other investment is measured at fair value through other comprehensive income.

9. Inventories

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Lab consumables, at cost	390,498	936,527	-	-
Recognised in profit or loss:				
Inventories recognised as cost of sales	2,133,118	1,225,453	-	1,332
Impairment loss on inventories	15,016	5,988	-	-
Reversal of impairment loss on inventories	(16,983)	(29,463)	-	-
Inventories written off	19,273	25,799	-	-

10. Trade and Other Receivables

	Note	Group		Company	
		2025 RM	2024 RM	2025 RM	2024 RM
Trade receivables	(a)	10,373,936	10,604,876	8,243,668	8,377,200
Less: ECL	(b)	(7,778,446)	(6,274,700)	(7,778,446)	(6,274,700)
		2,595,490	4,330,176	465,222	2,102,500
Other receivables		98,710	3,228	4,393	-
Deposits	(c)	9,212,387	9,563,196	1,130,940	1,128,940
Advance to suppliers	(d)	2,745,614	2,745,614	-	-
		11,958,001	12,308,810	1,130,940	1,128,940
Less: ECL					
At 1 January/31 December		(6,745,614)	(6,745,614)	-	-
		5,212,387	5,563,196	1,130,940	1,128,940
Prepayments		7,906,587	9,896,600	1,600,555	3,231,440
		191,327	254,008	43,164	87,037
		8,097,914	10,150,608	1,643,719	3,318,477

(a) The Group's and the Company's credit terms range from 30 to 90 days (2023: 30 to 60 days). Other credit terms are assessed and approved on case-by-case basis.

(b) The movement on the ECL on trade receivables of the Group and the Company during the financial year/period is disclosed in Note 23 to the financial statements.

10. Trade and Other Receivables (Continue)

(c) Included in the deposits is an amount of:

- i) RM1,000,000 (2024: RM1,000,000) with Genotec Sdn Bhd (Formerly known as Rinani Genotec Sdn Bhd) (“Genotec”)

On 8 December 2022, the Company signed a letter (“subscription letter”) with Genotec for the subscription of not more than 20% of the total shareholding of the ordinary shares in Genotec.

On 31 July 2024, the Company had subscribed 189,970 shares from Genotec in consideration of RM13.16 per subscription share for a total consideration of RM2,500,000.

- ii) RM4,144,957 (2024: RM4,497,766) with Rinani Renal Berhad (“RRB”)

On 1 August 2022, the Group entered into a Collaboration Agreement (“Agreement 1”) with RRB to appoint RRB as the exclusive consultant to obtain the exclusive rights to operate a hemodialysis treatment centre on behalf of Dewan Perniagaan Islam Antarabangsa Malaysia. There was on-going repayment during the financial year.

- iii) RM3,936,490 (2024: RM3,936,490) with Dynamic Prestige Consultancy Sdn Bhd (“DPCSB”)

On 15 November 2022, the Group entered into a Collaboration Agreement (“Agreement 2”) with DPCSB to undertake projects in Malaysia, whereby DPCSB had identified a potential partner that currently owned seven (7) dialysis centres with 91 chairs for collaboration to set up fifty (50) dialysis centres with 42 chairs for each centre. As the DPCSB is having an ongoing litigation case and hence, the recoverable risk are low. The Group viewed that even though the parties agreeable to enter into settlement agreement, impairments have been made in last financial year based on prudent basis.

The Group and the Company have expressed their intention to continue the share subscription and the collaborations. The Group and the Company are of the opinion that these deposits paid are recoverable except for Agreement 2 as DPCSB is having an ongoing litigation case and hence, the recoverable risk are low. The Group and the Company viewed that even though the parties are agreeable to enter into settlement agreement, impairments have been made in last financial year based on prudent basis.

(d) Included in the advance to suppliers is an amount of:

- i) RM2,745,614 (2024: RM2,745,614) with Dynamic Prestige Consultancy Sdn Bhd (“DPCSB”).

On 30 June 2022, the Group entered into an engagement letter with DPCSB as a Construction Consultant for Dialysis Centre for a total contract sum of RM3,500,000. On 15 July 2022, DPCSB issued an invoice amounting to RM2,969,783 for deposits as Construction Consultant.

Impairments have been made during last financial year based on prudent basis based on prudent basis as the party having ongoing litigation case, hence, the recoverable risk are low.

11. Amount Owning by/(to) Subsidiaries

	Company	
	2025 RM	2024 RM
<u>Amount owing by</u>		
Trade	266,147	266,147
Non-trade	21,072,635	20,924,394
	21,338,782	21,190,541
<u>Amount owing to</u>		
Trade	(359,213)	(359,213)

The amount owing by/(to) subsidiaries are trade and non-trade in nature, unsecured, interest-free and repayable on demand.



12. Cash and Cash Equivalents

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Cash and bank balances	1,018,686	270,758	172,235	107,772

13. Share Capital

	Group/Company			
	Number of Ordinary Shares		Amount	
	2025 Units	2024 Units	2025 RM	2024 RM
Issued and fully paid				
At 1 January	137,210,480	137,210,480	59,435,566	59,435,566
Share capital reduction	-	-	(42,000,000)	-
At 31 December	137,210,480	137,210,480	17,435,566	59,435,566

14. Lease Liabilities

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Analysed as:				
Non-current	920,738	1,225,862	920,738	1,225,862
Current	305,124	383,871	305,124	285,403
	1,225,862	1,609,733	1,225,862	1,511,265

The effective interest rate of the lease liabilities of the Group and the Company is 6.85% (2024: 5.45% and 6.85% respectively) per annum.

The cash flows movement of lease liabilities during the financial year are summarised as below:-

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Lease liabilities				
At 1 January	1,609,733	1,969,950	1,511,265	1,778,223
Transfer to accrual	(98,468)	(131,259)	-	(38,000)
Repayment during the financial year/period	(285,403)	(228,958)	(285,403)	(228,958)
At 31 December	1,225,862	1,609,733	1,225,862	1,511,265

15. Trade and Other Payables

	Note	Group		Company	
		2025 RM	2024 RM	2025 RM	2024 RM
Trade payables	(a)	11,074	288,196	3,010	5,129
Other payables	(b)	1,004,847	1,075,525	405,910	339,156
Accruals		1,656,995	1,768,646	659,469	1,061,738
Contract liabilities	(c)	2,672,916	3,132,367	1,068,389	1,406,023
		25,806	40,612	-	-
		2,698,722	3,172,979	1,068,389	1,406,023

- (a) The normal trade credit terms granted to the Group and the Company range from 30 to 60 days (2024: 30 to 60 days).
- (b) Included in the other payables is an amount of RMNil (2024: RM18,957) owing to a Director of a subsidiary and entities related to the Director. The Director of a subsidiary has been ceased to be a Director on 10 April 2025.

Included in the other payables is an amount of RM315,000 (2024: RMNil) owing to a Director.

- (c) The changes to contract liabilities during the financial year are summarised as follows:

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
At 1 January	40,612	288,639	-	18,733
Billing to a customer during the financial year	302,259	391,773	-	-
Revenue recognised during the financial year	(317,065)	(639,800)	-	(18,733)
At 31 December	25,806	40,612	-	-

Contract liabilities represents the Group's and the Company's obligation to transfer goods or services to customers for which the Group and the Company has billed to customer but remain unfulfilled. The transaction price allocated to remaining unfulfilled performance obligation of the Group and the Company is RM25,806 and RMNil (2024: RM40,612 and RMNil) respectively which will be recognised as revenue as the Group and the Company performs the services under the contract, which are expected to occur over the next 1 month (2024: 1 month).

16. Revenue

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Revenue recognised from contracts with customers:				
- genetic screening, genome sequencing services and other services	1,006,734	732,632	-	15,349
- biopharmaceutical and healthcare product	7,016,201	4,789,457	-	1,422
	8,022,935	5,522,089	-	16,771



16. Revenue (Continue)

Breakdown of the revenue recognised from contracts with customers is as follows:

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Timing of revenue recognition				
- at a point in time	8,022,935	5,522,089	-	16,771

17. (Loss)/Profit Before Taxation

(Loss)/Profit before taxation is derived after charging/(crediting):

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Auditors' remuneration:				
- current financial year/period	128,000	130,000	85,000	85,000
- over provision in prior year	(3,500)	-	-	-
- other services	5,000	14,000	5,000	5,000
Amortisation of intangible assets	421,906	422,372	92,806	93,273
Bad debts written off	-	-	28,757	-
Depreciation of property, plant and equipment	665,262	773,380	615,463	730,999
Depreciation of right-of-use assets	378,717	378,720	290,136	290,136
Directors' remuneration:				
- fees	148,390	254,728	148,390	254,728
- salaries and other emoluments	186,778	690,118	186,778	690,118
- employee provident fund	28,699	81,606	28,699	81,606
Impairment loss on:				
- trade receivables	1,522,896	121,130	1,522,896	121,130
- plant and equipment	211,480	-	-	-
- inventories	15,016	5,988	-	-
Interest expenses on lease liabilities	95,528	119,183	92,596	111,042
Interest income	-	(271)	-	-
Inventories written off	19,273	25,799	-	-
Gain on disposal of property, plant and equipment	-	(29,300)	-	(29,300)
Gain on derecognition of subsidiary companies struck off	(19,909)	-	-	-
Management fee	-	-	(3,720,000)	(5,388,000)
Retainer fee	-	-	36,000	36,000
Realised (gain)/loss on foreign exchange	(1,915)	3,614	(1,039)	814
Reversal of impairment on trade receivables	(19,150)	(1,561,130)	(19,150)	(1,561,130)
Reversal of impairment loss on inventories	(16,983)	(29,463)	-	-
Short-term leases expenses	2,784	121,107	1,044	113,597

18. Taxation

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Current taxation:				
- current year provision	309,621	-	-	-
- under provision in prior year	1,284	348	-	-
Taxation for the financial year	310,905	348	-	-

Income tax rate is calculated at the Malaysian statutory tax rate of 24% of the estimated accessible profit for the financial year.

A reconciliation of income tax expense applicable to (loss)/profit before taxation at the statutory income tax rate to income tax expense at the effective income tax rate of the Group and of the Company are as follows:

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Loss)/Profit before taxation	(2,486,525)	(4,514,373)	(1,853,821)	56,194
Taxation at statutory tax rate of 24%	(596,766)	(1,083,450)	(444,917)	13,487
Expenses not deductible for tax purposes	564,409	1,423,450	285,917	326,513
Income not subject to tax	(36,022)	-	-	-
Movement of deferred tax assets not recognised	378,000	(340,000)	159,000	(340,000)
Under provision of current tax in prior year	1,284	348	-	-
Taxation for the financial year	310,905	348	-	-

Unrecognised deferred tax assets

The deductible temporary differences, unutilised tax losses and unabsorbed capital allowances of the Group and the Company for which no deferred tax assets were recognised in the statements of financial position due to uncertainty of their realisation are as follows:

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Deductible temporary differences	11,844,000	10,254,000	7,902,000	6,305,000
Unutilised tax losses	23,486,002	23,402,000	15,581,000	16,389,000
Unabsorbed capital allowances	122,000	224,000	-	127,000
	35,452,002	33,880,000	23,483,000	22,821,000



18. Taxation (Continue)

Pursuant to Section 44(5F) of the Income Tax Act, 1967, unabsorbed business losses shall only be deductible for a period of 10 consecutive years of assessment and that period commences immediately following the relevant year of assessment and any amount or balance which is not deducted at the end of the period of 10th year shall be disregarded (with effective from year of assessment 2019). Consequently, the unabsorbed tax losses of the Group and of the Company at the end of the reporting period shall expire in the year of assessment as tabulated below :

Year of Assessment	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
2028	1,251,092	2,058,702	1,251,092	2,058,702
2029	3,423,063	3,423,063	3,423,063	3,423,063
2030	4,152,399	4,152,399	4,152,399	4,152,399
2031	3,192,275	3,192,275	3,192,275	3,192,275
2033	4,814,806	4,855,549	2,071,356	2,071,356
2034	5,719,679	5,719,679	1,490,823	1,490,823
2035	932,639	-	-	-
	23,485,953	23,401,667	15,581,008	16,388,618

19. Loss Per Share

(a) Basic earnings per share of the Group is calculated by dividing the consolidated I attributable to owners of the Company by the weighted average number of ordinary shares of the Company in issue during the financial year/period.

	Group	
	2025	2024
Loss for the financial year attributable to the owners of the Company (RM)	(2,381,172)	(4,191,392)
Weighted average number of ordinary shares issued	137,210,480	137,210,480
Basic loss per share (sen)	(1.74)	(3.05)

(b) Diluted loss per share

The diluted loss per share is equal to the basic loss per share as there are no outstanding potential dilutive instruments during the financial year.

20. Staff Costs

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Salaries, bonuses and other emoluments (excluding Directors)	2,431,888	2,762,823	1,289,175	1,537,563
Defined contribution plan and social security	310,353	326,401	186,183	203,479
Total staff costs	2,742,241	3,089,224	1,475,358	1,741,042
Staff costs charged to:				
- cost of sales	560,949	628,209	-	-
- administrative expenses	2,181,292	2,461,015	1,475,358	1,741,042
	2,742,241	3,089,224	1,475,358	1,741,042

21. Related Party Disclosures

For the purposes of these financial statements, parties are considered to be related to the Group if the Group or the Company has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

The significant related party transactions of the Group and of the Company, other than key management personnel compensation, are as follows:

	Group	
	2025 RM	2024 RM
Sales of goods to a related party, W360 Aesthetics Sdn Bhd	132,300	-
Rental of motor vehicles paid/payable to a related party, Rinani Motorsports Sdn Bhd*	17,300	103,000
Rental of motor vehicles paid/payable to a related party, Rinani Motorsports Sdn Bhd*	17,300	103,800
Management fee received/receivable from subsidiaries	3,720,000	5,388,000
Retainer fee paid/payable to a subsidiary	36,000	36,000

* The Group and the Company had related party transactions with Rinani Motorsport Sdn Bhd up to 19 February 2025. The related party relationship ceased on that date.

Key management personnel are defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group either directly or indirectly. The key management personnel include all the Directors of the Group, and certain members of senior management of the Group.

The key management personnel compensation is as follows:

	Group/Company	
	2025 RM	2024 RM
Salaries, bonuses and other emoluments	186,778	687,877
Defined contribution plan and social security	28,699	83,847
	215,477	771,724

22. Segment Information

The reportable segments of the Group derive their revenue primarily from the provision of personalised and precision medicine through genetics, genomics, immunotherapy and biopharmaceutical services within the healthcare segment.

Business segment

Information about operating segment has not been reported separately as the Group's revenue, profit or loss, assets and liabilities are mainly confined to a single operating segment which is under healthcare in Malaysia.



22. Segment Information (Continue)

Information about major customer

The following is the major customers with revenue equal to or more than 10% of the Group's total revenue arising from its healthcare segment:

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Customer #1	1,308,440	3,743,630	-	-
Customer #2	821,450	-	-	-

23. Financial Instruments

The following table analyses the financial assets and financial liabilities of the Group and of the Company by the classes and categories of financial instruments to which they are assigned, and therefore by the measurement basis:

	Financial assets and liabilities at amortised cost			
	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Financial assets				
Other investment	2,500,000	2,500,000	2,500,000	2,500,000
Trade and other receivables	7,906,587	9,896,600	1,600,555	3,231,440
Amount owing by subsidiaries	-	-	21,338,782	21,190,541
Cash and bank balances	1,018,686	270,758	172,235	107,772
	11,425,273	12,667,358	25,611,572	27,029,753
Financial liabilities				
Trade and other payables	2,672,916	3,132,367	1,068,389	1,406,023
Amount owing to subsidiaries	-	-	359,213	359,213
Lease liabilities	1,225,862	1,609,733	1,225,862	1,511,265
	3,898,778	4,742,100	2,653,464	3,276,501

Financial risk management

The Group's and the Company's financial risk management policy is to ensure that adequate financial resources are available for the development of the Group's and the Company's operations whilst managing its financial risks, including credit risk, liquidity risk and market risk.

Credit risk

Credit risk is the risk of a financial loss to the Group and the Company if a counterparty of a financial asset fails to meet its contractual obligations. The Group's and the Company's exposure to credit risk arises mainly from trade and other receivables and intercompany receivables.

Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis through the review of trade receivables ageing. The Group and the Company monitors the results of the related parties regularly to safeguard credit risk on balance from intercompany receivables.

The maximum exposure to credit risk for the Group and the Company is the carrying amount of the financial assets shown in the statements of financial position.

23. Financial Instruments (Continue)**Financial risk management (continued)**Credit risk (Continue)

The ageing analysis of the Group's and of the Company's trade receivables is as follows:

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Neither past due nor individually impaired	277,773	302,474	-	-
Past due but not individually impaired:				
- between 1 to 30 days	71,225	437,544	-	-
- between 31 to 60 days	34,630	362,390	-	-
- between 61 to 90 days	55,110	386,940	-	-
- between 91 to 120 days	16,330	291,450	-	-
- more than 121 days	2,835,143	3,244,099	1,159,943	2,797,221
	3,012,438	4,722,423	1,159,943	2,797,221
Individually impaired	7,083,725	5,579,979	7,083,725	5,579,979
	10,373,936	10,604,876	8,243,668	8,377,200

Trade receivables that are neither past due nor individually impaired are creditworthy debtors with good payment records with the Company. These debtors are mostly long term customers with no history of default in payments.

The Group's and the Company's trade receivables of RM2,317,717 and RM465,222 (2024: RM4,722,423 and RM2,797,221) respectively were past due but not individually impaired. These relate to a number of independent customers for whom there is no recent history of default.

The Group's and the Company's trade receivables of RM7,778,446 and RM7,778,446 (2023: RM5,579,979 and RM5,579,979) respectively were individually impaired. The individually impaired receivables mainly relate to trade receivables, which are facing difficulties in cash flows.

At reporting date, the Group's and the Company's concentration of top 5 and 1 (2024: 5 and Nil) trade customers of the Group and of the Company represent 88% and 100% (2023: 97% and Nil%) respectively of the total trade receivables.

Movement on the Group's and Company's expected credit loss allowance of trade receivables are as follows:

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
At 1 January	6,274,700	7,714,700	6,274,700	7,714,700
ECL during the financial year/period	1,522,896	121,130	1,522,896	121,130
Reversal of impairment	(19,150)	(1,561,130)	(19,150)	(1,561,130)
At 31 December	7,778,446	6,274,700	7,778,446	6,274,700
Represented by:				
Individually impaired	7,083,725	5,579,979	7,083,725	5,579,979
Collectively impaired	694,721	694,721	694,721	694,721
	7,778,446	6,274,700	7,778,446	6,274,700



23. Financial Instruments (Continue)

Financial risk management (continued)

Liquidity risk

Liquidity risk is the risk that the Group and the Company will not be able to meet its financial obligations as they fall due. The Group's and the Company's exposure to liquidity risk arises principally from trade and other payables, intercompanies and lease liabilities.

Cash flow forecasting is performed by monitoring the Group's and the Company's liquidity requirements to ensure that it has sufficient liquidity to meet operational, financing repayments and other liabilities as they fall due.

The table below summarises the maturity profile of the Group's and the Company's financial liabilities as at the end of the reporting year based on contractual undiscounted payments:

	Carrying amount RM	Contractual interest rate %	Contractual cash flow RM	On demand of within one year RM	Between two to five years RM
2025					
Group					
Trade and other payables	2,672,916	-	2,672,916	2,672,916	-
Lease liabilities	1,225,862	-	1,386,000	378,000	1,008,000
	3,898,778		4,058,916	3,050,916	1,008,000
Company					
Trade and other payables	1,068,389	-	1,068,389	1,068,389	-
Amount owing to subsidiaries	359,213	-	359,213	359,213	-
Lease liabilities	1,225,862	-	1,386,000	378,000	1,008,000
	2,653,464		2,813,602	1,805,602	1,008,000
2024					
Group					
Trade and other payables	3,132,367	-	3,132,367	3,132,367	-
Lease liabilities	1,609,733	-	1,865,400	479,400	1,386,000
	4,742,100		4,997,767	3,611,767	1,386,000
Company					
Trade and other payables	1,406,023	-	1,406,023	1,406,023	-
Amount owing to subsidiaries	359,213	-	359,213	359,213	-
Lease liabilities	1,511,265	-	1,764,000	378,000	1,386,000
	3,276,501		3,529,236	2,143,236	1,386,000

23. Financial Instruments (Continue)**Financial risk management (continued)**Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and cash flow and fair value interest rate risk that may affect the Group's financial position and cash flows.

(a) Foreign currency risk

The Group is exposed to foreign currency risk on sales and purchases that are denominated in currency other than Ringgit Malaysia. The currency giving rise to this risk is primarily United States Dollar ("USD") and Singapore Dollar ("SGD"). The Group monitors the foreign currency risks on an ongoing basis.

The net unhedged financial assets and liabilities of the Group that are not denominated in their functional currencies are as follows:

	Group	
	2025 RM	2024 RM
Financial assets/liabilities held in non-functional currency		
USD		
Trade receivables	-	115,630
Trade payables	8,106	(697)
Cash and bank balances	8,106	8,774
	8,106	123,707
SGD		
Cash and bank balances	6,311	6,495
	6,311	6,495

The following table shows the sensitivity of the Group's equity and profit net of tax to a reasonable possibly change in the USD and SGD exchange rates against the functional currency of the Group, with all other variable remain constant.

	Group	
	2025 RM	2024 RM
Group		
(Loss)/Profit net of tax		
USD/RM - strengthened 5% (2024: *%)	308	*
- weakened 5% (2024: *%)	(308)	*
SGD/RM - strengthened 5% (2024: *%)	240	*
- weakened 5% (2024: *%)	(240)	*

* The amount is less than 1

Fair value information

The carrying amounts of cash and cash equivalents, short term receivables and payables and short term borrowings reasonably approximate their fair values due to the relatively short term nature of these financial instruments.

The Group and the Compny uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:



23. Financial Instruments (Continue)

Financial risk management (continued)

Fair value information (continued)

Level 1 : Quoted prices in active markets for identical assets or liabilities.

Level 2 : Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 : Inputs for the asset or liability that is not based on observable market data.

(a) Financial instruments carried at amortised cost

The following table analyses the fair value hierarchy for financial instruments not carried at fair value in the statements of financial position:

	2025		2024	
	Carrying Amount RM	Level 2 Fair Value RM	Carrying Amount RM	Level 2 Fair Value RM
Group				
Financial liability				
Lease liabilities	1,225,862	1,225,862	1,609,733	1,609,733
Company				
Financial liability				
Lease liabilities	1,225,862	1,225,862	1,511,265	1,511,265

The fair value of long term lease liabilities carried on the statements of financial position are estimated using valuation technique under the hierarchy level 2 mentioned above whereby the expected future cash flows are discounted at the market interest rate for similar type of borrowings.

(b) Financial instruments carried at FVOCI

	2025		2024	
	Carrying Amount RM	Level 3 Fair Value RM	Carrying Amount RM	Level 3 Fair Value RM
Group and Company				
Other investment	250,000	250,000	250,000	250,000

The valuation technique used to derive the Level 3 disclosure for other investment is based on the estimated cash flow and discount rate of the underlying counterparty.

The Group and the Company do not anticipate the carrying amount of other financial instruments recorded as at the reporting date to be significant different from the values that would eventually settled.

24. Significant Event

On 8 May 2025, the Company announced the following corporate proposals:

- proposed private placement of up to 13,721,000 new ordinary shares, representing not more than 10.0% of the total number of issued ordinary shares in the Company, to independent third-party investor(s) to be identified and at an issue price to be determined at a later date ("Proposed Private Placement"); and
- proposed reduction of the issued share capital of RM42,000,000 in MGRC pursuant to Section 116 of the Companies Act, 2016 ("Act") ("Proposed Share Capital Reduction").

24. Significant Event (Continue)

On 12 June 2025, the Company announced an Extraordinary General Meeting ("EGM") had been scheduled to be convened on 2 July 2025 for the purpose of considering the share capital reduction proposal. The shareholders of the Company had approved the proposals in the EGM.

The proposed share capital reduction was completed on 23 October 2025 upon receipt of the Notice by Registrar of Companies dated 22 October 2025 that all requirements have been complied.

25. Subsequent Event

On 12 February 2026, the Private Placement was completed with the issuance of 13,721,000 placement shares, representing up to 10.0% of the Company's total issued ordinary shares, at an issue price of RM0.1810 per placement share.

26. Capital Management

The objective of the Group on capital management is to ensure that it maintains a strong credit rating and safeguard the Group's ability to continue as a going concern, so as to support its business, maintain the market confidence and maximise shareholder value.

During the financial year the Group is not subject to externally imposed capital requirement as it does not have any external borrowings.

27. Capital Commitments

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Approved but not contracted for:				
Purchase of others	388,624	140,660	-	81
Services	8,750	191,001	-	11,379
	397,374	331,661	-	11,460

28. Comparative Figures

The following comparative figures of the Company have been reclassified to conform with the current year presentation:

	As previously stated RM	Reclassification RM	As restated RM
Statement of Profit or Loss and Other Comprehensive Income 31 December 2024			
Group			
Administrative expenses	8,062,520	(127,118)	7,935,402
Impairment loss	-	127,118	127,118
Company			
Administrative expenses	5,211,156	(127,118)	5,048,038
Impairment loss	-	127,118	127,118

29. Date of Authorisation for Issue

The financial statements of the Group and of the Company for the financial year ended 31 December 2025 were authorised for issue in accordance with a resolution of the Board of Directors dated 27 April 2026.



Other Information

- 125** List of Material Properties
- 126** Analysis of Shareholdings
- 128** Notice of 20th Annual General Meeting
- Form of Proxy**



LIST OF MATERIAL PROPERTIES

There were no properties owned by the Company for the financial year ended 31 December 2025.



ANALYSIS OF SHAREHOLDINGS

As At 7 April 2026

Total Number of Issued Shares : 150,931,480 ordinary shares
 No. of holders : 1,780
 Class of shares : Ordinary shares
 Voting rights : One vote per ordinary share

DISTRIBUTION SCHEDULE (AS PER THE RECORD OF DEPOSITORS)

Size of Holdings	No. of Holders	%	No. of Ordinary Shares Held	%
1-99	25	1.40	726	0.00
100 to 1,000	401	22.53	223,854	0.15
1,001 to 10,000	799	44.89	4,226,900	2.80
10,001 to 100,000	472	26.52	15,906,500	10.54
100,001 to <5% of shares	79	4.44	82,393,200	54.59
5% and above	4	0.22	48,180,300	31.92
Total	1,780	100.00	150,931,480	100.00

SUBSTANTIAL SHAREHOLDERS AS AT 7 APRIL 2026

(As per Register of Substantial Shareholders)

The substantial shareholders (holding 5% or more of the issued capital) based on the Register of Substantial Shareholders of the Company and their shareholdings are as follows: -

No.	Name of Substantial Shareholder	No. of Shares held		No. of Shares held	
		Direct	%	Indirect	%
1.	PHILLIP NOMINEES (TEMPATAN) SDN BHD OCTOWILL TRUSTEES BERHAD FOR PROVEN VENTURE CAPITAL PLT	22,399,900	14.84	-	-
2.	PIXELVEST SDN. BHD.	9,551,300	6.33	-	-
3.	LEONG YIEN HUNG	8,433,000	5.59	-	-
4.	BIOV GLOBAL BERHAD	7,796,100	5.17	-	-

DIRECTORS' INTERESTS IN SHARES AS AT 7 APRIL 2026

(As per Register of Directors' Shareholdings)

The Directors' Shareholdings based on the Register of Directors' Shareholdings of the Company are as follows:-

No.	Name of Director	No. of Shares held		No. of Shares held	
		Direct	%	Indirect	%
1.	Leong Yien Hung	8,433,000	5.59	-	-
2.	Ler Pei Fen	3,887,000	2.58	-	-
3.	Yap Kok Wei	-	-	-	-
4.	Tan Yiing Fung	-	-	-	-
5.	Chung Eng Lam	-	-	-	-
6.	Lim Kok Kiong	-	-	-	-

LIST OF TOP 30 LARGEST SHAREHOLDERS AS AT 7 APRIL 2026

No.	Name of Shareholders	No. of Ordinary Shares	%
1.	PHILLIP NOMINEES (TEMPATAN) SDN BHD OCTOWILL TRUSTEES BERHAD FOR PROVEN VENTURE CAPITAL PLT	22,399,900	14.84
2.	PIXELVEST SDN. BHD.	9,551,300	6.33
3.	LEONG YIEN HUNG	8,433,000	5.59
4.	BIOV GLOBAL BERHAD	7,796,100	5.17
5.	JACQUELINE NGU HIA KEE	6,288,000	4.17
6.	CHUA MENG MIN	6,000,000	3.98
7.	LIEW YUEN TENG	5,861,700	3.88
8.	PM NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT - ECO ASIA VENTURES SDN BHD FOR CHAN YOK PENG	5,548,000	3.68
9.	ER KIAN HONG	5,117,000	3.39
10.	CHAN KOK SAN	4,000,000	2.65
11.	LER PEI FEN	3,887,000	2.58
12.	AFFIN HWANG NOMINEES (TEMPATAN) SDN. BHD. PLEDGED SECURITIES ACCOUNT FOR LIM GAIK ENG	3,453,900	2.29
13.	TING SIE HUOONG	3,234,000	2.14
14.	MAYBANK NOMINEES (TEMPATAN) SDN BHD LEE YOKE HEAN	2,923,100	1.94
15.	HEW CHUN SHUN	2,721,000	1.80
16.	LEE YOKE HEAN	2,692,600	1.78
17.	YEO TSU SIN	1,827,300	1.21
18.	KEJAYA KAYA SDN. BHD.	1,602,100	1.06
19.	LEE YOKE HAR	1,588,900	1.05
20.	ALLIANCEGROUP NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT FOR TAN KOK AUN	1,532,300	1.02
21.	CHONG TONG SIEW	1,480,000	0.98
22.	PM NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT - ECO ASIA VENTURES SDN BHD FOR JEFFERY DING CHOON YONG	1,367,000	0.91
23.	MOHD RAFAEL BIN MOHD SHAMSUDIN	1,187,600	0.79
24.	FOO CHAI LEE	1,144,000	0.76
25.	KHOO HAI CHEW	1,000,000	0.66
26.	MAYBANK NOMINEES (TEMPATAN) SDN BHD CHUA MENG MIN	1,000,000	0.66
27.	PM NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT - ECO ASIA VENTURES SDN BHD FOR GENTING UTAMA SDN. BHD.	1,000,000	0.66
28.	SHAHNIL BIN SHAMSUDDIN	1,000,000	0.66
29.	AFFIN HWANG NOMINEES (TEMPATAN) SDN. BHD. PLEDGED SECURITIES ACCOUNT FOR LEE CHOOI BIT	852,000	0.56
30.	ALLIANCEGROUP NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT FOR YONG LOY HUAT	700,000	0.46

**MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD**

Registration No. 200401014287 (652790-V) | (Incorporated in Malaysia)

NOTICE OF THE TWENTY-FIRST ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the Twenty-First (“21st”) Annual General Meeting of Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Company”) will be held at Westside Room 1, Level 8, St. Giles Boulevard, Mid Valley City, Lingkaran Syed Putra, 59200 Kuala Lumpur, Wilayah Persekutuan on Monday, 22 June 2026 at 11.00 a.m. or any adjournment thereof for the purpose of transacting the following businesses:

AS ORDINARY BUSINESS:

1. To receive the Audited Financial Statements for the financial year ended 31 December 2025 (Please refer to Explanatory Note 1) together with the Reports of the Directors and Auditors thereon.
2. To approve the payment of Directors’ fees and other benefits payable up to RM350,000 to be divided amongst the Directors in such manner as the Directors may determine for the period commencing from the conclusion of the 21st AGM until the conclusion of the next AGM of the Company in the year 2027. (Ordinary Resolution 1)
3. To re-elect the following Directors who are retiring in accordance with Clause 123 of the Company’s Constitution and being eligible, offered themselves, for re-election:
 - i. Yap Kok Wei
 - ii. Tan Yiing Fung(Ordinary Resolution 2)
(Ordinary Resolution 3)
4. To re-appoint Messrs Jamal, Amin & Partners (AF1067) as Auditors of the Company for the ensuing year and to authorise the Directors to fix their remuneration. (Ordinary Resolution 4)

AS SPECIAL BUSINESS:

To consider and if thought fit, pass the following as resolution:

5. **AUTHORITY TO ISSUE AND ALLOT SHARES PURSUANT TO SECTIONS 75 AND 76 OF THE COMPANIES ACT, 2016** (Ordinary Resolution 5)

“THAT pursuant to Sections 75 and 76 of the Act and subject to the approvals of the relevant governmental/ regulatory authorities, the Directors be and are hereby empowered to issue shares in the capital of the Company from time to time and upon such terms and conditions and for such purposes as the Directors, may in their absolute discretion deem fit, provided that the aggregate number of shares issued pursuant to this resolution does not exceed 10% of the total number of issued shares of the Company or such higher percentage as Bursa Malaysia Securities Berhad (“Bursa Securities”) allowed for the time being and that the Directors be and are hereby also empowered to obtain approval from the Bursa Securities for the listing and quotation of the additional shares so issued.

AND THAT such authority shall commence immediately upon the passing of this Resolution and continue to be in force until the conclusion of the next Annual General Meeting of the Company, unless revoked or varied by ordinary resolution of the Company at a general meeting.

AND THAT the new shares to be issued shall, upon allotment and issuance, rank equally in all respects with the existing shares of the Company, save and except that they shall not be entitled to any dividends, rights, allotments and/or any others forms of distribution that which may be declared, made or paid before the date of allotment of such new shares.”

6. To transact any other business of which due notice shall have been given in accordance with the Act

BY ORDER OF THE BOARD

TAN TONG LANG (SSM PC NO. 202208000250 / MAICSA 7045482)**THIEN LEE MEE (SSM PC No. 201908002254 / LS0010621)**

Company Secretaries

Dated: 30 April 2026

Notes:-

- i) In respect of deposited securities, only members whose names appear in the Record of Depositors as at 12 June 2026 (“General Meeting Record of Depositors”) shall be eligible to participate and vote at the 21st AGM of the Company.
- ii) A member of the Company who is entitled to participate at the 21st AGM shall be entitled to appoint not more than two (2) proxies to participate and vote on his/her behalf at the same meeting. Where a member appoints more than one (1) proxy, such appointment shall be invalid unless the member specifies the proportion of his/her shareholding to be represented by each proxy. A proxy may but need not be a member of the Company, and a member may appoint any person to be his/her proxy.
- iii) Where a member of the Company is an authorised nominee as defined under the Securities Industry (Central Depositories) Act, 1991 (“SICDA”), he/she may appoint at least one (1) proxy but not more than two (2) proxies in respect of each securities account it holds with ordinary shares of the Company standing to the credit of the said securities account. The appointment of two (2) proxies in respect of any securities account shall be invalid unless the authorised nominee specifies the proportion of his/her shareholding to be represented by each proxy.
- iv) Where a member of the Company is an exempt authorised nominee holding ordinary shares in the Company for multiple beneficial owners in one (1) securities account (“Omnibus Account”), there is no limit as to the number of proxies which the exempt authorised nominee may appoint in respect of each Omnibus Account it holds. An exempt authorised nominee refers to an authorised nominee defined under the SICDA who is exempted from compliance with the provisions of subsection 25A(1) of SICDA.
- v) The instrument appointing a proxy and the power of attorney or other authority, if any, shall be in writing under the hand of the appointer or a copy of that power of attorney, certified by an advocate and solicitor, or where the member is a body corporate, either under its seal or by the hand of an officer or attorney duly authorised. Any alteration in the form of proxy must be initiated.
- vi) The instrument appointing a proxy, a power of attorney or other authorities, where it is signed or certified shall be deposited at the Company’s Share Registrar’s Office, Aldpro Corporate Services Sdn Bhd at B-21-1, Level 21, Tower B, Northpoint Mid Valley City, No. 1, Medan Syed Putra Utara, 59200 Kuala Lumpur, Wilayah Persekutuan, not less than forty-eight (48) hours before the time appointed for holding the meeting or at any adjournment thereof at which the person named in the instrument proposes to vote, and in default the instrument of proxy shall not be treated as valid.
- vii) Pursuant to Rule 8.31A(1) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, all the resolutions set out in this Notice of Meeting shall be put to vote by poll.

Explanatory Notes to Ordinary and Special Business:-**1. Item 1 of the Agenda**

Agenda No. 1 is meant for discussion only as Section 340(1)(a) of the Companies Act, 2016 provides that the audited financial statements are to be laid in the general meeting and do not require a formal approval of the shareholders. Hence, this Agenda item is not put forward for voting.

2. Ordinary Resolution 1: To approve the payment of Directors’ Fees and other benefits payable

Pursuant to Section 230(1) of the Act, fees and benefits payable to the Directors of a public company or a listed company and its subsidiaries shall be approved by shareholders at a general meeting. The Directors’ benefits payable include meeting attendance allowances and other claimable benefits.

In determining the estimated total amount of Directors’ benefits, the Board has considered various factors, among others, the estimated claimable benefits and estimated number of meetings for the Board and Board Committees held for the period commencing from the conclusion of the 21st AGM until the next AGM of the Company in the year 2027.

In the event the proposed amount is insufficient (e.g. due to more meetings or enlarged Board size), approval will be sought at the next AGM for additional fees to meet the shortfall.



3. Ordinary Resolutions 2 to 3 – Re-elections of Directors in accordance with Clause 123 of the Company's Constitution

Clause 123 of the Company's Constitution states that an election of Directors shall take place each year. At the Annual General Meeting where one-third (1/3) of the Directors for the time being or if the number is not three (3) or a multiple of three (3) then the number nearest one-third (1 /3) shall retire from office provided always that all Directors including a Managing Director shall retire from office once at least in each three (3) years but shall be eligible for re-election. A retiring Director shall retain office until the close of the meeting at which he retires.

The Board, through Nomination Committee, carried out the necessary assessment of Mr. Yap Kok Wei and Ms. Tan Yiing Fung and concluded that they met the criteria as prescribed under Ace Market Listing Requirements of Bursa Securities on character, experience, integrity, competence and time commitment to effectively discharge their role as Director. The Board then recommended Mr. Yap Kok Wei and Ms Tan Yiing Fung for re-election to be tabled for shareholders' approval at the 21st Annual General Meeting. The information on her profiles is provided in the Company's Annual Report 2025.

4. Ordinary Resolution 4 – Re-appointment of Auditors

The Board, through the Audit and Risk Management Committee, conducted an assessment of the suitability, objectivity, and independence of Messrs Jamal, Amin & Partners (AF1067) for the financial year ended 31 December 2025. The Board was satisfied with the performance of Messrs. Messrs Jamal, Amin & Partners (AF1067) and recommended their re-appointment as the external auditors of the Company to hold office until the conclusion of the next Annual General Meeting, in accordance with Section 271 of the Act.

5. Special Business - Ordinary Resolution 5 Authority to Issue and Allot Shares Pursuant to Sections 75 And 76 of the Act

The proposed Ordinary Resolution 5, if passed, will grant a renewed general mandate and provide flexibility for the Company to empower the Directors of the Company, from the date of the above Annual General Meeting, to issue new ordinary shares of not more than 10% of the total number of issued shares (excluding treasury shares) of the Company for the time being. In order to avoid any delay and costs involved in convening a general meeting to approve such issuance of ordinary shares, this renewal of general mandate will provide flexibility to the Company for any possible fund raising activities for purpose of financing future investments, major capital expenditure, acquisitions, and/or working capital purposes. This authority, unless revoked or varied at a general meeting, will expire at the next Annual General Meeting of the Company.

The Company on 11 February 2026, issued and allotted 13,721,000 new shares at an issue price of RM0.1810 per placement share, pursuant to the general mandate obtained from the shareholders' approval at the 20th AGM held on 23 June 2025, which will lapse at the conclusion of the 21st AGM of the company. A total of approximately RM2,483,501.00 was raised from the Private Placement. The details and status of the utilization of the proceeds raised from the Private Placement are set out in the additional compliance information of this Annual Report.

STATEMENT ACCOMPANYING NOTICE OF ANNUAL GENERAL MEETING (pursuant to Rule 8.29 of AMLR of Bursa Securities)

As at date of this notice, there are no individuals who are standing for election as Directors (excluding the above Directors who are standing for re-election) at this forthcoming 21st Annual General Meeting.

The Company will seek shareholders' approval at the general meeting for the issue of securities under Rule 6.04(3) of the AMLR of Bursa Securities. Please refer to the Proposed Ordinary Resolution 5 as stated in the Notice of the 21st AGM of the Company for details.

PROXY FORM

I/We, _____ <small>(Full Name in Block Letters)</small>	Number of shares held	CDS Account No.
(NRIC/Company No.) _____ of _____ <small>(Full Address)</small>		
_____ <small>(Full Address)</small>		
Email Address _____ Tel No. _____ being a member of		

MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD [Registration No. 200401014287 (652790-V)], hereby appoint:

Name of Proxy 1 (Full Name)	NRIC No./Passport No.	% of Shareholding to be Represented (refer to Note (ii) set out below)
Address	Email Address:	Contact No.:

and/or failing *him/her,

Name of Proxy 2 (Full Name)	NRIC No./Passport No.	% of Shareholding to be Represented (Refer to Note iv)
Address	Email Address:	Contact No.:

Or failing him/her, the Chairman of the Meeting as *my/our proxy to vote for *me/us on *my/our behalf at the Twenty-First ("21st") Annual General Meeting of Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Company") will be held at Westside Room 1, Level 8, St. Giles Boulevard, Mid Valley City, Lingkaran Syed Putra, 59200 Kuala Lumpur, Wilayah Persekutuan on Monday, 22 June 2026 at 11.00 a.m. or any adjournment thereof as indicated below:

Please indicate with a (x) or (√) in the appropriate box against the resolution how you wish your vote to be casted. If no specific direction as to voting is given, the proxy will vote or abstain at his/her discretion.

No.	Ordinary Resolution		For	Against
1	To approve the payment of Directors' fees and other benefits payable up to RM350,000 to be divided amongst the Directors in such manner as the Directors may determine for the period commencing from the conclusion of the 21 st AGM until the conclusion of the next AGM of the Company in the year 2027.	Ordinary Resolution 1		
2	Re-election of Yap Kok Wei as Director	Ordinary Resolution 2		
3	Re-election of Tan Yiing Fung as Director	Ordinary Resolution 3		
4	Re-appointment of Messrs Jamal, Amin & Partners as Auditors	Ordinary Resolution 4		
5	Authority to Issue and Allot Shares pursuant to Sections 75 and 76 of the Companies Act, 2016	Ordinary Resolution 5		

* Delete if not applicable

Signed on this _____ day of _____ 2026.

Signature/ Common Seal of Shareholder

Notes:

- (i) In respect of deposited securities, only members whose names appear in the Record of Depositors as at 12 June 2026 ("General Meeting Record of Depositors") shall be eligible to participate and vote at the 21st AGM of the Company.
- (ii) A member of the Company who is entitled to participate at the 21st AGM shall be entitled to appoint not more than two (2) proxies to participate and vote on his/her behalf at the same meeting. Where a member appoints more than one (1) proxy, such appointment shall be invalid unless the member specifies the proportion of his/her shareholding to be represented by each proxy. A proxy may but need not be a member of the Company, and a member may appoint any person to be his/her proxy.
- (iii) Where a member of the Company is an authorised nominee as defined under the Securities Industry (Central Depositories) Act, 1991 ("SICDA"), he/she may appoint at least one (1) proxy but not more than two (2) proxies in respect of each securities account it holds with ordinary shares of the Company standing to the credit of the said securities account. The appointment of two (2) proxies in respect of any securities account shall be invalid unless the authorised nominee specifies the proportion of his/her shareholding to be represented by each proxy.

- (iv) Where a member of the Company is an exempt authorised nominee holding ordinary shares in the Company for multiple beneficial owners in one(1) securities account ("Omnibus Account"), there is no limit as to the number of proxies which the exempt authorised nominee may appoint in respect of each Omnibus Account it holds. An exempt authorised nominee refers to an authorised nominee defined under the SICDA who is exempted from compliance with the provisions of subsection 25A(1) of SICDA.
- (v) The instrument appointing a proxy and the power of attorney or other authority, if any, shall be in writing under the hand of the appointer or a copy of that power of attorney, certified by an advocate and solicitor, or where the member is a body corporate, either under its seal or by the hand of an officer or attorney duly authorised. Any alteration in the form of proxy must be initiated.
- (vi) The instrument appointing a proxy, a power of attorney or other authorities, where it is signed or certified shall be deposited at the Company's Share Registrar's Office, Aldpro Corporate Services Sdn. Bhd. at B-21-1, Level 21, Tower B, Northpoint Mid Valley City, No. 1, Medan Syed Putra Utara, 59200 Kuala Lumpur, Wilayah Persekutuan, not less than forty-eight (48) hours before the time appointed for holding the meeting or at any adjournment thereof at which the person named in the instrument proposes to vote, and in default the instrument of proxy shall not be treated as valid.
- (vii) Pursuant to Rule 8.31A(1) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, all the resolutions set out in this Notice of Meeting shall be put to vote by poll.

Fold Here

AFFIX
STAMP

THE SHARE REGISTRAR OF

MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Registration No. 200401014287 (652790-V)

C/O Aldpro Corporate Services Sdn. Bhd.
B-21-1, Level 21, Tower B
Northpoint Mid Valley City
No. 1, Medan Syed Putra Utara
59200 Kuala Lumpur, Wilayah Persekutuan

Fold Here



Malaysian
Genomics
Resource
Centre

Malaysian Genomics Resource Centre Berhad

200401014287 (652790-V)

8F Jalan Teknologi 3/6, Taman Sains Selangor 1, Kota Damansara (PJU 5)
47810 Petaling Jaya, Selangor Darul Ehsan, Malaysia

T : +603 7890 0015

+603 7890 0016

w : www.mgrc.com.my

E : enquiries@mgrc.com.my